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ABSTRACT 
Recently, the medial habenula-interpeduncular (MHb-IPN) axis has been 
hypothesized to modulate anxiety although neuronal populations and molecular 
mechanisms regulating affective behaviors in this circuit are unknown. Here we 
show that MHb cholinergic neuron activity directly regulates anxiety-like behavior. 
Optogenetic silencing of MHb cholinergic IPN inputs reduced anxiety-like 
behavior in mice. MHb cholinergic neurons are unique in that they robustly 
express neuronal nicotinic acetylcholine receptors (nAChRs), although their role 
as autoreceptors in these neurons has not been described. nAChRs are ligand-
gated cation channels that are activated by the excitatory neurotransmitter, 
acetylcholine (ACh), as well as nicotine, the addictive component of tobacco 
smoke. We expressed novel nAChR subunits that render nAChRs hypersensitive 
to ACh, ACh detectors, selectively in MHb cholinergic neurons of adult mice. 
Mice expressing these ACh detectors exhibited increased baseline anxiety-like 
behavior that was alleviated by blocking the mutant receptors. Under stressful 
conditions, such as during nicotine withdrawal, nAChRs were functionally 
upregulated in MHb cholinergic neurons mediating an increase in anxiety-like 
behavior. Together, these data indicate that MHb cholinergic neurons regulate 
anxiety via signaling through nicotinic autoreceptors and point toward nAChRs in 
MHb as molecular targets for novel anxiolytic therapeutics. 
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I.A. Anxiety disorder and current therapeutics 
What is anxiety disorder? 
Anxiety disorders are the major mental illness in the U.S., affecting 18% of the 
U.S. population (around 40 million adults in the United States) (Kessler, Chiu et 
al. 2005). It costs the United States economy more than $42 billion per year, 
which is almost one-third of the $148 billion total mental health bill of the country 
(Kessler, Chiu et al. 2005). 
Anxiety is the normal unpleasant feelings of dread in response to stress and can 
actually be beneficial in some situations. However, anxiety disorders are different 
from anxiety. Patients with anxiety disorder feel extremely fearful and unsure 
most of the time every day for at least 6 months (Morrison and Ressler 2014). 
They may also have difficulty controlling it and it may negatively affect their daily 
life. If the anxiety disorder is not treated, patients can get even worse. 
There are a wide variety of anxiety disorders, including generalized anxiety 
disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive disorder 
(OCD) and post-traumatic stress disorder (PTSD) (Farb and Ratner 2014). 
Anxiety disorders commonly occur along with other mental or physical illnesses, 
such as alcohol or substance abuse, which make the anxiety symptoms even 
worse (Grant, Stinson et al. 2004). Interestingly, women are more likely than men 
to experience an anxiety disorder over their lifetime (Farb and Ratner 2014). 
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Current therapeutics 
To date, there are two main approaches to treat anxiety disorders. 
The first-line treatment is selective serotonin re-uptake inhibitors (SSRIs) 
(Masand and Gupta 2003). SSRI are a class of compounds inhibiting serotonin 
reuptake into the presynaptic cell, and increase the extracellular level of the 
neurotransmitter serotonin (Barlow 2009). Although these compounds have been 
shown to be beneficial for the treatment of certain anxiety disorders, in many 
patients they showed delays in producing the desired clinical effect or even 
potential worsening of anxiety (Farb and Ratner 2014). 
Another class of drugs are benzodiazepines (BZDs), which work by increasing 
the efficiency of inhibitory neurotransmitter, gamma-aminobutyric acid (GABA),  
decreasing the excitability of neurons in the brain (Page C 2002). BZDs has 
played a central role in the pharmacologic management of anxiety disorders for 
about 50 years, but it has many side effects such as drowsiness, ataxia, drug 
dependence and impairment of cognition (Farb and Ratner 2014). 
Therefore, it is important to better understand the neural circuitry underlying 
anxiety as well as to develop a more effective approach to treat anxiety disorders. 
I.B. The brain circuitry of anxiety disorders 
Anxiety is a complicated emotional response that involves multiple 
neurotransmitters within several different brain regions, such as amygdala, the 
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bed nucleus of the stria terminalis (BNST), prefrontal cortex (PFC), nucleus 
accumbens (NAc) and hippocampus (Farb and Ratner 2014) (Fig I-1). In this 
thesis, the involvement of amygdala and the BNST in anxiety will be discussed in 
detail. 
The role of amygdala in anxiety 
The amygdala is one brain region in the limbic system, and it receives afferent 
input from the sensory cortex and sends projections to the hypothalamus, 
periaqueductal gray matter, locus ceruleus (LC), raphe nuclei (RN) and ventral 
tegmental area (VTA) (Sah, Faber et al. 2003).  
There are several sub-regions in the amygdala: the basolateral amygdala (BLA) 
and the central nucleus of the amygdala (for short, CeA, can be divided into the 
central lateral and central medial portion, CeL and CeM, respectively). The BLA 
mainly sends the excitatory glutamatergic projection to the CeA (Tye, Prakash et 
al. 2011), whereas the CeL sends the inhibitory input to the CeM, which is the 
main output of the amygdala (LeDoux 2000). 
In humans, several imaging studies have shown that amygdala is involved in 
anxiety. For example, people who have more anxiety showed higher amygdala 
volume, and patients with anxiety disorder showed increased amygdala 
activation (Boehme, Ritter et al. 2014, Machado-de-Sousa, Osorio Fde et al. 
2014, Qin, Young et al. 2014). In rodents, after exposure to anxiogenic 
stimulation, the immediate early gene was activated in the amygdala, and 
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pharmacological inactivation of the CeA, but not into the BLA, by GABAA 
receptor agonist, muscimol, is anxiolytic in the elevated plus maze (EPM) 
(Silveira, Sandner et al. 1993, Butler, White et al. 2012). These lines of evidence 
suggest that the amygdala is critical for the anxiety in both humans and rodents. 
Lesion studies and local drug infusion studies indicate that the CeA, but not the 
BLA is required for avoidance of open spaces (Moller, Wiklund et al. 1997, 
Moreira, Masson et al. 2007, Carvalho, Moreira et al. 2012). However, these 
pharmacological studies and lesion studies might provide the inaccurate 
information because of methodological limitations (Adhikari 2014). Recently, 
optogenetic techniques allow researchers to overcome these limitations (Adhikari 
2014). Optogenetics is the combination of genetics and optics to control the firing 
rate of specific type of neurons quickly and reversibly by light (Tye, Prakash et al. 
2011). It was shown that optogenetic activation of the entire glutamatergic BLA 
somata increased anxiety, while selective activation of the projection from the 
BLA to CeA decreased anxiety, suggesting that multiple subpopulations or 
projections of BLA neurons can act in opposition in anxiety-like behavior (Tye, 
Prakash et al. 2011).  
The role of BNST in anxiety 
Bed nucleus of the stria terminalis (BNST) receives a major output from the 
amygdala, and  has been shown to be involved in anxiety in both human and 
rodents (Adhikari 2014) (Fig I-1). 
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In human imaging studies, it has been shown that the BNST of generalized 
anxiety disorder patients was activated when they participate in high uncertainty 
task (Yassa, Hazlett et al. 2012). Moreover, the BNST showed greater 
recruitment in individuals with greater anxiety (Somerville, Whalen et al. 2010). In 
rodents, it also has been shown that BNST lesion had an anxiogenic effect on 
the plus maze test (Duvarci, Bauer et al. 2009), and infusion of glutamate 
antagonists in the BNST was anxiolytic in the light potentiated startle paradigm 
(Walker and Davis 1997).  
Like the amygdala, BNST also has several sub-nuclei which have different 
anatomical and neurochemical features. Optogenetic studies have shown that 
inactivation of the oval nucleus of the BNST is anxiolytic, while decreasing the 
activity of the anterodorsal BNST is anxiogenic (Kim, Adhikari et al. 2013). It also 
has been shown that three distinct anterodorsal BNST efferent projections 
implemented independent features of anxiolysis: the lateral hypothalamus 
reduced risk-avoidance, the parabrachial nucleus reduced respiratory rate, and 
the VTA increased positive valence, respectively (Kim, Adhikari et al. 2013). 
Another optogenetic study showed that when mice were presented with aversive 
stimuli, the firing rate of BNST glutamatergic neurons increased, whereas the 
firing rate of BNST GABAergic neurons decreased (Jennings, Sparta et al. 2013). 
Moreover, activation of BNST glutamatergic projections by optogenetics resulted 
in aversive and anxiogenic phenotypes, whereas activation of BNST GABAergic 
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projections produced rewarding and anxiolytic phenotypes (Jennings, Sparta et 
al. 2013).  
Taken together, BNST is involved in anxiety and different subregions of BNST 
have specific functions.  
Conclusion: 
In conclusion, there has been an explosion of research into the biological 
mechanism, especially the brain circuitry, underlying anxiety disorders. There are 
many brain regions that work together to modulate the anxiety state in humans 
and rodents. The development of new technologies might facilitate the search for 
new brain regions that are involved in anxiety disorders, and provide new 
therapeutic targets. 
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Figure I-1. Brain circuitry implicated in anxiety disorders 
The red solid lines represent excitatory glutamatergic afferents to NAc from 
mPFC, amygdala, and hippocampus, and glutamatergic innervation of VTA by 
amygdala. The purple solid lines are GABAergic inhibitory circuits including 
connections from NAc to VTA and hypothalamus. Green solid lines are dopamine 
neurons projecting from VTA to a range of limbic targets, including NAc, mPFC, 
amygdala, and hippocampus. Peptidergic pathways though which the 
hypothalamus (e.g., ARC, arcuate nucleus, and LH, lateral hypothalamus) alters 
neurotransmission in NAc and VTA are shown in solid black lines. Each structure 
contains specialized neuronal cell types thought to regulate anxiety disorders. 
These cell types, color–coded to reflect the transmitter signal they convey, 
include amygdala, PFC and hippocampal glutamatergic neurons (red), 
GABAergic NAc medium spiny neurons (purple), hypothalamic peptidergic 
9 
 
neurons (black), and VTA dopaminergic neurons (blue). CP, caudate-putamen; 
DMT, dorsomedial thalamus; SC, superior colliculus; IC, inferior colliculus; VP, 
ventral pallidum; SNr, substantia nigra; PAG, periaqueductal gray; DR, dorsal 
raphe; and LC, locus ceruleus. Figure modified with permission from (Russo, 
Murrough et al. 2012) 
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I.C. The anatomy of medial habenula and interpeduncular nucleus pathway 
Habenula 
The habenula (meaning “little rein” in Latin) is a bilateral small, complex and well-
conserved structure, which located by the third ventricle (Klemm 2004). It can be 
divided into medial habenula and lateral habenula (MHb and LHb, respectively) 
based on their anatomical and functional differences (Klemm 2004, Lecourtier 
and Kelly 2007). The habenula is part of the dorsal diencephalic conduction 
(DDC) system, which connects the limbic forebrain with the midbrain and 
hindbrain (Lecourtier and Kelly 2007). Interestingly, a recent study of human 
fetuses showed that the habenulo-interpeduncular (Hb-IPN) tract is one of the 
first major fiber tracts to form in the developing brain, being present as early as 
eight weeks gestation (Antolin-Fontes, Ables et al. 2014). 
 It has been shown that habenula plays an important role in many behaviors 
including sleep (Haun, Eckenrode et al. 1992, Valjakka, Vartiainen et al. 1998), 
circadian rhythm (Zhao and Rusak 2005), stress response (Carboni, Carletti et al. 
1998, Sugama, Cho et al. 2002, Lecourtier, Neijt et al. 2004, Mathuru and 
Jesuthasan 2013), pain (Michl, Jocic et al. 2001, Plenge, Mellerup et al. 2002), 
feeding (Sandyk 1991), depression (Shumake, Edwards et al. 2003), memory 
(Kobayashi, Sano et al. 2013) as well as nicotine withdrawal (Salas, Sturm et al. 
2009, Fowler, Lu et al. 2011, Frahm, Slimak et al. 2011). 
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In the past ten years, many studies have focused on the function of the lateral 
habenula, whereas the medial habenula remains largely understudied. Therefore, 
the medial habenula anatomy and histochemical characters will be discussed 
here. 
Medial habenula afferents and efferents 
Afferents 
The medial habenula receives major inputs via a white matter bundle called stria 
medullaris (sm) (Herkenham and Nauta 1977, Qin and Luo 2009). The most 
prominent input is from the two nuclei in the posterior septum: the triangular 
septal nucleus (TSN) and septofimbrial nucleus (SFi), which release glutamate 
and ATP to the MHb (Herkenham and Nauta 1977, Qin and Luo 2009). 
Interestingly, the MHb contains the highest expression level of GABAB receptors 
in the brain, suggesting the presence of strong inhibitory inputs (Bischoff, 
Leonhard et al. 1999, Durkin, Gunwaldsen et al. 1999, Charles, Evans et al. 2001, 
Wang, Gong et al. 2006). It has been shown that the GABAergic inputs to the 
MHb are from the Nucleus of Diagonal band (NDB) and the medial septum (MS) 
(Qin and Luo 2009). Moreover, it also has been reported that MHb received 
monoaminergic inputs, including the dopaminergic inputs from the interfascicular 
nucleus of VTA (Phillipson and Pycock 1982, Viswanath, Carter et al. 2013) and 
noradrenergic inputs from the locus coeruleus and superior cervical ganglion 
(Gottesfeld 1983). In addition, physiological and neurochemical studies have 
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shown that the MHb also has the highest expression of nicotinic acetylcholine 
receptors (nAChRs) (Sheffield, Quick et al. 2000). Evidence from lesion studies 
showed that the NDB or posterior septum might send the cholinergic input to the 
MHb, but more precise research still needs to be done (Contestabile and 
Fonnum 1983). 
Efferents 
The MHb has several subregions, in which the neurotransmitter expression 
pattern is highly localized: the superior MHb (MHbS) have vesicular glutamate 
transporters and therefore are glutamatergic; the dorsal region of the MHb 
(MHbD) expresses substance (SP) and glutamate (Glu); and the ventral region 
MHb (MHbV) (can be divided into the ventro-medial (MHbVm), the ventrocentral 
(MHbVc) and the ventro-lateral (MHbVl) subnuclei) expresses acetylcholine (ACh) 
and Glu (Contestabile, Villani et al. 1987, Aizawa, Kobayashi et al. 2012). In 
addition to the highly localized expression of neurotransmitters, expression 
pattern of other markers has also been shown to be subnuclei specific. For 
instance, the mu-opioid receptor (Oprm) is only expressed in the MHbVl part, and 
interleukin 18 (IL-18) is only expressed in the MHbS and MHbD parts (Aizawa, 
Kobayashi et al. 2012, Antolin-Fontes, Ables et al. 2014). 
The medial habenula sends major inputs to the interpeduncular nucleus (IPN) via 
the internal portion of an axon bundle called fasciculus retroflexus (fr) 
(Herkenham and Nauta 1977, Carlson, Noguchi et al. 2001). It is interesting that 
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habenular fibers traverse the entire width of the IPN several times to make 
various synaptic connections with the IPN neurons (Lenn 1976).  MHb projects to 
distinct subnuclei of the IPN, and releases three distinct neurotransmitters: ACh, 
Glu, and SP (Ren, Qin et al. 2011, Aizawa, Kobayashi et al. 2012). The dorsal 
MHb innervate the lateral IPN (IPL and IPR, described below) in a cluster pattern 
and release the SP; the Choline acetyltransferase (ChAT) positive neurons in the 
ventral MHb innervate the ventral IPN (IPC and IPI, described below) 
(Contestabile, Villani et al. 1987) and the MHbVl part only innervates the dorsal 
IPN (IPR, described below) (Shih, Engle et al. 2014), and they release ACh and 
Glu at different transmission modes (Herkenham and Nauta 1979, Contestabile 
and Flumerfelt 1981, Ren, Qin et al. 2011). This highly restricted neurotransmitter 
expression and projection pattern suggest that the subnuclei might have specific 
functions in the brain. 
 It also has been reported that the MHb might project to the pineal gland 
(Ronnekleiv and Moller 1979). In addition, there are two observations suggesting 
that the intrinsic habenular circuitry exist and the direction is from medial to 
lateral. One of the evidence is that boutons en passant were found from MHb to 
the LHb, but not from the LHb to the MHb (Kim and Chang 2005). The other 
evidence is that the sectioning of the MHb efferent axons reduced SP levels in 
the LHb (Sutherland 1982). These evidence suggest that MHb may regulate LHb 
activity, while the LHb probably does not directly influence activity in the MHb. 
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Interpeduncular nucleus afferents and efferents 
The Interpeduncular nucleus (IPN) is an unpaired midline structure in the 
posterior part of the midbrain (Klemm 2004). In rodents, it lies just above the 
pituitary gland. IPN is surrounded dorsally by the ventral tegmental area (VTA) 
and median raphe, anteriorly by the mammillary bodies of the hypothalamus, 
posteriorly by the pontine nuclei (Klemm 2004). Based on anatomical features 
and neurotransmitter expression pattern, at least seven subnuclei were identified. 
They were divided into two groups: unpaired and paired subnuclei. There are 
three unpaired subnuclei: Apical sub-nucleus (IPA), Central sub-nucleus (IPC), 
Rostral sub-nucleus (IPR); and four paired subnuclei: Dorsolateral sub-nucleus 
(IPDL), Dorsomedial sub-nucleus (IPDM), Intermediate sub-nucleus (IPI) and 
Lateral sub-nucleus (IPL) (Hamill and Lenn 1984). 
Afferents 
As discussed above, the IPN receives major input from the MHb via the 
fasciculus retroflexus, and this connection is highly conserved throughout the 
vertebrate lineage (Shibata, Suzuki et al. 1986, Viswanath, Carter et al. 2013). It 
also receives the input from several other brain regions in the limbic forebrain, 
including the medial frontal cortex, the nucleus of the diagonal band, substantia 
innominata, preoptic and hypothalamic nuclei and the supramammillary nucleus 
(Hamill and Fass 1984, Woolf and Butcher 1985, Shibata, Suzuki et al. 1986, 
Dinopoulos, Papadopoulos et al. 1989). In addition, several brain regions in the 
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brain stem also project to the IPN, including the raphe nucleus (RN), locus 
coeruleus (LC) and dorsal tegmental region (DTR) (Contestabile and Flumerfelt 
1981, Hamill and Jacobowitz 1984, Shibata, Suzuki et al. 1986, Vertes and Fass 
1988, Takagishi and Chiba 1991).   
Biochemical studies have shown extremely high levels of acetylcholine, choline 
acetyltransferase, acetylcholine esterase and high-affinity choline uptake within 
the IPN, suggesting that the IPN received very strong cholinergic input 
(Contestabile and Fonnum 1983).  MHb is the major cholinergic input to the IPN, 
and dorsal tegmental region and mediobasal forebrain area might also send the 
cholinergic projection to the IPN (Contestabile and Fonnum 1983, Woolf and 
Butcher 1985). Other neurotransmitters present in the IPN, include GABA, 
substance P, and various monoamines (noradrenaline, dopamine and serotonin) 
Morley (1986). 
Efferents 
The IPN is well known for its widespread projections. The dorsal tegmental 
region and the raphe nucleus are the major projection targets of IPN (Hamill and 
Lenn 1984). It also has been reported that IPN sends the output to the 
hippocampus, entorhinal cortex, hypothalamus, thalamus and the septum (Hamill 
and Lenn 1984).  
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Conclusion: 
The anatomical studies show that the MHb-IPN tract is the key connection that 
links these forebrain and midbrain structures. Habenula and IPN both have 
multiple sub-nuclei, but not much is known about the specific input and output of 
each sub-nucleus and their interaction or function. 
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Figure I-2. The neuroanatomy of MHb-IPN pathway. 
A. Schematic sagittal view of rodent brain showing known MHb and IPN 
connectivity. The MHb receives input mainly from the limbic system through stria 
medullaris (sm) and sends output through fasciculus retroflexus (fr) to the IPN, 
which projects to the raphe nuclei.  
B. Afferent and efferent connections of the MHb and IPN. TSN and SFi send the 
excitatory projection to the MHb and release ATP/Glu, whereas the NDB and MS 
send the inhibitory projection to the MHb and release GABA. MHb can be divided 
into the MHbD, MHbS and MHbV (can be further divided into MHbVm, MHbVc 
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and MHbVl). The MHbD projects to the IPL to release SP, which is involved in 
fear. MHbV projects to the rest of the IPN to release ACh and Glu, which is 
involved in anxiety. The IPN can be divided into IPR, IPC, IPA, IPDM, IPDL, IPI 
and IPL.  
Abbreviations for the brain regions indicated are: TSN, the triangular septal 
nucleus; SFi, the septofimbrial nucleus; NDB, the nucleus of diagonal band; MS, 
the medial septum; sm, stria medullaris;  MHb, medial habenula; fr, fasciculus 
retroflexus; IPN, interpeduncular nucleus; MHbS, medial habenula superior;  
MHbD, the dorsal region of medial habenula; MHbVm, the ventro-medial region 
of medial habenula; MHbVc, the ventrocentral region of medial habenula; MHbVl, 
the ventro-lateral region of medial habenula; IPDM, dorsomedial sub-nucleus of 
IPN; IPDL, dorsolateral sub-nucleus of IPN; IPR, rostral sub-nucleus of IPN; IPL, 
Lateral sub-nucleus of IPN; IPI, intermediate sub-nucleus of IPN; IPC, Central 
sub-nucleus of IPN; DTR, Dorsal tegmental region; RN, raphe nucleus. 
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I.D. The role of MHb in anxiety, fear, and depression 
The study of MHb had a first golden age in the 1970‟s, when there were several 
high quality reports about the MHb anatomical connections and possible 
functions (Cuello, Emson et al. 1978, Herkenham and Nauta 1979, Herkenham 
1981, Stern, Johnson et al. 1981, Hamill, Olschowka et al. 1984). However, the 
pace of MHb functional studies slowed down because of its small size, the 
complexity of its role and the lack of suitable pharmacological agents (Baldwin, 
Alanis et al. 2011). Recently, thanks to the emergence of new techniques that 
allow researchers to study the small brain regions specifically, such as high 
resolution functional magnetic resonance imaging (fMRI), immunotoxin-mediated 
cell targeting, as well as optogenetics, the habenula has attracted great attention 
again. 
In a human positron emission tomography (PET) study, the habenula has been 
shown to be hyperactive in patients with major depression (Morris, Smith et al. 
1999). Another fMRI study showed that self-detected errors or negative feedback 
in a dynamically adaptive motion prediction task activated the habenular complex, 
suggesting that the habenular complex might regulate the human reward system 
(Ullsperger and von Cramon 2003). 
In 2010, the medial habenula was shown to regulate the expression of fear in 
zebrafish (Agetsuma, Aizawa et al. 2010). Following genetic silencing with 
tetanus toxin or lesion with nitroreductase, both adult and larval zebrafish 
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showed enhanced freezing in aversive conditioning paradigms compared to the 
control animals (Agetsuma, Aizawa et al. 2010, Lee, Mathuru et al. 2010). In 
detail, when first exposed to an electric shock paired with a red light, both control 
and lesioned fish froze. As more shocks were delivered, freezing decreased in 
control fish, but not in habenula-lesioned fish (Agetsuma, Aizawa et al. 2010). 
Similarly, in larval zebrafish, they learn to avoid a light that has been paired with 
a mild shock but fail to do so when pre-exposed to inescapable shock. In this test, 
freezing appeared gradually in lesioned fish in the latter half of the conditioning 
session, but never in control fish (Lee, Mathuru et al. 2010). These studies 
suggest that habenula is critical for stress, and its disruption could contribute to 
anxiety disorders. 
However, in rodents, the role of habenula in depression is contradictory. One 
study showed that habenula lesions reduced avoidance deficits caused by 
inescapable shock (Amat, Sparks et al. 2001). In contrast, other studies conclude 
that habenula lesions cause avoidance deficits (Thornton and Bradbury 1989). 
These contradictory results may be caused by imprecise lesions induced by 
traditional methods, as the habenula is a small brain structure (Wilcox, Christoph 
et al. 1986). The new specific genetic lesion approaches overcome these 
limitations and provide more accurate information.  MHb was selectively lesioned 
by genetic approaches, and the MHb lesions led to abnormalities in a wide range 
of behavioral tests, such as hyperlocomotion during the early night period, delay 
and effort aversion in a decision-making test, deficits in spatial memory, a subtle 
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increase in anxiety levels, and attenuated sensorimotor gating (Kobayashi, Sano 
et al. 2013). These findings demonstrate that the MHb is involved in inhibitory 
control and cognition-dependent executive functions. 
Recently, the MHb has been shown to play an important role in anxiety and fear 
(Yamaguchi, Danjo et al. 2013). The posterior septum, consisting of the 
triangular septum (TS) and the bed nucleus of the anterior commissure (BAC), 
has been implicated in the control of anxiety and fear responses (Yamaguchi, 
Danjo et al. 2013). Interestingly, anatomical studies showed that TS projects to 
ventral MHb whereas the BAC projects to dorsal MHb (Yamaguchi, Danjo et al. 
2013). By immunotoxin-mediated cell targeting, the projection from the TS to 
MHbV or from BAC to the MHbD was selectively eliminated, respectively 
(Yamaguchi, Danjo et al. 2013). The behavioral data showed that ablation of the 
projection from the TS to the MHbV reduced anxiety whereas ablation of the 
projection from the BAC to the MHbD showed enhancement of fear responses 
and fear learning (Yamaguchi, Danjo et al. 2013). These data suggest that the 
TS-MHbV and BAC-MHbD pathways have distinct roles in the regulation of 
anxiety and fear, respectively (Yamaguchi, Danjo et al. 2013). 
Conclusion: 
MHb is involved in anxiety, fear and depression. In addition, it seems that the 
different sub-region of MHb modulate different behaviors. However, the role of 
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different neuronal population and the molecular mechanisms underlying different 
behaviors still need to be studied. 
I.E. nAChR: Structure, Function and the role in anxiety 
Overview: 
Acetylcholine (ACh) is one of the most important neurotransmitters in the central 
nervous system (Woolf and Butcher 1985). Acetylcholine receptor (AChR), as its 
name indicates, is an integral membrane protein that responds to the binding of 
ACh (Gotti and Clementi 2004). AChRs not only respond to endogenous 
neurotransmitter, ACh, they also respond to other exogenous molecules, like 
nicotine (the main addictive substance in tobacco) and muscarine 
(toxins from various mushrooms) (Rubio, Perez et al. 2006). According to their 
relative affinities and sensitivities to different molecules, AChR can be divided 
into two main classes: nicotinic acetylcholine receptors (nAChR) and muscarinic 
acetylcholine receptors (mAChR) (Bikadi and Simonyi 2003). Both of them are 
expressed by neuronal and non-neuronal cells throughout the body (Gotti and 
Clementi 2004, Dani and Bertrand 2007). 
nAChR (also known as "ionotropic" acetylcholine receptors) are cation channels 
and they are particularly responsive to nicotine in micro- to submicro- second 
range (Bikadi and Simonyi 2003). In contrast, mAChR (also known as 
"metabotropic" acetylcholine receptors) are particularly responsive to muscarine, 
responding relatively slowly in the milliseconds to seconds range and they are G-
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protein-coupled receptors that activate other ionic channels and other cellular 
processes via a second messenger cascade (Bikadi and Simonyi 2003). 
nAChRs: Structure 
nAChRs belong to the large superfamily of Cystine-loop ligand-gated ion 
channels, that also includes GABAA/C, glycine and 5-HT3 ionotropic receptors 
(Romanelli, Gratteri et al. 2007). Like all of the other members of the Cystine-
loop ligand-gated ion channel superfamily, all nAChR subunits have an 
approximately 200 amino acid long relatively hydrophilic extracellular amino 
terminal portion that carries the ACh binding site, followed by three hydrophobic 
transmembrane domains (TM1-TM3), a large intracellular domain which varies 
significantly from one subunit to the other, then a fourth hydrophobic 
transmembrane domain (TM4) and an extracellular carboxy terminal (Gorne-
Tschelnokow, Strecker et al. 1994). Both the amino- and the carboxy- terminals 
are extracellular (Zoli, Pistillo et al. 2014).  
In the first extracellular domain, there is a cysteine-loop (Cys-loop) defined by 
two cysteines (Cys) that are separated by 13 intervening amino acids, which is 
required for agonist binding (Kao and Karlin 1986, Karlin, Cox et al. 1986, 
Cockcroft, Osguthorpe et al. 1990, Lansdell and Millar 2000, Albuquerque, 
Pereira et al. 2009, Tsetlin, Kuzmin et al. 2011). Subunits are classified into α- 
and non-α subunits based on the presence of a Cys-Cys pair: α subunits has 
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Cys-Cys pair, whereas non-α subunits are lacking the Cys-Cys pair (Nef, 
Oneyser et al. 1988, Lukas, Changeux et al. 1999) 
Each nAChR is composed of five subunits that combine to form a functional 
receptor and all five subunits contribute to channel kinetics, ion conductance and 
selectivity (Steinbach 1989, Albuquerque, Pereira et al. 2009). The agonist-
binding site is a hydrophobic pocket at the interface formed between α subunits 
and adjacent subunits, where the Cys-Cys pair is required (Karlin, Cox et al. 
1986). The TM2 segment of all five subunits forms the conducting pore of the 
channel, and the regions in the TM2 intracellular loop is critical for the ion 
selectivity, permeability and channel gating of the receptor (Kuryatov, Gerzanich 
et al. 1997, Lester, Fonck et al. 2003). When a ligand, such as nicotine or ACh, 
binds to the interface, it produces a rotational force in the β-barrel of the 
extracellular domain that produces torque on TM2 to rotate it from a hydrophobic-
based, channel closed configuration to a more open hydrophilic channel that 
favors ion passage (Akabas, Kaufmann et al. 1994, Wilson and Karlin 1998). 
This conformational change happens within microseconds. The L9′S mutation in 
the TM2 pore forming region produces a partial relief of the gate and increase 
channel permeability nonspecifically (Tapper, McKinney et al. 2004). 
Three functional states have been described in ACh receptors: the resting 
(closed) state (R), the open state (O), and the desensitized (closed) state (D) 
(Baenziger, Miller et al. 1992, Champtiaux, Gotti et al. 2003, Albuquerque, 
25 
 
Pereira et al. 2009). The resting state is the most stable state in the absence of 
agonists and the channel is closed; the open state is the transient metastable 
states when agonist occupies the ligand binding site and the channel is open to 
allow the cations to flow down their electrochemical gradient; the desensitized 
state is the most stable state in the presence of agonists and the receptor is not 
responsive to the ligand (Edelstein, Schaad et al. 1996). Recovery from the 
desensitization state will take seconds to minutes (Fenster, Rains et al. 1997).  
nAChRs: The subunit diversity  
In vertebrate species, 17 nAChR subunits have been identified (α1- α10, β1-β4, 
γ,δ and ε) (Dani and Bertrand 2007). Historically, nAChRs are subdivided into 
muscle or neuronal subtypes based on their major expression site. Muscle 
nAChRs are either (α1)2β1γδ in the embryonic tissues or (α1)2β1εδ in the adult 
tissues (Mishina, Takai et al. 1986),  whereas neuronal nAChRs can be either 
homopentamers (α)5 or heteropentamers (α)2(β)3 or (α)3(β)2 (Dani and Bertrand 
2007). 
Of 17 nAChR subunits, there are 12 neuronal nAChR subunit genes in 
vertebrates and they are classified into two subfamilies: nine alpha subunits (α2– 
α10) and three beta subunits (β2– β4)  (Le Novere and Changeux 1995).   
For the homomeric nAChRs, they are preferentially formed by α7, α8, or α9 
subunits (Couturier, Bertrand et al. 1990, Gerzanich, Anand et al. 1994) and 
overall they have high Ca2+ permeability (comparable to the NMDA receptors), a 
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rapid desensitization rate and can be blocked by nanomolar concentrations of α-
Bungarotoxin (α-Bgtx) (Gotti and Clementi 2004) . Therefore they were called α-
Bgtx sensitive nAChRs. Of which, α7 containing nAChRs are one of the most 
abundantly expressed subtypes in the brain (Gotti and Clementi 2004), α8 
nAChRs have only been identified in the chick nervous system (Gotti, Hanke et al. 
1994), whereas α9 can form homomeric nAChRs but more efficiently when co-
expressed with α10 subunit (Elgoyhen, Vetter et al. 2001, Sgard, Charpantier et 
al. 2002). 
For the heteromeric nAChRs, they are formed by α2-6 and β2-4 subunits, which 
have high affinity for nicotine, but are insensitive to α-Bgtx. Therefore they were 
called α-Bgtx insensitive nAChRs. In the brain, α4β2* nAChRs (an asterisk in 
nAChR nomenclature indicates that other nAChR subunits are also present and 
can be read as “α4β2-containing nAChRs”) are the most abundant and widely 
expressed subtype. But in different brain regions, the diversity of the nAChR 
subtype can be huge. 
For instance, α3β4* subtype is highly expressed in the autonomic ganglia and 
MHb as well as the IPN (Zoli, Pistillo et al. 2014). The dopaminergic (DAergic) 
neurons of the VTA express not only α4 β2 subunit but also α6 β3 subunits, and 
they can form α4α6β2β4* nAChRs, which has totally different properties 
compared to α4β2* subtype (Grady, Salminen et al. 2007). 
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The vast diversity of nAChR subtype expression determines the specialized 
properties and functions of the mature receptors, like the receptor open time, the 
channel conductance as well as the pharmacological properties (Albuquerque, 
Pereira et al. 2009). 
nAChRs: The expression location 
Electrophysiological recording combined with pharmacological tools provided a 
wealth of knowledge regarding the localization of native nAChRs on discrete 
neuronal compartments and enhanced our understanding of the role of various 
nAChRs in mediating or modulating synaptic transmission (Albuquerque, Pereira 
et al. 2009). Multiple lines of evidence have shown that nAChRs are located at 
five primary locations: the cell soma, dendrites, pre-terminal axon regions, axon 
terminal and myelinated axons on the neurons (Wonnacott 1997, MacDermott, 
Role et al. 1999, Gotti, Clementi et al. 2009). The different location of unique 
nAChR subtype might have specific functional implications (Wonnacott 1997, 
MacDermott, Role et al. 1999, Albuquerque, Pereira et al. 2009). For instance, in 
the mesolimbic dopamine pathway, different subtypes of nAChRs are found to be 
expressed on DAergic neurons, GABAergic neurons and glutamatergic neurons: 
DAergic neurons in the VTA project to the NAc and α4β2* , α6β2*, α7 subtypes 
are expressed in the soma and the presynaptic terminals; GABAergic neurons 
are interneurons in the VTA and α4β2* and α7 subtypes are expressed; 
glutamatergic input to the VTA is from the prefrontal cortex, synapsing on 
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DAergic neurons that express α7 nAChRs on the pre-synaptic terminals 
(Champtiaux, Gotti et al. 2003). When people smoke, nicotine from the tobacco 
rapidly crosses the blood brain barrier within 5 seconds and binds to the nAChRs 
in the DAergic neurons of VTA, which will induce the increase of burst firing and 
increase the dopamine release in the NAc (Dani and Bertrand 2007). Similar 
activation of these pathways in mice will cause the nicotine reward behaviors. 
Interestingly, when nicotine binds to the nAChR, the α4β2* nAChRs on the 
DAergic neurons will transit to the desensitized state rapidly (Dani and Bertrand 
2007), while the α7 nAChRs at the terminal of glutamate neurons will not 
significantly desensitize and will continue to increase the glutamatergic 
transmission onto the DAergic neurons (Mansvelder and McGehee 2000). 
Therefore, the net effect of decreased GABAergic transmission and increase 
glutamatergic transmission result in the overall excitation of the mesolimbic DA 
reward system (Mansvelder, Keath et al. 2002). 
nAChRs: Long term nicotine treatment regulate the expression of nAChRs 
Long term exposure of nicotine increase the density of nicotinic receptor binding 
sites in rodent and primates brains (Marks, Burch et al. 1983, Parker, Fu et al. 
2004, McCallum, Parameswaran et al. 2006, Hong, Jhou et al. 2011). Similarly, 
in human, the tobacco smoker brains showed increased nAChR density 
compared to non-smokers brains by  membrane binding studies, 
autoradiography studies and PET studies (Benwell, Balfour et al. 1988, Perry, 
29 
 
Davila-Garcia et al. 1999, Brody, Mandelkern et al. 2004, McClernon, Kozink et 
al. 2008, Mukhin, Kimes et al. 2008, Cosgrove 2010).   
More specifically, when mice were chronically treated with nicotine by continuous 
intravenous infusion of 4.0 mg/kg/hr for 10 d,  L-3H-nicotine binding in cortex and 
midbrain increased, but there was no change in cerebellum (Marks, Pauly et al. 
1992). Another study showed that chronic nicotine treatment (48 mg/kg/day 
administrated for 10 days by means of an osmotic minipump, MP) upregulates 
functional alpha 4* nAChRs in the cortex, midbrain and hypothalamus, but not in 
the thalamus or cerebellum (Nashmi, Xiao et al. 2007). Consistent with this study, 
by autoradiography, immunoprecipitation and western blotting studies, it has 
been shown that animals chronically treated with nicotine (6-48 mg/kg/day 
administrated for 14 days by means of an MP) increase in 3H-epibatidine binding, 
suggesting that there is an increase in the number of α4β2 receptors (Mugnaini, 
Tessari et al. 2002, Marks, Rowell et al. 2004, Perry, Mao et al. 2007, Mao, Perry 
et al. 2008, Gotti, Guiducci et al. 2010). Interestingly, in the presence of α5 
subunit, the α4β2 subtype did not up-regulated in vivo in rat hippocampus, 
striatum, cerebral cortex and thalamus (Mao, Perry et al. 2008, Gotti, Guiducci et 
al. 2010). In addition, the α3β4* subtype, which is highly expressed in the pineal 
gland, medial habenula, nucleus interpeduncularis and autonomic ganglia, 
seems to be resistant to up-regulation (Nguyen, Rasmussen et al. 2003).  
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It has been shown that α6* receptors play an important role in striatal dopamine 
release, locomotion and nicotine self-administration (Gotti, Clementi et al. 2009). 
Intravenous nicotine self-administration (approximately 1.5 mg free base/kg/day) 
increased α6* nAChRs expression in VTA/SN and nucleus accumbens (Parker, 
Fu et al. 2004). In contrast, chronic nicotine treatment by minipump (3–6 
mg/kg/day administrated for 14 days by means of an MP) or by drinking water 
(50–300 μg/ml for up to 6 weeks) decreases the number of α6* receptors in 
midbrain dopaminergic neurons (Mugnaini, Tessari et al. 2002, Lai, 
Parameswaran et al. 2005, Perry, Mao et al. 2007, Gotti, Guiducci et al. 2010).  
In contrast, α2, α3, α4, α5 or β2 mRNA levels in chronic nicotine (intravenous 
infusion of 4.0 mg/kg/hr for 10 d) treated mouse brain did not differ from control 
brains, suggesting that the increase of nAChR expression is due to post-
transcriptional mechanisms (Marks, Pauly et al. 1992). In another study, when 
mice were treated with chronic nicotine for 10 days (1.5 and 30.0 mg/kg/day), 
levels of alpha7 subunit mRNA were significantly elevated in SNpc, SNpr and 
VTA, but were unchanged in cortex and hippocampus (Ryan and Loiacono 2001). 
In conclusion, the regulation of nAChRs by long-term nicotine treatment in 
rodents may strongly depend on the dosage of nicotine, the method of nicotine 
delivery, the rodent strain and the brain region. Also, the change of mRNA level 
does not positively correlate with the change of protein level. 
nAChRs: The genetic modified nAChR mice model 
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Because of the huge nAChR diversity and the lack of subunit specific 
pharmacological tools, genetically modified nAChR mouse model can provide 
considerable insights into the basic neurobiological mechanisms of disease, such 
as addiction (Fowler and Kenny 2012). Genetically modified nAChR mice in 
combination with nAChR pharmacology are even more powerful. 
Conventional knockout mice 
Conventional knockout mice are made by introducing site-specific genetic 
deletion into the genome of mouse embryonic stem cells and the target gene will 
not be expressed throughout their entire lifespan in the whole body (Fowler and 
Kenny 2012). 
The first genetically modified nAChR mouse was made by deleting a region of 
DNA that encodes the β2 subunit gene, Chrnb2, termed “β2 knock-out” and 
abbreviated as β2 KO (Picciotto, Zoli et al. 1995). Importantly, these mice 
develop and breed normally and they were tested for many disease related 
behaviors (Picciotto, Zoli et al. 1995).  
Since 1995, knock-out nAChR mice has been made for the α7, α4, α3, β4, α5, α6, 
and β3 nAChR subunits (Orr-Urtreger, Goldner et al. 1997, Xu, Gelber et al. 1999, 
Ross, Wong et al. 2000, Champtiaux and Changeux 2002, Champtiaux, Han et 
al. 2002). 
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In this thesis, the α4 knock out mouse (α4 KO) will be used. In the homozygous 
α4 KO mouse, a 750 bp fragment from the fifth exon of the Chrna4 gene was 
removed, which contains DNA encoding the first hydrophobic transmembrane 
domain through the second cytoplasmic loop, therefore the mice do not express 
functional α4* nAChRs (Ross, Wong et al. 2000). Homozygous knockout mice 
are born in normally expected ratios, are capable of reproduction and have no 
physical abnormalities (Ross, Wong et al. 2000). Importantly, there is no 
significant difference in the expression of other nAChR subunits such as α3, α5, 
or α6, indicating that deletion of the α4 gene does not induce compensatory 
changes in other nAChR subunit mRNAs or proteins (Marubio, del Mar Arroyo-
Jimenez et al. 1999).  
Conventional knockin mice 
As opposed to knockout mice, knockin mice are made by expressing the protein 
product with altered function than the wildtype product from the endogenous 
locus. 
Another mouse model used in this thesis is the Leu9'Ala α4 knock-in mouse 
(L9'A). This mouse line contains a single point mutation from Leucine to Alanine 
at the 9' position of the transmembrane 2 pore-forming domain, causing these 
receptors to be 50-fold more sensitive to nicotine and endogenous acetylcholine 
(Tapper, McKinney et al. 2004). This hypersensitive mutation allows for selective 
activation of α4* nAChRs with low doses of nicotine that have no effect in WT 
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mice. For example, mice with this mutation developed nicotine-induced 
locomotor sensitization and nicotine conditioned place preferences at very low 
doses of nicotine that have no effect in WT mice (Tapper, McKinney et al. 2004).  
Other transgenic mice 
Other than the conventional knockout and knockin mice, several different 
genetically modified mice have been generated. For instance, transgenic mice 
can be created by injecting the bacterial artificial chromosome vector into a 
fertilized egg which carries large DNA inserts and will produce the transgene, 
such as the hypersensitive α6 nAChR mice (Leu9'Ser α6 nAChR) (Drenan, 
Nashmi et al. 2008). In conditional knockout mice, the target gene can be 
disrupted in a spatially and temporally controlled manner. Florescent knockin 
mouse with green fluorescent protein (GFP) -tag infused to different nAChR 
subunits are very useful to study the subunit expression pattern in the brain (Shih, 
Engle et al. 2014). These lines are very useful to study the role of nAChRs in 
disease and the expression pattern of the nAChRs. 
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Figure I-3. Structure of nAChRs.  
A. Coronal sections of the mice brain with [3H] nicotine binding, showing that the 
nAChRs are highly expressed in the MHb (upper) and IPN (lower). Figure 
modified with permission from (Marks, Burch et al. 1983) 
B. Schematic representation of an individual nAChR subunit. Each subunit 
consists of an extracellular amino (N) and carboxy (C) terminal, four 
transmembrane domains (M1-M4), and a large intracellular loop between M3 and 
M4 (upper). Five subunits co-assemble to form homomeric (middle) or 
heteromeric (lower) nAChR subtypes. White circles in the center of each 
pentamer represent the pore region. Diamonds represent ligand binding sites 
Figure modified with permission from (Improgo, Tapper et al. 2011). 
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nAChRs: The native subtypes in the IPN and MHb 
It has been shown that there is strongest [3H] nicotine binding in the mice MHb 
and IPN, which suggest that the nAChRs are highly expressed in the MHb-IPN 
tract (Marks, Smith et al. 1998). Then, several subunits are expressed in the 
MHb as shown by in situ hybridization (ISH) and single cell PCR, such as α3, α4, 
α5, α6, α7, β2, β3 and β4 subunit (Sheffield, Quick et al. 2000). 
Notably, the MHb-IPN tract highly expresses the unique CHRNA5-A3-B4 gene 
cluster which encodes α5, α3 and β4 subunits (Antolin-Fontes, Ables et al. 2014). 
It has been shown that variants of this gene cluster are associated with higher 
levels of nicotine consumption and dependence in human genetics studies 
(Berrettini, Yuan et al. 2008, Ware, van den Bree et al. 2011).  
Biochemical and immunoprecipitation studies have confirmed the heterogeneity 
of the nAChR subtypes expressed in the MHb-IPN tract. Basically, there are two 
major populations: β2* and β4* receptors. In the MHb, the β2* population mainly 
co-assemble with the α3 and α4 subunits, some of which also contain the 
accessory α5 or β3 subunits, whereas the β4* population mainly contains α3, α4 
and β3 (Grady, Moretti et al. 2009). In the IPN, the β2* nAChRs consist of three 
populations of approximately equal size: α2β2*, α3β2* and α4β2*, whereas the 
β4* population mainly contains α3, α4 and β3, which is very similar to the MHb 
(Grady, Moretti et al. 2009). 
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Even though the immunoprecipitation studies provide evidence of the native 
nAChR subtypes, their spatial resolution is not high enough to map the subregion 
expression pattern in the brain circuitry (Zoli, Pistillo et al. 2014). Recently, the 
knockin mouse strains expressing GFP tagged α3, α4, α6,  β2, β3, or β4 nAChR 
subunits have made it possible to determine the precise localization of the 
receptors (Fowler and Kenny 2012). 
For the study of α4 subunit expression pattern in MHb, two knock-in mice lines 
were used: one mouse line expresses fluorescently tagged α4* nAChRs (α4YFP 
(Nashmi, Xiao et al. 2007), and the other one is the hypersensitive α4* nAChRs 
mice line, as mentioned above, where there is a single point mutation at the 9' 
position of the TM2 domain from Leucine to Alanine α4L9'A, (Tapper, McKinney 
et al. 2004, Fonck, Cohen et al. 2005). Combining electrophysiological and 
genetic approaches in these two mice lines, it has been demonstrated that 
nAChRs containing α4 subunits are mainly localized in the ventrolateral MHb and 
they contribute to the selective activation of these neurons in the ventrolateral 
MHb (Fonck, Nashmi et al. 2009). This result is consistent with previous in situ 
hybridization study (Le Novere, Zoli et al. 1996).    
The high-resolution mapping of nAChR expression in the MHb-IPN pathway was 
extended by using many more GFP-tagged mice (Shih, Engle et al. 2014). It was 
shown that α3 and β4 nAChR subunits are highly expressed throughout the 
MHbV, which is consistent with the previous studies by western blot, in situ 
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hybridization and transgenic studies (Sheffield, Quick et al. 2000). In contrast, α6, 
β2, β3, and α4 subunits are selectively expressed in some, but not all, areas of 
MHbV and showed localization gradient across both MHb and IPN (Shih, Engle 
et al. 2014, Zoli, Pistillo et al. 2014). All subunits were found in both ChAT-
positive and ChAT-negative cells in MHbV (Shih, Engle et al. 2014). 
nAChRs: The function in the IPN and MHb 
Several evidence showed that the nAChRs in MHb-IPN pathway regulate 
nicotine intake, mediate nicotine aversive properties as well as nicotine 
withdrawal related behaviors (Antolin-Fontes, Ables et al. 2014).  
Withdrawal behaviors 
Adverse health consequence caused by smoking kills approximately 6 million 
people annually, making tobacco use a major health problem worldwide 
(Picciotto and Kenny 2013). Upon cessation of tobacco use, unpleasant 
withdrawal syndromes occur in tobacco dependent individuals, which often drives 
relapse (Benowitz 2008). 
Both humans and rodents with chronic nicotine consumption will show withdrawal 
symptoms if nicotine intake is suddenly stopped (spontaneous withdrawal) or a 
nicotinic antagonist, such as mecamylamine (non-specific nAChR antagonist), is 
administered (Antolin-Fontes, Ables et al. 2014). The nicotine withdrawal 
symptoms can be divided into affective and physical symptoms (Kenny and 
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Markou 2001). In humans, affective symptoms include anxiety, depressed mood, 
difficulty concentrating, disrupted cognition and nicotine craving; and physical 
symptoms include bradycardia, gastrointestinal discomfort and increased 
appetite accompanied by weight gain (Dani and De Biasi 2013). In rodents, 
physical signs (also called “somatic signs”) include increased scratching, rearing, 
jumping, head nods, and body shakes (Damaj, Kao et al. 2003, Grabus, Martin et 
al. 2005); whereas affective signs include anxiety-like behaviors and withdrawal-
induced conditioned place aversion (CPA) (Jackson, Martin et al. 2008). 
It has been shown that mecamylamine infusion into the habenula or the IPN, but 
not into the cortex, VTA or hippocampus, precipitated withdrawal symptoms in 
chronic nicotine treated mice, suggesting that the nAChRs in the MHb-IPN 
pathway are involved in nicotine withdrawal (Salas, Sturm et al. 2009). As the α2, 
α5, β2 and β4 subunits are highly expressed in the MHb-IPN tract, the authors 
then demonstrated that the α2, α5 and β4 subunits are necessary for the somatic 
manifestations of nicotine withdrawal by using the α2, α5 and β4 knockout mice 
(Jackson, Martin et al. 2008, Salas, Sturm et al. 2009). Interestingly, knockout β2 
subunit or blockade of α6 containing nAChRs by the selective antagonist (α-
conotoxin H9A) decreased anxiety-related behavior and blocked the withdrawal 
induced conditional place aversion but the somatic signs of nicotine withdrawal 
are unaltered (Jackson, Martin et al. 2008). 
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In agreement with these studies, our lab showed that chronic nicotine treatment 
upregulated gene expression of β3 and β4 nAChR subunits in somatostatin 
positive neurons in the IPN, and infusion of the β4 nAChR antagonist SR16584 in 
the IPN elicited somatic signs of nicotine withdrawal (Zhao-Shea, Liu et al. 2013).  
Taken together, these studies indicate that α2, α5 and β4 containing nAChRs in 
the MHb-IPN pathway contribute to the physical symptoms of nicotine withdrawal 
whereas α2, β2 and α6 contribute to the affective component of withdrawal 
(Antolin-Fontes, Ables et al. 2014).  
Nicotine intake and aversion 
Nicotine intake shows an inverted U-shaped dose effect curve, in which the 
ascending limb reflects an increase in reinforcing efficacy that is not readily 
satisfied, whereas the descending limb reflects satiation as well as aversive 
properties of high doses of nicotine (Morel, Fattore et al. 2014). 
It has been shown that the α5* nAChRs play an important role in regulating 
nicotine intake (Fowler, Lu et al. 2011). In detail, α5 knockout mice self-
administer significantly greater quantities of nicotine than their wild-type 
littermates, and this enhanced intake in the mutant mice was blocked by virus-
mediated re-expression of α5 nAChR subunits specifically in the MHb–IPN tract 
(Fowler, Lu et al. 2011). In addition, they found that the α5 KO mice diminished 
induction of c-Fos immunoreactivity in IPN in response to nicotine injections, 
suggesting that IPN neurons were relatively insensitive to nicotine in the mutant 
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mice (Fowler, Lu et al. 2011). Moreover, lidocaine-induced inactivation of the 
MHb and IPN or blockade of the NMDA receptor mediated transmission in the 
MHb-IPN pathway increased nicotine self-administration in rats (Fowler, Lu et al. 
2011).  
Consistent with these findings, overexpression of β4 nAChR subunits in the 
MHb–IPN tract reduced consumption of nicotine in mice and enhanced aversion 
to nicotine during the conditional place aversion procedure (Frahm, Slimak et al. 
2011). Moreover, virus-mediated expression of mutant α5 subunit gene (α5 
D398N variant, which decreases the function of α5-containing nAChRs), reduced 
aversion to nicotine and enhanced nicotine intake in the β4 subunit-
overexpressing mice (Frahm, Slimak et al. 2011). In addition, several SNPs have 
been found in the β4 subunit gene, which are related to the cigarette 
consumption in human (Liang, Salas et al. 2005). When these β4 variants are 
overexpressed in the mice MHb by virus-mediated gene expression system, the 
mice showed aversion or preference for nicotine depending on whether the 
variants increase or decrease nicotine currents (Slimak, Ables et al. 2014). 
Taken together, nAChRs in the MHb-IPN tract control the aversion of nicotine. 
High dose nicotine activates the MHb through α5 and/or β4-containing nAChRs 
and gives a negative motivational signal in turn blocking the nicotine intake. 
I.F. Nicotine, nAChR and anxiety 
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In both human and animal studies, it has been shown that nicotine has effects on 
anxiety and depression, but nicotine treatment can be either anxiolytic or 
anxiogenic depending on the regimen of administration (acute, different chronic 
regimens, withdrawal), the anxiety model tested (elevated plus maze, social 
interaction, light-dark box, mirrored chamber), the route of nicotine administration 
(i.p., s.c., i.v., smoked), the time course of administration as well as the 
behavioral state of the experimental subjects (relaxed, stressed, in nicotine 
withdrawal) (Picciotto, Brunzell et al. 2002).  
For example, in the social interaction test, acute, systemic nicotine can be either 
anxiolytic or anxiogenic in rats: low doses (0.01. and 0.1 mg/kg) were anxiolytic 
and high doses 0.5 and 1.0 mg/kg were anxiogenic (File, Kenny et al. 1998). At 
low dose, the effect was time dependent: at 5 min low-dose nicotine was 
anxiogenic, at 30 min it was anxiolytic, and at 60 min it produced a second 
anxiogenic response (File, Kenny et al. 1998). In contrast, in elevated plus maze 
test, systemic acute injection of nicotine (0.5 and 1 mg/kg, i.p. or 0.35 mg/kg i.c.) 
had anxiogenic effects in rats (Ouagazzal, Kenny et al. 1999, Olausson, Akesson 
et al. 2001). Similarly, nicotine elicits an anxiogenic response 7 min but not 30 
min after nicotine i.p. injection with doses of 0.25 and 0.5 mg/kg in mice (O'Neill 
and Brioni 1994, Zarrindast, Homayoun et al. 2000). Taken together, these 
studies suggest that low dose (0.01 mg/kg - 0.05 mg/kg) of acute nicotine 
administration has anxiolytic effect; whereas high dose (0.5 mg/kg) of acute 
nicotine administration has anxiogenic effect in mice (File, Kenny et al. 1998, 
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Ouagazzal, Kenny et al. 1999, Zarrindast, Homayoun et al. 2000, Cheeta, Tucci 
et al. 2001, McGranahan, Patzlaff et al. 2011, Varani, Moutinho et al. 2012).  
Interestingly, it has been shown that nicotine can both activate and desensitizes 
nAChRs at different concentration: at low concentration, nicotine desensitize 
nAChR (preferentially β2* nAChRs), which makes them unavailable to be further 
activated by nicotine (Lester and Dani 1995, Fenster, Rains et al. 1997, 
Pidoplichko, DeBiasi et al. 1997, Mansvelder, Keath et al. 2002, Buccafusco, 
Shuster et al. 2007). This evidence suggests that desensitizing nAChRs is 
anxiolytic whereas activating nAChRs is anxiogeneic. Recently, a study by 
Brunzell lab proved this idea. They showed that low-dose nicotine (0.05 mg/kg) 
pretreatment blocks high dose nicotine (0.5 mg/kg) induced anxiogenic effect in 
light–dark box assay and EPM assay, confirming that low dose of nicotine 
desensitized nAChRs in the brain and prevented them from further activation by 
high dose of nicotine treatment, in turn blocking its anxiogenic effect (Anderson 
and Brunzell 2015). 
In addition, it also has been shown that selective inhibition of β2* nAChRs by 
DhβE or low dose of 5I-A85380 (0.001 mg/kg) reduces anxiety in elevated plus 
maze test and marble burying test (Turner, Castellano et al. 2010, Anderson and 
Brunzell 2012, Anderson and Brunzell 2015).This evidence suggests that high 
doses of nicotine may induce anxiogenic effect via high-affinity β2*nAChRs. This 
idea was proved by Brunzell lab by showing that genetic disruption of β2 nAChR 
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or pharmacological block of β2 by DHβE blocked anxiogenic-like effects of 
0.5 mg/kg nicotine (Anderson and Brunzell 2015). 
The studies in the genetically modified mice also showed that nAChRs are 
involved in anxiety. For α4* nAChRs, knockout mice lacking the α4 subunit and 
the hypersensitive L9'A α4 mice showed increased anxiety in the elevated plus 
maze and the mirrored chamber (Ross, Wong et al. 2000, Labarca, Schwarz et al. 
2001, Picciotto, Brunzell et al. 2002). For α5* nAChRs, only female α5KO mice, 
but not the male mice, displayed anxiolytic-like phenotype in the elevated plus 
maze, not in the open field activity and light-dark box (Gangitano, Salas et al. 
2009). For α7* nAChRs, knockout mice lacking the α7 subunit showed lower 
level of anxiety than wild type mice in the open field test, but not in the light-dark 
box (Paylor, Nguyen et al. 1998). For β2* nAChRs, knockout mice lacking the β2 
subunit did not show difference in the anxiety level compared to wild type mice in 
the elevated plus maze, light dark exploration test and mirriored chamber test 
(Picciotto, Zoli et al. 1997). 
In conclusion, the large variety of nAChRs expressed in all the brain regions is 
critical in modulating anxiety, and defining the site specific roles of individual 
receptor subtypes could be useful in drug development to cure the anxiety 
disorder. 
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CHAPTER II 
Medial habenula cholinergic neurons are involved in anxiety 
 
 
Contributions: 
Jennifer Ngolab made the virus construct. Liwang Liu did the electrophysiological 
recordings. All other research was done by me. Dr. Andrew Tapper wrote part of 
the body of the text, while I made the Figures, Materials and Methods and 
provided feedback on the other sections. 
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II.A. Introduction 
Up to 40 million patients suffer from anxiety disorders in the United States alone 
highlighting the need for identification of the underlying neuroanatomical bases 
and molecular underpinnings of anxiety (Kessler, Chiu et al. 2005).   
Multiple brain regions are involved in the anxiety disorders, such as Amygdala, 
BNST, PFC, hippocampus, etc (Adhikari 2014). Recently, the role of Hb-IPN tract 
in anxiety has attracted much attention.  
The habenula (Hb) is a small, epithalamic structure, which can be divided into 
medial (MHb) and lateral (LHb) sub-regions (Hikosaka 2010).  The Hb projects to 
its target brain regions through a conspicuous bundle of axons that form the 
fasciculus retroflexus (fr).   
The LHb receives the input mainly from the basal ganglia and send output to the 
rostromedial tegmental nucleus that is involved in the modulation of dopamine 
(DA) release from the substantia nigra pars compacta and ventral tegmental area 
(VTA) (Kaufling, Veinante et al. 2009, Balcita-Pedicino, Omelchenko et al. 2011, 
Hong, Jhou et al. 2011, Lecca, Melis et al. 2011).  Activation of the LHb signals 
aversion (Hong, Jhou et al. 2011).  
On the other hand, the MHb receives the major inputs via a white matter bundle, 
the stria medullaris (Herkenham and Nauta 1977, Qin and Luo 2009). The 
triangular septal nucleus (TSN) and septofimbrial nucleus (SFi) release 
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glutamate and ATP to the MHb (Herkenham and Nauta 1977, Qin and Luo 2009), 
whereas Nucleus of Diagonal band (NDB) and the medial septum (MS) send 
GABAergic input to the MHb (Qin and Luo 2009). In addition, MHb also has the 
highest expression of nicotinic acetylcholine receptors (nAChRs) (Marks, Smith 
et al. 1998), but where the cholinergic input comes from is still unclear.  
The MHb mainly projects to IPN via another white matter bundle, the fasciculus 
retroflexus. The dorsal MHb innervate the lateral IPN and release Substance P, 
while the cholinergic neurons in the ventral MHb innervate the ventral IPN 
(Contestabile, Villani et al. 1987) and release ACh and Glu at different 
transmission modes (Herkenham and Nauta 1979, Contestabile and Flumerfelt 
1981, Ren, Qin et al. 2011). This highly restricted neurotransmitter expression 
and projection pattern suggest that the subnuclei might have specific functions. 
Human imaging studies and the rodent pharmacological studies have shown that 
MHb is involved in anxiety (Thornton and Bradbury 1989, Morris, Smith et al. 
1999, Amat, Sparks et al. 2001, Ullsperger and von Cramon 2003). Interestingly, 
selective ablation of septal glutamatergic ventral MHb afferents reduces anxiety-
like behavior in mice, while selective ablation the bed nucleus of the anterior 
commissure (BAC) dorsal MHb afferents enhanced fear responses, suggesting a 
role for the different subregion of MHb in controlling anxiety and fear (Yamaguchi, 
Danjo et al. 2013).  However, how the ventral cholinergic neurons controls 
anxiety is still unclear. 
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Optogenetics, which combines genetics and optics, can control the specific 
neuronal activity (Fenno, Yizhar et al. 2011). Channelrhodopsin (ChR) is a light-
activated cation channel which can induce action potentials and “turn the 
neurons on” when stimulated with blue light (Fenno, Yizhar et al. 2011). In 
contrast, halorhodopsin (NpHR) is a light-gated chloride pump, which can induce 
hyperpolarization to turn neurons off when stimulated with yellow light (Fenno, 
Yizhar et al. 2011). Here, in this chapter, we will use NpHR or ChR2 to silence or 
activate the cholinergic neurons, respectively, and test the hypothesis that the 
cholinergic neurons in the MHb control anxiety via the nAChRs. 
II.B. Materials and methods 
Mice 
C57BL/6J and ChAT-Cre mice were used in experiments as indicated. As 
described above, ChAT-Cre knock-in mice, were purchased from Jackson 
Laboratories (stock number: 006410) and bred in the UMMS animal facility. For 
ChAT-Cre mice, genotypes were determined by PCR as previously described 
(Rossi, Balthasar et al. 2011) and also on Jackson Laboratories website. PCR of 
mouse tail genomic DNA was performed with three specific primers, WT F (5′-
GTT TGC AGA AGC GGT GGG-3′), mutant F (5′-CCT TCT ATC GCC TTC 
TTG ACG -3′) and Common R (5′-AGA TAG ATA ATG AGA GGC TC -3′). 
These primers amplify DNA fragments of 272 bp in wild-type (WT) mice, and 350 
bp in ChAT-Cre mutant mice. DNA fragments were separated by agarose gel 
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electrophoresis and visualized with ethidium bromide. Breeding was conducted 
by mating heterozygous pairs. Mice were group-housed four mice/cage on a 12-h 
light dark cycle with lights on at 7:00 a.m. and off at 7:00 p.m, and given food and 
water ad libitum. Male mice were used for all experiments. Mice were at least 8 
weeks old at the start of each experiment. Behavioral experiments were 
performed during the light phase of the light-dark cycle.  
Independent groups of animals were used for each behavioral experiment unless 
otherwise noted. All experiments were conducted in accordance with the 
guidelines for care and use of laboratory animals provided by the National 
Research Council, as well as with an approved animal protocol from the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School. 
Surgical procedures for virus microinjection 
Packaging of AAV-Ef1A-DIO-ChR2-eYFP, AAV-Ef1A-DIO-NpHR-eYFP and 
AAV-eGFP plasmids into AAV2 viral particles was done by the University of 
Massachusetts Medical School Viral Vector Core. For viral particle injection, 
ChAT-Cre mice were anesthetized with a mixture of ketamine (100 mg/kg) and 
xylazine (10 mg/kg) (VEDCO). The surgical area was shaved and disinfected. 
Mice were placed in a stereotaxic frame (Stoelting Co.) with mouse adaptor and 
a small incision was cut in the scalp to expose the skull. Using bregma and 
lambda as landmarks, the skull was leveled in the coronal and sagittal planes. 
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The viral particles (1x1012 viral particles/μl) were injected into the ChAT-Cre mice 
MHb according to the coordinates: AP, -1.94, ML, 0.2, DV, -2.25. The viral 
particles (1.5 μl/side) were injected bilaterally at a flow rate of 0.3 μl/min. The 
injection needle was kept in place for 5 min post-injection. The incision was 
sutured and mice were returned to their home cages. 
Optic fiber placement and the optic stimulation  
Infected ChAT-Cre mice with optic fiber implants were gently connected to a 
patch cable using a mating sleeve (Doric Lenses). The optic fiber was attached 
through an FC/patch cable adaptor to a fiber-coupled LED light source. Yellow 
light pulses (593 nm) or blue light pulse (470 nm) were generated through an 
LED driver. 
To activate the neurons by ChR2, low frequency stimulation (5 Hz trains of blue 
light pulses 20 s on, 10 s off, 300 mA current) was delivered over the course of 
20 min in the marble burying test (MBT) and 5 min in the elevated plus maze 
(EPM). In the high frequency stimulation, 50 Hz trains of blue light pulses (20 s 
on, 10 s off, 300 mA current) were delivered over the 10 min of locomotor test. 
To silence the neurons by NpHR, constant light (593 nm) stimulation (20 s on, 10 
s off) was delivered over the course of 20 min in the marble burying test (MBT) 
and 5 min in the elevated plus maze (EPM).  
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After recording, the optic cannula was disconnected from the LED patch cable. 
Mice were euthanized and the brains were harvested for analysis of virus 
injections and fiber implantations. 
Electrophysiology 
For the electrophysiological recording, ChAT-Cre mice were infected with the 
virus when the mice were 3 weeks old. Four weeks later, brains were quickly 
removed and placed in oxygenated ice-cold high sucrose artificial cerebrospinal 
fluid (SACSF) containing kynurenic acid (1 mM, Sigma, St. Louis, MO). SACSF 
solution contained (in mM): 250 sucrose, 2.5 KCl, 1.2 NaH2PO4•H2O, 1.2 
MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose. Coronal brain slices 
containing IPN brain regions (~180 μm) were made using a Leica VT1200 
vibratome. Spontaneous EPSCs were obtained in the whole-cell configuration 
and gap free acquisition mode in Clampex (Axon Instruments). Neurons were 
held at a resting membrane potential of -70 mV. For optical recordings, 
eYFP/eGFP-positive neurons were identified under fluorescence microcopy. In 
the ChR2 expressing neurons, 30 sec trains of blue light were applied to neurons 
under current clamp. In the NpHR expressing neurons, constant yellow light was 
applied to neurons under current clamp. All recordings were filtered at 1 kHz 
using the amplifier's four-pole, low-pass Bessel filter, digitized at 10 kHz with an 
Axon Digidata 1440A interface and stored on a personal computer. ACSF was 
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used for bath solution and contained (in mM): 125 NaCl, 2.5 KCl, 1.2 
NaH2PO4•H2O, 1.2 MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose.  
Marble burying test (MBT) 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), mice were 
habituated in the standard mouse cage with ~5 - 6 cm layer of bedding for 2 days 
(45 min/day) before the test. On the test day, 15 clean 1.5 cm glass marbles 
were evenly spaced in five rows of three, each 4 cm apart on the thick of bedding. 
A mouse was placed in its test cage and left for 30 minutes, and the number of 
marbles buried (to 2/3 their depth) with bedding was counted every 5 min or after 
30 min (as noted in the figures), then mice were removed from their test cages. 
Elevated plus maze (EPM) 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the 
experimental apparatus consisted of a central axis and four arms elevated 45 cm 
above the floor, with each arm positioned at 90° relative to the adjacent arms. 
One red fluorescent light arranged at 100 cm above the maze was used as the 
source of illumination. The mice were individually placed in the center of the 
maze with their heads facing one of the open arms and allowed 5 min of free 
exploration. The number of entries into the open and closed arms, and the total 
time spent in the open and closed arms were measured by MED-PC IV software 
(MED Associates, Inc.). The time spent in open and closed arms was calculated 
as standard anxiety indices. The total number of arm entries was considered as 
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an index of locomotor activity. The apparatus was cleaned thoroughly between 
trials. Trials in which mice froze in the initial arm without moving were not 
included in the analysis.  
Guide cannula placement 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the guide 
cannulas were surgically implanted at least 3 days prior to the experiment. Mice 
were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 
mg/kg) (VEDCO) and placed on a stereotaxic frame (Stoelting Co.). The surgical 
area was shaved and disinfected and the skull was exposed. Using bregma and 
lambda as landmarks, the skull was leveled in the coronal and sagittal planes.  A 
hole was drilled and stainless steel guide cannulas were inserted into the brain 
and secured to the skull with instant adhesive. The coordinates relative to 
bregma were: MHb (AP, -1.94, ML, ±0.2, DV, -2.25) or IPN (AP, -3.4, DV, -4.75). 
The scalp incision was stitched and dental cement was used to stabilize the 
cannula on the skull. After surgery, the mice were kept on a heating pad to 
prevent hypothermia. Mice were allowed to recover in individual cages for at 
least 3 days prior to drug infusion and behavioral testing.  
Intra-MHb and intra-IPN infusions 
Mice were anesthetized with 2% isoflurane via a nose cone adaptor at a flow rate 
of 800 ml/L. Once anesthetized, an infusion cannula designed to reach −0.25 mm 
below the guide cannula was inserted into the guide cannula.  
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Mecamylamine is a nonselective antagonist of nAChR and we use a relatively 
low dose according to the literature (Levin, Briggs et al. 1994, Kim and Levin 
1996, Wickham, Solecki et al. 2013) 
Vehicle (ACSF), mecamylamine (2 μg/μl, 1μl) or AP-5 (1 μg/μl, 1μl) was infused 
at a rate of 1 μl/min. After infusion, the infusion cannula was left in place for 2 
minutes prior to retraction. Mice were placed back into their home cages and the 
behavior tests were conducted after the mice were totally awake. After 
completion of behavioral experiments, mice were culled, brains isolated, and 
cannula placement verified. To verify the guide cannula placement, the brains 
were cut in 30 µm sections and the location of the guide cannula was determined 
by neutral red staining using light microscopy. In addition, the injection sites were 
double verified histologically by microinjection of DiI cell labeling solution 
(Invitrogen). Only mice with cannulas in the right placement were included in the 
statistical analysis. 
Data analysis 
Data were analyzed using One- or Two-way ANOVA followed by Bonferroni post 
hoc tests or t-tests as indicated. Results were considered significant at p < 0.05. 
All data are expressed as mean ± S.E.M. 
II.C. Results 
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nAChR activity in the MHb but not the IPN regulates anxiety-like behavior in 
mice 
Cholinergic neurons of the MHb robustly express nAChRs (Grady, Moretti et al. 
2009). To test the hypothesis that MHb nAChRs regulate anxiety-like behavior 
we selectively infused saline or the non-specific nAChR antagonist, 
mecamylamine (2 μg) into the MHb through guide cannulas targeting this brain 
region in adult C57Bl/6J mice (Fig. II-1). Following infusions, mice were tested in 
two assays of anxiety-like behavior, the elevated plus maze (EPM) and marble 
burying test (MBT). After behavioral tests, guide cannula placement and drug 
infusions were verified as described (See Methods and Fig. II-3). Infusion of 
mecamylamine into the MHb significantly increased the time spent on the EPM 
open arms compared to a saline infusion (t17=2.94, p < 0.01, Fig. II-1C). Mice 
receiving mecamylamine infusions did not differ in total open arm entries 
compared to saline-infused animals, indicating that differences in open arm time 
did not simply reflect an effect of the drug on general locomotor activity (Fig. II-
1E). In the MBT test, infusion of mecamylamine decreased the number of 
marbles buried compared to a saline infusion (t27=3.74, p< 0.001, Fig. II-1G).  
While blockade of nAChRs at the level of dendrites and soma may directly 
regulate MHb neuronal excitability, nAChRs are also expressed in presynaptic 
terminals where they facilitate neurotransmitter release (Grady, Moretti et al. 
2009). To test the hypothesis that terminal MHb nAChRs regulate anxiety-like 
behavior, we also infused mecamylamine (2 μg) and saline in the IPN, the output 
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region of MHb projections. Infusion of mecamylamine did not significantly affect 
performance on the EPM or MBT compared to saline IPN infusion (Fig. II-1D, 1F, 
1H). Interestingly, cholinergic MHb neurons have recently been found to 
synthesize and release glutamate into the IPN (Qin and Luo 2009). To test the 
hypothesis that glutamatergic signaling in the IPN modulates anxiety-like 
behavior, we infused saline or the NMDA receptor antagonist, AP-5 (1 μg) into 
the IPN prior to the EPM and MBT assays (Fig. II-2). Mice that received AP-5 
IPN infusions in the EPM test spent significantly less time in the open arms 
compared to mice receiving a saline infusion (t9=2.46, Fig. II-2A, top), whereas 
total arm entries did not differ between groups (Fig. II-2A, bottom). Similarly, AP-
5-infused animals buried more marbles compared to saline-infused animals in 
the MBT assay (t9=3.59, Fig. II-2B). Together, these data indicate that nAChRs in 
dendrites/soma, but not presynaptic terminals, of MHb neurons inherently 
modulate anxiety-like behaviors. Furthermore, glutamatergic signaling in the IPN 
modulates anxiety-like behavior; whereas signaling via IPN nAChRs does not. 
Silencing of MHb cholinergic neurons decreases anxiety-like behaviors 
To test the hypothesis that MHb cholinergic neurotransmission is involved in 
anxiety-like behavior, we selectively expressed halorhodopsin in MHb cholinergic 
neurons to silence neurotransmission in the IPN of mice while measuring 
anxiety-like behavior by the EPM and MBT. Halorhodopsin (version 3.0) with an 
eYFP tag (eNpHR-eYFP) was expressed in the MHb of ChAT-Cre mice, in which 
56 
 
Cre is under the control of the ChAT promoter, using AAV2-mediated gene 
delivery of a plasmid containing eNpHR-eYFP in a double-inverted open reading 
frame (Fig. II-4A) (Gradinaru, Thompson et al. 2008). Four weeks post-infection, 
strong eYFP signal was observed in ChAT-expressing neurons and terminals 
innervating the IPN, indicating proper localization to cholinergic MHb neurons 
(Fig. II-4B, top). Light stimulation of current-clamped eNpHR-eYFP-positive 
neurons in MHb slices from eNpHR-eYFP-infected ChAT-Cre mice dramatically 
silenced action potential firing (Fig. II-4B, bottom). These data confirmed that 
eNpHR-eYFP was expressed and functional in cholinergic neurons of the MHb.  
To test the hypothesis that neurotransmission from cholinergic MHb inputs to the 
IPN modulated anxiety-like behavior, ChAT-Cre mice were infected with AAV2-
eNpHR-eYFP or control virus (AAV2-eGFP) with subsequent implantation of 
optic cannulas targeting the MHb terminal inputs to the IPN (Fig. II-4C). Light 
stimulation (593 nm) was applied through the optic fiber cannula for the entirety 
of the MBT and EPM assays (20 s light on, 10 s light off for 25 min, Fig. II-4D). 
Mice expressing halorhodopsin and receiving light stimulation spent significantly 
more time in the open arms of the EPM compared to control mice receiving light 
stimulation (t10 = 2.79, p = 0.019, Fig. II-4E, left). Importantly, total arm entries 
between groups did not differ, indicating that silencing of MHb cholinergic inputs 
did not affect locomotor activity (Fig. II-4E, right). In the MBT, at the end of the 
assay there was a significant decrease in the cumulative number of marbles 
buried in light-stimulated halorhodopsin-expressing ChAT-Cre mice compared to 
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light-stimulated control virus-expressing ChAT-Cre mice (Fig. II-4F, inset, 
t17=3.826, p < 0.01).  
To test the hypothesis that activation of MHb cholinergic neurons is sufficient to 
increase the anxiety-like behavior, we selectively expressed channelrhodopsin 
with an eYFP tag (ChR2-eYFP) in the MHb of ChAT-Cre mice using the same 
strategy as describe above (Fig. II-5A) (Fenno, Yizhar et al. 2011). Four to six 
weeks post-infection, significant eYFP signal was observed in MHb ChAT-
expressing neurons and terminals innervating the IPN, indicating proper 
localization to cholinergic neurons (Fig. II-5B, top). Light stimulation of ChR2-
eYFP-positive neurons in MHb slices from ChR2-eYFP-infected ChAT-Cre mice 
elicited robust trains of action potentials (Fig. II-5B, bottom). In contrast, neurons 
from mice with control virus infection did not respond to light (data not shown). 
These data confirmed that ChR2-eYFP was expressed and functional within the 
MHb. 
To activate MHb cholinergic neurons in vivo, ChAT-Cre mice were infected with 
AAV2-ChR2-eYFP or control (AAV2-eGFP) virus and optic cannulas were 
implanted targeting the IPN in mice 4–6 weeks post-infection (Fig. II-5C). Blue 
light (via 473 nM LED) was delivered to the IPN in vivo through the optic fiber 
during the entirety of the MBT and EPM assays (5Hz, 20 s light on, 10 s light off 
for 25 min) (Fig. II-5D). The time spent in the open arms and the total arm entries 
of the EPM did not differ between the mice expressing ChR2 receiving light 
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stimulation and control mice receiving light stimulation (Fig. II-5E). In the MBT, at 
the end of the assay there was a significant increase in the cumulative number of 
marbles buried in light-stimulated ChR2-expressing ChAT-Cre mice compared to 
light-stimulated control virus-expressing ChAT-Cre mice (Fig. II-5F, inset, 
t16=2.245, p < 0.05).  
Together, these data indicate that MHb cholinergic neuron inputs to the IPN 
modulate anxiety-like behavior. 
Activation of MHb cholinergic neurons induced hypolocomotion 
As the cholinergic neurons in the MHb release Glu with low frequency (10 Hz) 
stimulation and ACh at high frequency (50 Hz) stimulation (Ren, Qin et al. 2011), 
here we test the hypothesis that high stimulation-induced ACh release will cause 
the aversive-like behavior. 4-6 weeks after ChAT-Cre mice were infected with 
AAV2-ChR2-eYFP or control (AAV2-eGFP) virus, the novel cage locomotor 
activity was measured for 5 min without the light stimulation, and there was no 
difference between the groups (Fig. II-6A.B.C). When the blue light was turned 
on for the next 10 min, the ChR2-expressing mice showed hypolocomotion 
compared to the control mice (t20=3.974, p<0.001, Fig. II-6C), and the 
hypolocomotion gradually recovered to the same as control mice after the blue 
light was turned off (Fig. II-6A.B.C). These data indicate that ACh release from 
the MHb to the IPN induced hypolocomotion.  
II.D. Discussion 
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Previous work indirectly demonstrated a role for the MHb in anxiety regulation, 
either through lesioning of the habenula itself or through selective ablation of 
presumed septal glutamatergic inputs into the MHb (Yamaguchi, Danjo et al. 
2013). Interestingly, a recent study indicated that cholinergic MHb neurons 
synthesize and co-release the neurotransmitter glutamate, in addition to ACh 
(Ren, Qin et al. 2011). Our data indicate that nAChRs expressed at the level of 
the soma/dendrites of these neurons likely regulate neuronal activity and anxiety, 
because mecamylamine infusion into the MHb reduced anxiety-like behaviors, 
whereas blockade of MHb presynaptic nAChRs in the IPN or IPN nAChRs 
themselves did not affect anxiety-like behavior. In contrast, blockade of NMDA 
receptors in the IPN decreased anxiety-like behavior. These data indicate that 
glutamate release, but not ACh release, from dual cholinergic/glutamatergic MHb 
neurons regulates anxiety-like behavior. 
Furthermore, here we showed that MHb cholinergic neurons, which are clustered 
in the ventral portion of the MHb, regulate anxiety-like behavior directly using 
optogenetics. Silencing MHb cholinergic neuronal inputs to the IPN reduced 
anxiety-like behaviors in both the EPM and MBT assays. On the other hand, 
activating MHb cholinergic neuronal input to the IPN at the low frequency (5 Hz) 
has a trend to increase anxiety-like behavior in the MBT.   
While optogenetics provide an important tool to precisely define the relationship 
between neuronal activity and behavior in a given circuit, the endogenous 
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mechanisms that may regulate this activity still need to be studied. In addition, 
the expression of our control eGFP virus used in this study is not Cre-dependent, 
therefore, eGFP could express not only in cholinergic neurons but also in other 
neurons within the targeted region. This nonspecific expression of eGFP could 
possible influence the results. For future studies, Cre-dependent AAV-EGFP 
should be used. 
In addition, the mice showed hypolocomotion when we activating MHb 
cholinergic neuronal input to the IPN at the high frequency (50 Hz). These data 
suggest that the high frequency stimulation induced ACh release from MHb to 
IPN. As IPN talks to VTA and Substantial Nigra (Lammel, Lim et al. 2014, Zhao-
Shea, DeGroot et al. 2015), the release of ACh to IPN might indirectly influence 
the dopamine release from dopaminergic area into striatum, in turn reducing the 
locomotion in mice. In addition, we conclude that the low frequency induced 
glutamate release and high frequency induced ACh release from the MHb to the 
IPN might mediate different behavior in mice.   
Together, our data indicate that MHb cholinergic neuron activity regulates 
anxiety-like behaviors. In addition, nAChR signaling in MHb cholinergic neurons 
are involved in the anxiety-like behavior. Thus, nicotinic acetylcholine 
autoreceptors in MHb cholinergic neurons should be considered molecular 
targets for novel anxiolytic therapeutics. 
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Figure II-1. nAChR activity in the MHb but not the IPN regulates anxiety-like 
behavior in mice.   
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Mecamylamine (Mec) or vehicle (Veh) was infused into the MHb (A, C, E, G) or 
IPN (B, D, F, H) prior to testing in the EPM and MBT assays.  Infusion of Mec (2 
μg) in the MHb increased time spent in the open arms of the EPM compared to 
Veh (C), while not affecting total arm entries (E).  In the MBT, Mec infusion 
decreased the number of marbles buried (G).  Infusion of Mec into the IPN did 
not significantly influence time spent in the open arms (D) or total arm entries (F) 
in the EPM, nor did it affect number of marbles buried in the MBT compared to 
Veh infusion (H).  Data are expressed as average values ± S.E.M.  *** p < 0.001, 
Student‟s t-test. 
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Figure II-2. Blockade of NMDA receptors in the IPN reduces anxiety-like behavior 
in C57BL/6J mice.   
AP-5 (1 μg) or Saline was infused into the IPN prior to testing in the EPM and 
MBT assays.  Infusion of AP-5 in the IPN increased time spent in the open arms 
of the EPM compared to Saline (A, top) while not affecting total arm entries (A, 
bottom).  In the MBT, AP-5 infusion decreased number of marbles buried at 
different time points (B) and the end of the assay (B, inset).  Data are expressed 
as average values ± S.E.M.  * p < 0.05. Student‟s t-test is used to analyze the 
inset. 
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Figure II-3. Verification of cannula placement and drug infusions.  
Depiction of a representative coronal section from MHb (A, left) and IPN (B, left).  
Red “x‟s” indicate location of guide cannula tracks as identified by neutral red 
staining. Note that infusion cannula project 0.25 mm past guide cannulas.  A 
representative image of dye infusion post-behavior experiments for double 
verification of infusion location is also shown (A, B, right).  
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Figure II-4. Silencing of MHb cholinergic neurons decreases anxiety-like 
behaviors. 
A. Schematic diagram of the double-floxed Cre-dependent AAV vector 
expressing NpHR-YFP cDNA under the control of an Ef-1α promoter. Expression 
of Cre induces recombination and causes the cDNA insert to flip into the sense 
orientation.  
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B. Representative micrographs showing NpHR expression in the MHb and IPN 
(top). Representative whole-cell current clamp recording from an AAV-NpHR-
infected neuron in the MHb exposed to 593 nm yellow light (yellow bar)(bottom).  
C and D. Schematic diagram of the experimental strategy and neurotransmission 
silencing protocol.  
E. Average time spent in the open-arm (left), and total-arm entries (right) in the 
EPM during light stimulation in ChAT-Cre mice infected with control virus or 
AAV2-NpHR-eYFP. F. The average number of marbles buried in the MBT in 
control or AAV2-NpHR-eYFP-infected ChAT-Cre mice at baseline prior to light 
stimulation and during light stimulation is shown. Inset, averaged marbles buried 
at t=20 min. * p < 0.05, **p < 0.001, ***p < 0.001. Student‟s t-test is used to 
analyze the inset. 
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Figure II-5.  Activating of MHb cholinergic neurons has tendency to change 
anxiety-like behaviors. 
A. Schematic diagram of the double-floxed Cre-dependent AAV vector 
expressing ChR2-YFP cDNA under the control of an Ef-1α promoter. Expression 
of Cre induces recombination and causes the cDNA insert to flip into the sense 
orientation.  
B. Representative micrographs showing ChR2 expression in the MHb and IPN 
(top). Representative whole-cell current clamp recording from an AAV-ChR2-
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infected neuron in the MHb exposed to 473 nm blue light (blue dots, 20 Hz) 
(bottom).  
C and D. Schematic diagram of the experimental strategy and neurotransmission 
stimulating protocol.  
E. Average time spent in the open-arm (left), and total-arm entries (right) in the 
EPM during light stimulation in ChAT-Cre mice infected with control virus or 
AAV2-ChR2-eYFP.  
F. The average number of marbles buried in the MBT in control or AAV2-ChR2-
eYFP-infected ChAT-Cre mice at baseline prior to light stimulation and during 
light stimulation is shown. Inset, averaged marbles buried at t=20 min.  * p < 0.05, 
**p < 0.001, ***p < 0.001. Student‟s t-test is used to analyze the inset. 
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Figure II-6.  Activation of MHb cholinergic neurons induced hypolocomotion. 
A. Schematic diagram of the experimental stimulating protocol.  
B. Average ambulation during light stimulation in ChAT-Cre mice infected with 
control virus or AAV2-ChR2-eYFP.  
C. The average total ambulation in the light-on or light-off period in control or 
AAV2-ChR2-eYFP-infected ChAT-Cre mice.* p < 0.05, **p < 0.001, ***p < 0.001. 
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Chapter III 
nAChRs in the MHb cholinergic neurons are critical for anxiety 
 
Contributions: 
Jennifer Ngolab made the virus construct. Liwang Liu did the electrophysiological 
recordings. Rubing Zhao-Shea did the qRT-PCR. All other research was done by 
me. Dr. Andrew Tapper wrote part of the body of the text, while I made the 
Figures, Materials and Methods and provided feedback on the other sections. 
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III.A. Introduction 
Anxiety disorders are the most common mental illnesses in the United States, 
affecting 40 million adults in the United States alone, clearly highlighting the need 
for identification of the underlying neuroanatomical bases and molecular 
underpinnings of anxiety (Kessler, Chiu et al. 2005). Recently, the habenulo-
interpeduncular pathway has been hypothesized to modulate anxiety 
(Yamaguchi, Danjo et al. 2013). MHb projects to its primary target brain region, 
IPN, through a conspicuous bundle of axons called the fasciculus retroflexus (fr) , 
and the IPN in turn projects to the median and dorsal raphe nuclei, as well as 
other brain regions (Morley 1986). Selective ablation of septal glutamatergic MHb 
afferents reduces anxiety-like behavior in mice, suggesting a role for the MHb in 
controlling anxiety (Yamaguchi, Danjo et al. 2013).   
nAChRs are ligand-gated ion-channels that are activated by the endogenous 
neurotransmitter, ACh (Improgo, Scofield et al. 2010).  Twelve mammalian genes 
encoding neuronal nAChR subunits have been identified (α2-α10, β2-β4) and five 
subunits coassemble to form either homomeric (like α7) or heteromeric (like α4β2) 
receptors (Dani and Bertrand 2007). Cholinergic signaling through nAChRs has 
been shown to be involved in anxiety (Picciotto, Brunzell et al. 2002), for instance 
the mice lacking the α4 subunit showed increased anxiety in the elevated plus-
maze assay (Ross, Wong et al. 2000). 
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It has been shown that nicotinic AChRs are highly expressed in the MHb-IPN 
tract (Marks, Smith et al. 1998). Cholinergic neurons within the MHb robustly 
express almost all the nAChR subunits (such as α3, α4, α5, α6, α7, β2, β3 and 
β4 subunit). Interestingly, cholinergic neurons within the MHb robustly express 
rare neuronal nAChR subtypes containing the α3 and β4 subunits, as well as the 
α4 subunit among others (Fonck, Nashmi et al. 2009, Salas, Sturm et al. 2009, 
Fowler, Lu et al. 2011). However, whether cholinergic signaling via nAChRs 
specifically in MHb cholinergic neurons modulates anxiety state is unknown. 
Thus, we focused on testing the hypothesis that activation of MHb cholinergic 
neurons via nAChR signaling modulates anxiety. 
III.B. Materials and methods 
Mice 
C57BL/6J, α4 L9'A, α4 KO, and ChAT-Cre mice were used in experiments as 
indicated. ChAT-Cre knock-in mice, were purchased from Jackson Laboratories 
(stock number: 006410) and bred in the UMMS animal facility. Breeding was 
conducted by mating heterozygous pairs. For ChAT-Cre mice, genotypes were 
determined by PCR as previously described (Rossi, Balthasar et al. 2011) and 
also on Jackson Laboratories website. PCR of mouse tail genomic DNA was 
performed with three specific primers, WT F (5′-GTT TGC AGA AGC GGT 
GGG-3′ ), mutant F (5′ -CCT TCT ATC GCC TTC TTG ACG -3′ ) and 
Common R (5′ -AGA TAG ATA ATG AGA GGC TC -3′ ). These primers 
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amplify DNA fragments of 272 bp in wild-type (WT) mice, and 350 bp in ChAT-
Cre mutant mice. DNA fragments were separated by agarose gel electrophoresis 
and visualized with ethidium bromide. L9'A mice and α4 KO mice on a C57BL/6J 
background have been described previously (Ross, Wong et al. 2000, Tapper, 
McKinney et al. 2004). Mice were group-housed four mice/cage on a 12-h light-
12 h dark lighting cycle with lights on at 7:00 a.m. and off at 7:00 p.m, and given 
food and water ad libitum. Male mice were used for all experiments. Mice were at 
least 8 weeks old at the start of each experiment. Behavioral experiments were 
performed during the light phase of the lighting cycle.  
Independent groups of animals were used for each behavioral experiment unless 
otherwise noted. All experiments were conducted in accordance with the 
guidelines for care and use of laboratory animals provided by the National 
Research Council, as well as with an approved animal protocol from the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School. 
Immunostaining 
Mice were injected with saline (i.p.) for three days prior to the start of the 
experiment to habituate them to handling and to reduce c-Fos activation due to 
stress. On the experiment day, C57BL/6J, L9'A and α4 KO mice were injected 
with nicotine (1 mg/kg or 3 mg/kg) or saline (i.p.).  
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Ninety minutes after the injection, all mice were deeply anesthetized with sodium 
pentobarbital (200 mg/kg, i.p.) and perfused transcardially with 10 ml of 0.01 M 
phosphate-buffered saline (PBS) followed by 10 ml of 4 % paraformaldehyde in 
0.01 M sodium phosphate buffer (pH 7.4). Brains were removed and post-fixed 
for 2 h with the same fixative and cryoprotected in sodium phosphate buffer 
containing 30% sucrose until brains sank. MHB serial coronal sections (20 μm) 
were cut on a microtome (Leica CM 3050S, Leica Microsystems Inc.) and 
collected into a 24-well tissue culture plate containing 1 X PBS. After rinsing 
sections in PBS twice for 5 min, they were treated with 0.4 % Triton X-100 PBS 
(PBST) twice for 2 min, followed by incubation in 2% BSA/PBS for 30 min. 
Sections were washed with PBS once and then incubated in a cocktail of primary 
antibodies for ChAT (Goat, 1:100, Millipore) and c-Fos (rabbit polyclonal, 1:800, 
Santa Cruz) in 2% BSA/PBS overnight at 4° C. The sections were then washed 
with PBS three times for 5 min followed by incubation in secondary fluorescent 
labeled antibodies (donkey anti-rabbit Alexa Fluor® 488 and donkey anti-goat 
Alexa Fluor® 594, 1:500, Molecular Probes, Inc., Eugene, USA) at room 
temperature in dark for 30 min. After washing with PBS five times for 5 min/wash, 
sections were mounted on slides by using VECTASHIELD® Mounting Medium 
(Vector laboratories, Inc., Burlingame, CA). The number of positive neurons was 
counted under a fluorescence microscope (Zeiss, Carl Zeiss MicroImaging Inc., 
NY) at a magnification of 40X. Neurons were counted as signal positive if 
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intensities were at least two times higher than that of the average value of 
background (sections staining without primary antibodies). 
Engineering of viral plasmids 
The yellow fluorescent protein (YFP) -tagged α4 nAChR subunit cDNA construct 
is commercially available (Addgene plasmid 15245) and has been described 
previously (Nashmi, Dickinson et al. 2003). Using a Quickchange Site-Directed 
Mutagenesis Kit (Agilient Technologies), PCR mutagenesis was used to convert 
the 9' leucine of the M2 pore-forming domain to a serine (changing the codon 
from CTT to TCT). This mutation has been shown to render nAChRs containing 
the Leu9'Ser α4 subunit to be hypersensitive to agonists, including ACh (Labarca, 
Nowak et al. 1995, Labarca, Schwarz et al. 2001). Constructs were verified 
through sequence analysis (Genewiz). The mutated cDNA inserts were 
subsequently removed from the pCI-neovector by digestion with EcoRI. pAAV-
EF1a-DIO-hChR2(H134R)-EYFP-WPRE-pA was digested using AscI and NheI 
to excise the hChR2-YFP insert.  T4 DNA polymerase (NEB) was used to fill 
overhangs followed by blunt ligation to subclone the L9'S α4-YFP nAChR subunit 
cDNA between two pairs of distinct lox sites (loxP and lox2722). Orientation of 
insert and verification of lox sites was confirmed through sequence analysis. 
Surgical procedures for virus microinjection 
Packaging of AAV-Ef1A-DIO-L9'S-YFP plasmids into AAV2 viral particles was 
done by the University of Massachusetts Medical School Viral Vector Core. For 
76 
 
viral particle injection, ChAT-Cre mice were anesthetized with a mixture of 
ketamine (100 mg/kg) and xylazine (10 mg/kg) (VEDCO). The surgical area was 
shaved and disinfected. Mice were placed in a stereotaxic frame (Stoelting Co.) 
with mouse adaptor and a small incision was cut in the scalp to expose the skull. 
Using bregma and lambda as landmarks, the skull was leveled in the coronal and 
sagittal planes. The AAV2-Ef1A-DIO-L9'S-YFP viral particles (1x1012 viral 
particles/μl) were injected into the ChAT-Cre mice MHb according to the 
coordinates: AP, -1.94, ML, 0.2, DV, -2.25. The viral particles (1.5 μl/side) were 
injected bilaterally at a flow rate of 0.3 μl/min. The injection needle was kept in 
place for 5 min post-injection. The incision was sutured and mice were returned 
to their home cages. 
Electrophysiology 
For the electrophysiological recording in this experiment, ChAT-Cre mice were 
infected with the virus when the mice were 3 weeks old. Four weeks later, brains 
were quickly removed and placed in oxygenated ice-cold high sucrose artificial 
cerebrospinal fluid (SACSF) containing kynurenic acid (1 mM, Sigma, St. Louis, 
MO). SACSF solution contained (in mM): 250 sucrose, 2.5 KCl, 1.2 
NaH2PO4•H2O, 1.2 MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose. 
Coronal brain slices containing IPN (~180 μm) were made using a Leica VT1200 
vibratome. Spontaneous EPSCs were obtained in the whole-cell configuration 
and gapfree acquisition mode in Clampex (Axon Instruments). For whole-cell 
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responses to ACh, neurons were held at -70 mV and ACh (0.3 mM) was applied 
via bath perfusion for 10 min. Whole cell responses to ACh were measured in the 
presence of atropine (1 μM) to block muscarinic receptors, bicuculline (20 μM) to 
block GABAA receptors, CNQX (10 μM) to block AMPA receptors, and AP5 (50 
μM) to block NMDA receptors. All recordings were filtered at 1 kHz using the 
amplifier's four-pole, low-pass Bessel filter, digitized at 10 kHz with an Axon 
Digidata 1440A interface and stored on a personal computer. ACSF was used for 
bath solution and contained (in mM): 125 NaCl, 2.5 KCl, 1.2 NaH2PO4•H2O, 1.2 
MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose.  
Marble burying test (MBT) 
Four weeks after the virus infection, the mice were subjected to the MBT. As 
described in our previous paper (Zhao-Shea, Liu et al. 2013), mice were 
habituated in the standard mouse cage with ~5 - 6 cm of bedding for 2 days (45 
min/day) before the test. On the test day, 15 clean 1.5 cm glass marbles were 
evenly spaced in five rows of three, each 4 cm apart on the bedding. A mouse 
was placed in its test cage and left for 30 minutes, and the number of marbles 
buried (to 2/3 their depth) with bedding was counted every 5 min or after 30 min 
(as noted in the figures), then mice were removed from their test cages. 
For the mecamylamine injection experiment, mice were injected with 
mecamylamine (0.3 mg/kg, i.p.). Thirty minutes later, mice were assessed in the 
MBT. 
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Elevated plus maze (EPM) 
Four weeks after the virus infection, the mice were studied using for the EPM test. 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the 
experimental apparatus consisted of a central axis and four arms elevated 45 cm 
above the floor, with each arm positioned at 90° relative to the adjacent arms. 
One red light arranged at 100 cm above the maze was used as the source of 
illumination. The mice were individually placed in the center of the maze with 
their heads facing one of the open arms and allowed 5 min of free exploration. 
The number of entries into the open and closed arms, and the total time spent in 
the open and closed arms were measured by MED-PC IV software (MED 
Associates, Inc.). The time spent in open and closed arms was calculated as 
standard anxiety indices. The total number of arm entries was considered as an 
index of locomotor activity. The apparatus was cleaned thoroughly between trials. 
Mice that froze in the initial placed arm without moving were not included in the 
analysis.  
For the mecamylamine injection experiment, mice were injected with 
mecamylamine (0.3 mg/kg, i.p.). Thirty minutes later, mice were subjected to the 
EPM. 
Guide cannula placement 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the guide 
cannulas were surgically implanted at least 3 days prior to the experiment. Mice 
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were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 
mg/kg) (VEDCO) and placed in a stereotaxic frame (Stoelting Co.). The surgical 
area was shaved and disinfected and the skull bone was exposed. Using bregma 
and lambda as landmarks, the skull was leveled in the coronal and sagittal 
planes. A hole was drilled and stainless steel guide cannulas were inserted into 
the brain and secured to the skull with instant adhesive. The coordinates relative 
to the bregma were: MHb (AP, -1.94, ML, 0.2, DV, -2.25). The scalp incision was 
stitched and dental cement was used to stabilize the cannula on the skull. After 
surgery, the mice were kept on a heating pad to prevent hypothermia. Mice were 
allowed to recover in individual cages for at least 3 days prior to drug infusion 
and behavioral testing.  
Intra-MHb infusions 
Mice were anesthetized with 2% isoflurane via a nose cone adaptor at a flow rate 
of 800 ml/L. Once anesthetized, an infusion cannula designed to reach −0.25 mm 
below the guide cannula was inserted into the guide cannula. Vehicle or 
mecamylamine (0.5 or 2 μg/μl, 1μl) was infused at a rate of 1 μl/min. After 
infusion, the infusion cannula was left in place for 2 minutes prior to retraction. 
Mice were placed back into their home cages and the behavior tests were 
conducted 30 min after the drug infusion. After completion of behavioral 
experiments, mice were culled, brains isolated, and cannula placement verified. 
To verify the guide cannula placement, the brains were cut in 30 µm sections and 
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the location of the guide cannula was determined by neutral red staining using 
light microscopy. In addition, the injection sites were double verified histologically 
by microinjection of DiI cell labeling solution (Invitrogen). Only mice with cannulas 
in the right placement were included in the statistical analysis. 
Locomotor activity 
Locomotor activity was recorded using an automated system (San Diego 
Instruments, La Jolla, CA, USA) with photobeams, which recorded ambulation 
(consecutive beam breaks). A translucent cage was placed between photobeams. 
Individual mice were moved from their home cage to this cage, and ambulatory 
activity was defined as the successive interruption of two of the four beams 
crossing the cage. All data were presented as total ambulations. 
For the baseline locomotor activity experiment, four weeks after the virus 
infection, mice were placed individually in a novel cage and recorded for 60 min 
for their baseline locomotor activity. 
For the locomotor activity after the nicotine injection, an independent group of 
mice were recorded for the locomotor activity in a novel cage right after nicotine 
i.p. injection (1.5 mg/kg) for 90 min.  
Data analysis 
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Data were analyzed using One- or Two-way ANOVA followed by Bonferroni post 
hoc tests or t-tests as indicated. Results were considered significant at p < 0.05. 
All data are expressed as means ± SEM. 
III.C. Results 
nAChRs are highly expressed in MHb cholinergic neurons 
Cholinergic neurons of the MHb exhibit strong expression of genes encoding 
distinct nAChR subunits (Sheffield, Quick et al. 2000, Grady, Moretti et al. 2009) 
suggesting that they could serve as a point of regulation for anxiety-like behavior.  
To determine the precise repertoire of nAChR subunits specifically expressed in 
MHb cholinergic neurons, cholinergic neurons were laser-microdissected and 
neuronal nAChR subunit gene expression (α2-α7 and β2-β4 nAChR subunit 
genes) was measured using quantitative RT-PCR (Table III-1). All nAChR 
subunit genes except α2 were detected in cholinergic MHb neurons. Expression 
of the nAChR α3 and α4 subunit genes was relatively strong compared to the 
house-keeping gene GAPDH; whereas, expression of the α5, α6, and α7 genes 
was less robust. In addition, expression of the nAChR β2 β3 and β4 subunit 
genes was high relative to GAPDH.  
α4* nAChRs are necessary and sufficient for nicotine activation of MHb 
cholinergic neurons  
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As α4 nAChR subunit gene expression was highly expressed in the MHb, we 
verified α4 subunit functional expression by measuring nicotine activation of MHb 
cholinergic neurons in two complementary mouse lines using the immediate early 
gene c-Fos as a molecular marker of neuronal activation (Cole, Saffen et al. 
1989). For this analysis we used the α4 knockout (α4 KO) mouse line which does 
not express chrna4 and the L9'A mouse line, a knock-in mouse line that 
expresses a single point mutation in chrna4 that renders nAChRs hypersensitive 
to agonist (Ross, Wong et al. 2000, Tapper, McKinney et al. 2004). When 
challenged with 1 mg/kg nicotine, one-way ANOVA indicated a significant main 
effect of genotype on the number of c-Fos immunopositive MHb neurons (F4, 10 = 
73.6, p < 0.001). Post-hoc analysis indicated L9'A animals exhibited prominent c-
Fos expression in MHb (Fig.III-1 A, B) compared to WT or α4 KO mice after 1 
mg/kg nicotine challenge. Conversely, when challenged with 3 mg/kg nicotine, 
WT mice exhibited significant c-Fos expression in MHb; whereas c-Fos 
expression was dramatically reduced in MHb of α4 KO mice. 
Together, these data indicate that functional nAChRs containing the α4 subunit 
are critical for nicotine activation of MHb cholinergic neurons. 
“AChR detectors” are functionally expressed in MHb cholinergic neurons 
To test the hypothesis that activation of nAChRs specifically in MHb cholinergic 
neurons inherently regulates anxiety-like behavior, we selectively expressed 
novel mutant α4 nAChR subunits that render nAChRs hypersensitive to ACh 
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(“Ach detectors”) in MHb cholinergic neurons of adult mice. This was done by 
engineering a viral plasmid for expression of mutated α4 nAChR subunits 
selectively in Cre-expressing neuronal populations. This plasmid includes the α4 
nAChR subunit cDNA containing an agonist-hypersensitive L9'S mutation in the 
M2 transmembrane sequence in addition to a yellow fluorescent protein (YFP) 
tag, engineered in the M3-M4 intracellular loop, where it does not interfere with 
expression or function of nAChRs (Labarca, Nowak et al. 1995, Labarca, 
Schwarz et al. 2001, Nashmi, Dickinson et al. 2003). Specifically, the L9'S-YFP 
cDNA was sub-cloned into the double-inverted open (DIO) reading frame of the 
pAAV-EF1a-DIO viral plasmid in the antisense orientation (i.e., the same 
expression plasmid used for the halorhodopsin experiments described in Chapter 
II). Thus, the cDNA insert is flanked by two pairs of distinct Lox sites that regulate 
L9'S-YFP α4 subunit cDNA expression by rearranging the cDNA into the sense 
orientation wherever Cre recombinase is expressed (Fig. III-2A) (Tsai, Zhang et 
al. 2009). To selectively infect cholinergic MHb neurons, L9'S-YFP AAV2 viral 
particles were intracranially injected into the MHb of ChAT-Cre mice. As a control, 
AAV2-eGFP particles (not Cre dependent) were similarly injected into the MHb of 
ChAT-Cre mice. Mice were allowed to recover 4-6 weeks post-infection to 
maximize plasmid expression. To verify expression, brains from infected animals 
were sliced and immunolabeled for ChAT and YFP (Fig. III-2B). YFP-expression 
was primarily restricted to the ventral MHb (i.e., where cholinergic neurons are 
clustered) and in ChAT-immunopositive neurons from L9'S-YFP-infected animals. 
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To confirm functional expression, acute coronal sections containing the MHb 
were isolated and whole-cell currents in response to ACh were measured from 
YFP- or GFP (control)-positive neurons using patch-clamp electrophysiology. 
Bath application of 300 μM ACh elicited inward currents in both control and L9'S-
YFP-infected neurons (Fig. III-2C). However, currents in L9'S-YFP-infected 
neurons were significantly larger compared to controls, indicating increased 
functional expression of nAChRs in these animals (Fig. III-2C, p < 0.01, Mann-
Whitney test). Together, these data indicate that L9'S nAChR subunits were 
properly expressed in MHb cholinergic neurons and formed “gain-of-function” 
nAChR ACh detectors to boost nAChR signaling in MHb cholinergic neurons. 
“ACh detector” expressing mice showed increased anxiety-like behavior  
To test the hypothesis that increased nAChR signaling in MHb cholinergic 
neurons modulates anxiety, we evaluated anxiety-like behavior in the EPM and 
MBT assays. In the EPM, mice infected with the L9'S-YFP virus spent 
significantly less time in the open arms compared to control-infected mice (t19.4 = 
2.24, p < 0.05, Fig. III-2E, left). Total arm entries between groups did not differ 
(Fig. III-2E, right). In the MBT, L9'S-YFP-infected animals buried significantly 
more marbles at each time point in the assay, but most importantly, there was an 
overall increase in the number of marbles buried at the end of the assay (Fig. III-
2F, inset, T-Test, p< 0.001). To determine if increased burying in L9'S-expressing 
mice compared to control mice was a non-specific phenotype elicited by 
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increased locomotor activity, we measured ambulation during one hour in both 
groups (Fig. III-2D). Two-way ANOVA indicated that locomotor activity did not 
significantly differ between groups. 
To test the hypothesis that increased anxiety-like behavior in L9'S-infected mice 
was due to ACh-mediated activation of the agonist-hypersensitive nAChRs in 
cholinergic MHb neurons, control and L9'S-infected mice were challenged with 
either saline or a low dose of the nAChR antagonist mecamylamine (0.3 mg/kg, 
i.p.) prior to testing in the EPM and MBT assays (Fig. III-3). In the EPM, two-way 
ANOVA indicated an overall main effect of virus (F1, 33 =9.64, p < 0.01) and drug 
injection (F1, 33 = 7.83, p < 0.01) and significant virus × drug interaction (F1,33 = 
5.41, p<0.05). Post-hoc analysis revealed that mice expressing L9'S nAChRs in 
MHb cholinergic neurons spent significantly less time in the open arms of the 
EPM after saline treatment compared to control mice receiving saline (Fig. III-3A, 
p<0.01). Mecamylamine injection to L9'S expressing animals significantly 
increased time spent in the open arm compared to a saline injection (Fig. III-3A, 
p<0.01); whereas the low dose of antagonist did not significantly alter time spent 
in the open arms in control mice. Two-way ANOVA indicated that neither virus 
infection nor drug injection significantly altered total arm entries in the EPM (Fig. 
III-3B). In the MBT assay, mecamylamine did not significantly alter the number of 
marbles buried in control animals compared to a saline injection (Fig. III-3C). 
Mecamylamine significantly reduced the number of marbles buried in mice 
expressing L9'S nAChRs in MHb cholinergic neurons compared to a saline 
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injection at each time point and such that, at the end of the assay, the cumulative 
number of marbles buried was significantly reduced (p < 0.001, Fig. III-3D, inset). 
To verify that systemic antagonist injections were actually acting at mutant 
nAChRs in the MHb, we implanted cannulas targeting the MHb and infused 
vehicle or mecamylamine (0.5 μg, Fig. III-4) in the MHb of L9'S-expressing and 
control ChAT-Cre mice prior to testing in the EPM and MBT assays. In the EPM, 
two-way ANOVA indicated a significant effect of virus (F1, 28 = 8.74, p < 0.01) and 
drug infusion (F1, 28 = 4.52, p < 0.05), and a virus × infusion interaction (F1, 28 = 
6.23, p < 0.05). Post-hoc analysis revealed that in control-virus expressing mice, 
0.5 μg mecamylamine had little effect compared to vehicle infusion; whereas the 
antagonist significantly increased time spent in the open arms compared to a 
vehicle infusion in L9'S-expressing ChAT-Cre mice (Fig. III-4A). Infusion of 
mecamylamine did not alter total arm entries (Fig. III-4B). Similarly, infusion of 
0.5 μg mecamylamine did not alter marble burying in control mice compared to 
vehicle infusion (Fig. III-4C) but significantly reduced the number of marbles 
buried in the MBT of L9'S-expressing ChAT-Cre mice compared to vehicle (p < 
0.0001, Fig. III-4C). Proper placement of cannulas and drug infusions were 
verified after behavioral experiments as described in Methods (Fig. III-5). 
Together, these data indicate that L9'S expression in MHb cholinergic neurons 
increased anxiety-like behavior through increased endogenous activation of L9'S 
α4* nAChRs. 
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“ACh detector” expressing mice showed prolonged hypolocomotion by 
high dose of nicotine 
In addition, we also tested the reaction of L9'S-expressing ChAT-Cre mice to 
high dose nicotine. When challenged with a high dose of nicotine (1.5 mg/kg), 
control virus expressing mice showed hypolocomotion for 30 min, and gradually 
recovered to the baseline at 60 min (Fig. III-6A). In contrast, the L9'S-expressing 
ChAT-Cre mice showed a prolonged hypolocomotion for 60min, but after the 
recovery, the peak of the locomotor activity is lower than the control mice (Fig. III-
6A). The quantification of the total ambulation over the first 90 min showed that 
there is a significant difference between the two groups (Fig. III-6B). 
IV.D. Discussion 
Cholinergic signaling through nAChRs has been implicated in a variety of 
physiological and pathophysiological processes including attention, striatal 
dopamine release, and nicotine dependence (Guillem, Bloem et al. 2011, 
Threlfell, Lalic et al. 2012, Picciotto and Kenny 2013). However, behavioral 
responses mediated by cholinergic signaling have been difficult to properly 
assess likely due to a predominant neuromodulatory role of ACh.  
Here we first test the necessity and sufficiency of the α4 subunit for the MHb 
cholinergic neuron activation. We showed that the α4 KO mice lacked c-Fos 
expression when challenged with high dose of nicotine, while L9'A mice showed 
significantly more c-Fos expression compared to the wild type mice when 
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challenged with low dose of nicotine (1 mg/kg).  These results suggest that α4 
nAChRs are necessary and sufficient for nicotine induced neuronal activation in 
the MHb cholinergic neurons, which is consistent with a previous study (Fonck, 
Nashmi et al. 2009).  
In addition, it has been shown that systemic (i.p.) nicotine (0.5 mg/kg) has 
anxiogenic effect in mice mainly via β2* nAChRs in the brain (Zarrindast, 
Homayoun et al. 2000, Anderson and Brunzell 2015), but we did not find c-fos 
expression in MHb after 1 mg/kg nicotine injection. It has been shown that GABA 
receptors are highly expressed in MHb, suggesting that there is a strong 
inhibitory projection to MHb. In addition, the diversity of distinct nAChR subtypes 
found in MHb is huge compared to other brain areas, since most nAChR subunits 
are expressed in MHb (Dineley-Miller and Patrick, 1992; Marks et al., 1992). It is 
possible that the activation of MHb neurons by nicotine is more difficult compared 
to other brain regions, due to the strong GABA inhibition and the high expression 
of the relatively low affinity nAChR subtypes. 
On the other hand, c-fos, has been extensively used as a marker for the neuronal 
activation since 1987  (Hunt, Pini et al. 1987), but it does not necessarily mean 
there is no neuronal activation without c-fos expression. Therefore, it is also 
possible that 1 mg/kg nicotine injection activated the MHb neurons but it is not 
enough to induce the c-Fos expression. 
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Then, to test the behavioral function of endogenous role of nAChRs in the MHb-
IPN circuitry, we have designed a system to express Leu9′Ser α4 nAChR 
subunits that render nAChRs hypersensitive to ACh in discreet neuron population 
using viral mediated gene delivery combined with the Cre-Lox system.  These 
ACh detectors should facilitate identification of the behavioral role of ACh through 
nAChR signaling in individual circuits.  For the current work, we focused on the 
MHb-IPN axis which robustly expresses a wide variety of nAChR subtypes 
(Grady, Moretti et al. 2009). Our data indicate that expression of α4 nAChR 
subunit ACh detectors selectively in MHb cholinergic neurons increased anxiety-
like behavior.  Anxiety was alleviated by blocking the hypersensitive nAChRs with 
a low dose of antagonist or locally within the MHb, indicating that heightened 
anxiety was mediated through activation of ACh detector nAChRs and not due to 
additional factors such as nAChR desensitization or excitotoxicity. Thus, our data 
directly implicate nAChRs on cholinergic MHb neurons specifically in regulating 
anxiety. Our data also suggest that cholinergic signaling via nAChRs expressed 
in MHb cholinergic neurons is an endogenous mechanism governing the 
regulation of anxiety-like behaviors. 
In addition, we also found that the expression of α4 nAChR subunit ACh 
detectors selectively in MHb cholinergic neurons caused prolonged 
hypolocomotion in the mice. In Chapter II, we have shown that high frequency 
stimulation of MHb cholinergic neurons - presumably induced ACh release in the 
IPN - induced hypolocomotion. These two lines of evidence together suggest that 
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the high dose of nicotine may induce ACh release in the IPN, and the 
hypersensitive L9'S ACh detector is more sensitive to high dose of nicotine, thus 
the mice showed prolonged hypolocomotion. Previous studies have shown that 
the α3 and β4 nAChRs are necessary for nicotine-induced hypolocomotion using 
the α3KO mice and β4KO mice (Salas, Cook et al. 2004). As α3 and β4 are 
highly expressed in the MHb-IPN tract, together with our data, it suggests that 
the nAChRs in the MHb-IPN tract are critical for nicotine induce hypolocomotion. 
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Table III-1.  Relative Gene Expression of nAChR subunit genes in MHb 
cholinergic neurons.  
 
 2 3 4 5 6 7 2 3 4 
 N.D. -2.41 
±0.36 
-5.04 
±0.42 
-9.72 
±0.57 
-11.59 
±0.51 
-9.63 
±0.55 
-5.11 
±0.20 
-4.99 
±0.53 
-4.30 
±0.31 
 
Values represent the change in the threshold cycle (-∆Ct) compared with GAPDH. 
n = 4. N.D., Not detected. 
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Figure III-1. α4* nAChRs are necessary and sufficient for nicotine activation of 
MHb cholinergic neurons.  
A. Representative images of coronal sections from the MHb of C57BL/6J wild 
type mice, α4 knockout mice or Leu9'Ala mutant mice injected with saline or 
nicotine. Immunolabeling was performed to detect c-Fos expression (green, left 
columns) and ChAT expression (red, middle columns). Merged images are 
represented in the right column. The MHb is highlighted by the white-dotted line. 
B. Quantification of the number of c-Fos immunopositive neurons within the MHb 
after each drug treatment (10–15 slices analyzed per mouse, n = 3 
mice/treatment). *** p <0.001. One-way ANOVA with Tukey Post-hoc analysis. 
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Figure III-2. Selective expression of agonist-hypersensitive α4* nAChRs in MHb 
cholinergic neurons.  
A. Schematic diagram of the double-floxed Cre-dependent AAV vector 
expressing L9„S α4-YFP nAChR subunit cDNA under the control of the Ef-1α 
promoter.  
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B. Left, Representative images of coronal sections illustrating the expression of 
L9„S-YFP (green signal) in the MHb (20x). Right, 60x photomicrograph from the 
section indicated in the square outline of the 20x image. Cholinergic signal (red, 
top panel), YFP signal (green, middle panel) and merged signals (yellow, bottom 
panel) are shown.  
C. Representative whole-cell voltage-clamp recording from eGFP-positive (left, 
control) or L9'S-YFP-positive neurons (right) in response to 0.3 mM ACh in acute 
MHb slices from ChAT-Cre mice. Average currents recorded from eGFP- and 
L9'S-YFP-positive neurons are shown below. ** p < 0.01, Student‟s t-test. 
D. Locomotor activity (ambulation) did not differ between Control-infected and 
AAV2 L9'S-infected ChAT-Cre mice. Each data point represents summed 5 min 
total ambulation. 
E. Time spent in the open arms of the EPM in Control- and AAV2 L9'S-infected 
ChAT-Cre mice (left). Total EPM arm entries of each group (right). *p < 0.05, 
Student‟s t-test. 
F. Cumulative number of buried marbles at different time points in the MBT from 
Control-infected and AAV2 L9'S-infected ChAT-Cre mice. Inset, averaged 
marbles buried at t=20 min. Data are expressed as average values ± S.E.M. *p < 
0.05, ** p < 0.01, *** p < 0.001. Student‟s t-test is used to analyze the inset. 
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Figure III-3. Increased anxiety-like behavior is mediated by increased nAChR 
activity in mice expressing Leu9'Ser α4-YFP nAChRs in MHb cholinergic neurons.  
A. Time spent in the open arms of the EPM in Control- and AAV2 L9'S-infected 
ChAT-Cre mice after challenge with Vehicle (Veh) or low dose mecamylamine 
(Mec, 0.3 mg/kg, i.p.). 
B. Total EPM arm entries of each group from panel A.  
C. Cumulative number of buried marbles at different time points in the MBT from 
control-infected ChAT-Cre mice challenged with Veh or Mec. Inset, averaged 
marbles buried at t=20 min.  
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D. Cumulative number of buried marbles at different time points in the MBT from 
AAV2-L9'S-infected ChAT-Cre mice challenged with Veh or Mec. Inset, averaged 
marbles buried at t=20 min. Data are expressed as average values ± S.E.M. 
^^p<0.01 compared to control group with Veh. ** p < 0.01, *** p < 0.001 
compared to within group vehicle. 
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Figure III-4. Infusion of mecamylamine in the MHb of L9'S α4-YFP nAChR-
expressing ChAT-Cre mice alleviates increased anxiety-like behavior.  
A. Time spent in the open arms of the EPM in Control- and AAV2 L9'S-infected 
ChAT-Cre mice after infusion of vehicle (Veh) or low dose mecamylamine (Mec, 
0.5 μg).  
B. Total EPM arm entries of each group from panel A.  
C. Cumulative number of buried marbles at different time points in the MBT from 
control-infected ChAT-Cre mice infused with Veh or Mec.  
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D. Cumulative number of buried marbles at different time points in the MBT from 
AAV2-L9'S-infected ChAT-Cre mice infused with Veh or Mec. Data are 
expressed as average values ± S.E.M. ^^p<0.01 compared to between group 
control. * p < 0.05, *** p < 0.001 compared to within group vehicle. 
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Figure III-5. Verification of cannula placement and drug infusions.  
Depiction of representative coronal sections from MHb at coordinates relative to 
bregma in mm as indicated. Green circles indicate guide cannula placements 
from L9„S mice infused with mecamylamine in Chapter III. Red circles indicate 
cannula placements from control- or nicotine-treated mice infused with different 
nAChR antagonists in Chapter IV. Note that infusion cannulas project 0.25 mm 
past guide cannulas. Right image shows representative dye infusions post-
behavior experiments to double verify infusion location. 
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Figure III-6. Activation of MHb cholinergic neurons by nicotine modulates 
hypolocomotion 
A. Average number of ambulation in the novel cage locomotion test following the 
nicotine (1.5 mg/kg, i. p.) injection in the mice with AAV2-eGFP or AAV2-L9‟S 
infection. 
B. Average total number of ambulation of first 90 min in the mice treated as A. t-
test was used for statistics. * p < 0.05, ** p < 0.01, *** p < 0.001 
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CHAPTER IV 
nAChRs upregulation on MHb cholinergic neurons are critical for nicotine 
withdrawal symptoms 
 
 
Contributions: 
Jennifer Ngolab made the virus construct. Liwang Liu did the electrophysiological 
recordings. Rubing Zhao-Shea did the qRT-PCR. All other research was done by 
me. Dr. Andrew Tapper wrote part of the body of the text, while I made the 
Figures, Materials and Methods and provided feedback on the other sections. 
 
 
 
 
 
 
 
 
102 
 
IV.A. Introduction 
Despite considerable educational and legislative efforts, tobacco use kills 
approximately 6 million people annually, which makes nicotine addiction the 
primary cause of preventable mortality in the world (Picciotto and Kenny 2013). 
Smokers attempting to quit oftentimes relapse, because during the tobacco 
cessation, the dependent individuals will show the unpleasant withdrawal 
symptoms (Benowitz 2008), which include somatic (physical), and affective 
withdrawal symptoms (Kenny and Markou 2001). Rodent somatic symptoms 
include increased scratching, head nods and body shakes (Damaj, Kao et al. 
2003, Grabus, Martin et al. 2005); whereas affective symptoms include anxiety 
and aversion (Jackson, Martin et al. 2008). 
Nicotine, the addictive component of tobacco smoke, mediates its 
pharmacological effect by binding to, activating, and/or desensitizing neuronal 
nicotinic acetylcholine receptors (nAChRs) (Improgo, Scofield et al. 2010). The 
nAChRs are cation selective ligand-gated ion-channels that can be activated by 
the endogenous neurotransmitter, acetylcholine (ACh) (Improgo, Schlichting et al. 
2010). Twelve mammalian genes encoding nAChR subunits have been identified 
(α2-α10, β2-β4) and five subunits coassemble to form a functional receptor (Dani 
and Bertrand 2007).  Because multiple distinct alpha subunits can combine with 
multiple distinct beta subunits, the potential number of nAChR subtypes is vast 
and is usually brain region-specific (Millar and Gotti 2009).   
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One of the most robust nAChR-expressing circuits in the central nervous system 
is the medial habenulo-interpeduncular pathway(Leslie, Mojica et al. 2013).  
Interestingly, cholinergic neurons within the MHb robustly express rare neuronal 
nAChR subtypes containing the α3 and β4 subunits, as well as the α4 subunit 
among others (See Page 85, Table III-1) (Fonck, Nashmi et al. 2009, Salas, 
Sturm et al. 2009, Fowler, Lu et al. 2011).  
While the neurocircuitry underlying withdrawal remains to be completely 
elucidated, the habenular-interpeduncular axis has recently been implicated in 
nicotine intake and aversion (Fowler, Lu et al. 2011, Frahm, Slimak et al. 2011). 
It has been shown that direct infusion of the non-specific nAChR antagonist, 
mecamylamine, into the interpeduncular nucleus (IPN) can precipitate somatic 
withdrawal in nicotine-dependent mice, suggesting that the habenulor-
interpeduncular axis may be important for the expression of somatic signs of 
nicotine withdrawal (Zhao-Shea, Liu et al. 2013). In addition, knock-out mice that 
do not express nAChR α2, α5, or β4 subunits, which are particularly abundant in 
the MHb-IPN tract, exhibit fewer withdrawal symptoms during nicotine withdrawal 
(Salas, Sturm et al. 2009). However, how nAChRs on the MHb cholinergic 
neurons modulates nicotine withdrawal is still unknown.  Thus, in this chapter, we 
focused on testing the hypothesis that nAChRs on MHb cholinergic neurons are 
involved in affective nicotine withdrawal symptoms. 
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IV.B. Materials and methods 
Animals 
C57BL/6J mice, α4 knock-out (α4KO) mice and their wild type (WT) littermates 
were used for the experiments in this chapter. The genetic engineering of the 
α4KO mouse line has been described previously (Ross, Wong et al. 2000). The 
α4KO mouse line has been back-crossed to a C57BL/6J background for at least 
nine generations. All the mice used in the experiments were bred in our animal 
facilities. The mice were group housed four mice/cage on a 12-h light, 12-h dark 
lighting cycle with lights on at 7:00 a.m. and off at 7:00 p.m, and given food and 
water ad libitum. Mice were at least 8 weeks old at the beginning of each 
experiment. Behavioral experiments were performed during the light cycle. 
Independent groups of animals were used for each behavioral experiment unless 
otherwise noted.  
All experiments were conducted in accordance with the guidelines for care and 
use of laboratory animals provided by the National Research Council (National 
Research Council Institute for Laboratory Animal 1996), as well as with an 
approved animal protocol from the Institutional Animal Care and Use Committee 
of the University of Massachusetts Medical School. 
Drugs and drinking solutions 
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Nicotine and control drinking solutions were prepared from nicotine hydrogen 
tartrate or L-tartaric acid (Sigma-Aldrich), which were dissolved in tap water with 
concentrations of 200 μg/ml (nicotine base) and 300 μg/ml, respectively.  
Saccharin Sodium (Fisher Scientific) was added to each solution to sweeten the 
taste with a concentration of 3 mg/ml.  For brain infusions, mecamylamine (2 μg, 
1 μl), Dihydro-β-erythroidine hydrobromide (DHβE) (3 μg, 1 μl), SR16584 (2 μg, 1 
μl) and α-conotoxin MII [E11A] (5 μM, 1 μl) were dissolved in artificial 
cerebrospinal fluid (ACSF) prior to delivery.  Mecamylamine is a nonselective 
antagonist of nAChR and we use a relatively low dose according to the literature 
(Levin, Briggs et al. 1994, Kim and Levin 1996, Wickham, Solecki et al. 2013). 
DHβE is a competitive nAChR antagonist, selective for the α4* nAChRs (IC50 
values are 0.19 and 0.37 μM for α4β4 and α4β2 receptors respectively) (Harvey, 
Maddox et al. 1996) and we use a relatively low dose according to the literature 
(Raybuck and Gould 2010, Wickham, Solecki et al. 2013). SR 16584 is a 
selective antagonist of the α3β4 nAChR subtype (IC50 = 10.2 μM), and we chose 
the dose base on the previous literature (Zaveri, Jiang et al. 2010, Zhao-Shea, 
Liu et al. 2013). α-conotoxin MII [E11A] is an antagonist selectively for α6* 
nAChRs (IC50 = 0.15 nM). At higher dose, α-conotoxin MII [E11A] can also block 
α3 2 nAChR (IC50 = 8.72 nM) (McIntosh, Azam et al. 2004, Wickham, Solecki et 
al. 2013). Here we use a dose that is relatively low (8.8ng/side) according to the 
literature and it supposed to selectively antagonize the α6* nAChRs  (Wickham, 
Solecki et al. 2013).  
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Laser Capture micro-dissection. 
Six weeks after nicotine or control solution exposure, mice were decapitated and 
the brains were removed, snap-frozen in dry ice-cooled 2-methylbutane (−60 °C) 
and stored at −80 °C. Coronal serial sections (10 μm) of medial habenula were 
cut using a cryostat (Leica Microsystems Inc.) and mounted on pre-cleaned glass 
slides (Fisher Scientific). The sections were immediately placed in a slide box on 
dry ice until completion of sectioning, followed by storage at −80 °C. A quick 
immunofluorescence staining protocol was used to identify cholinergic neurons.  
First, frozen sections were allowed to thaw for 30 s. Slides were immediately 
fixed in ice-cold acetone for 4 min and then washed in PBS, incubated with 
mouse anti-ChAT primary antibody (Millipore, 1: 50 dilution for 10 min), washed 
in PBS once, followed by incubation in secondary fluorescently-labeled 
antibodies (Molecular Probes; donkey anti-goat Alex Fluor 594, 1: 100) for 10 min.  
The slides were washed in PBS once, and then subsequently dehydrated in 
graded ethanol solution (30 s each in 70% ethanol, 95% ethanol, 100% ethanol, 
and once for 5 min in xylene). Slides were allowed to dry for 5 min.  All antibodies 
were diluted in PBS, including 2% BSA and 0.2% Triton X-100. PBS and dH2O 
were treated with diethylpyrocarbonate (DEPC) for RNA preservation. All ethanol 
solutions and xylene were prepared fresh to preserve RNA integrity. A Veritas 
Microdissection System Model 704 (Arcturus Bioscience) was used for laser 
capture microdissection (LCM). ChAT immunopositive neurons were captured on 
CapSure Macro LCM caps (Arcturus Bioscience) for total RNA isolation. 
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Real-time PCR 
Total RNA was extracted from individual samples using a Micro Scale RNA 
Isolation Kit (Ambion). RNA samples extracted from cholinergic neurons of 
chronic nicotine or control MHb were reverse-transcribed into cDNA using a 
TaqMan Reverse Transcription Kit (Applied Biosystems). Quantitative reverse 
transcription-PCR (qRT-PCR) was performed using an Applied Biosystems 7500 
Real-Time System and TaqMan assays (Applied Biosystems). Samples 
containing no reverse transcriptase were used as negative controls. Relative 
gene expression differences between control-treated mice and chronic nicotine-
treated mice were calculated using the 2−ΔΔCt method.  Expression values are 
relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Samples were 
analyzed in triplicate. Student‟s t-test was used for statistical analysis. 
Western blot 
For antibody test, α4, α6, β3, β4 knockout mice and their wild type litter mates 
were used (these mice brains are gifts from Picciotto lab and verified the 
genotype by PCR as described previously by them) (Picciotto, Zoli et al. 1995, 
Orr-Urtreger, Goldner et al. 1997, Xu, Gelber et al. 1999, Ross, Wong et al. 2000, 
Champtiaux and Changeux 2002). For the chronic nicotine treatment experiment, 
C57BL/6 mice were treated with nicotine-containing water for 6 weeks (described 
above) and the brains were removed for western blot. MHb was punched out and 
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three of them from the same treatment group were pooled together as one 
sample to get enough protein. 
The tissue was lysed in RIPA buffer (Radioimmunoprecipitation assay buffer) 
containing protease inhibitors and protein concentrations were determined using 
the Bradford protein assay (Pierce). After boiling, approximately 30 μg of each 
sample was loaded in each well and separated by 10% SDS–polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Blots 
were blocked with 5% milk in phosphate-buffered saline with 0.05% (v/v) Tween-
20 (PBST) for 60 min at room temperature, washed three times in PBST for 5 
min, and then incubated at 4 degrees overnight in primary antibody diluted in 
PBST [α4 nAChR (rabbit, 1:500),  β3 nAChR (rabbit, 1:500), or  4 nAChR (rabbit, 
1:500), from Alomone Labs]. Blots were washed three times in PBST and 
incubated in secondary antibody for 60 min at room temperature (HRP-Goat anti-
rabbit IgG, 1:2000, from Santa Cruz). Blots were washed three times in PBST, 
and then immunoreactive bands were detected with Super Signal West Dura 
(Pierce). The images were captured using a Versa Doc Imaging station (Biorad). 
Nonsaturating bands were quantified using Quantity One software (Biorad). 
Electrophysiological recording 
Mice were treated with chronic nicotine water or control solution for 3 weeks 
starting from 3 weeks old. Brains were quickly removed and placed in 
oxygenated ice-cold high sucrose artificial cerebrospinal fluid (SACSF) 
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containing kynurenic acid (1 mM, Sigma, St. Louis, MO). SACSF solution 
contained (in mM):  250 sucrose, 2.5 KCl, 1.2 NaH2PO4•H2O, 1.2 MgCl2•6H2O, 
2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose. Coronal brain slices (~180 μm) 
containing MHb brain regions were made using a Leica VT1200 vibratome.  
Current responses to ACh or nicotine were obtained in the whole-cell 
configuration and gap-free acquisition mode in Clampex (Axon Instruments).  
Neurons were held at a resting membrane potential of -70 mV. For whole-cell 
responses to nicotine and ACh, neurons were held at -70 mV and nicotine (10 
μM) or ACh (300 μM) was applied via bath perfusion for 10 min. Whole-cell 
responses to agonists were measured in the presence of atropine (1 μM) to block 
muscarinic receptors, bicuculline (20 μM) to block GABAA receptors, CNQX (10 
μM) to block AMPA receptors, and AP5 (50 μM) to block NMDA receptors.  All 
recordings were filtered at 1 kHz using the amplifier's four-pole, low-pass Bessel 
filter, digitized at 10 kHz with an Axon Digidata 1440A interface and stored on a 
personal computer. ACSF was used for bath solution and contained (in mM): 125 
NaCl, 2.5 KCl, 1.2 NaH2PO4•H2O, 1.2 MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 
11 D-Glucose.  
Marble burying test (MBT) 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), mice were 
habituated in the standard mouse cage with ~5 - 6 cm layer of bedding for 2 days 
(45 min/day) before the test. On the test day, 15 clean 1.5 cm glass marbles 
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were evenly spaced in five rows of three, each 4 cm apart on the bedding. A 
mouse was placed in its test cage and left for 30 minutes, and the number of 
marbles buried (to 2/3 their depth) with bedding was counted every 5 min or after 
30 min (as noted in the figures), then mice were removed from their test cages. 
Elevated plus maze (EPM) 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the 
experimental apparatus consisted of a central axis and four arms elevated 45 cm 
above the floor, with each arm positioned at 90° relative to the adjacent arms. 
One red light arranged at 100 cm above the maze was used as the source of 
illumination. The mice were individually placed in the center of the maze with 
their heads facing one of the open arms and allowed 5 min of free exploration. 
The number of entries into the open and closed arms, and the total time spent in 
the open and closed arms were measured by MED-PC IV software (MED 
Associates, Inc.) The time spent in open and closed arms was calculated as an 
index of anxiety. The total number of arm entries was considered as an index of 
locomotor activity. The apparatus was cleaned thoroughly between trials. Mice 
that froze in the initial arm without moving were not included in the analysis.  
Guide cannula placement 
As described in our previous paper (Zhao-Shea, Liu et al. 2013), the guide 
cannulas were surgically implanted at least 3 days prior to the experiment. Mice 
were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 
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mg/kg) (VEDCO) and placed on a stereotaxic frame (Stoelting Co.). The surgical 
area was shaved and disinfected and the skull bone was exposed. Using bregma 
and lambda as landmarks, the skull was leveled in the coronal and sagittal 
planes. A hole was drilled and stainless steel guide cannulas were inserted into 
the brain and secured to the skull with instant adhesive. The coordinates relative 
to the bregma were: MHb (AP, -1.94, ML, 0.2, DV, -2.25). The scalp incision was 
stitched and dental cement was used to stabilize the cannula on the skull. After 
surgery, the mice were kept on a heating pad to prevent hypothermia. Mice were 
allowed to recover in individual cages for at least 3 days prior to drug infusion 
and behavioral testing.  
Intra-MHb infusions 
Mice were anesthetized with 2% isoflurane via a nose cone adaptor at a flow rate 
of 800 ml/L. Once anesthetized, an infusion cannula designed to reach −0.25 mm 
below the guide cannula was inserted into the guide cannula. Vehicle or drug 
was infused at a rate of 1 μl/min. After infusion, the infusion cannula was left in 
place for 2 min prior to retraction. Mice were placed back into their home cages 
and the behavior tests were conducted after the mice were awake. After 
completion of behavioral experiments, mice were culled, brains isolated, and 
cannula placement verified. To verify the guild cannula placement, the brains 
were cut in 30 µm sections and the location of the guide cannula was determined 
by neutral red staining using light microscopy. In addition, the injection sites were 
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double verified histologically by microinjection of DiI cell labeling solution 
(Invitrogen). Only mice with cannulas in the right placement were included in the 
statistical analysis. 
Data analysis 
Data were analyzed using One- or Two-way ANOVA followed by Bonferroni post 
hoc tests or t-tests as indicated. Results were considered significant at p < 0.05. 
All data are expressed as means ± SEM. 
IV.C. Results 
α4* nAChRs are critical for the increased anxiety during nicotine 
withdrawal  
Withdrawal from drugs of abuse, including nicotine, is a stressor and anxiogenic 
(Tsai, Zhang et al. 2009). To test the hypothesis that nAChRs containing the α4 
subunit are critical for the increased anxiety during nicotine withdrawal, we 
measured anxiety-like behaviors during nicotine withdrawal in nicotine-dependent 
WT and α4 KO mice. Nicotine dependence was induced via 4-6 weeks of 
nicotine-laced drinking water as reported previously (Zhao-Shea, Liu et al. 2013). 
Nicotine-naïve mice received either nicotine solution or control solution. 
Withdrawal was induced by replacing the nicotine solution with water and 
behaviors were measured 24 hours post nicotine cessation. Interestingly, while 
nicotine-dependent WT mice undergoing withdrawal displayed decreased time-
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spent in the open arms of the EPM and increased marble burying, withdrawn 
nicotine-dependent α4 KO mice did not differ in anxiety-like behaviors compared 
to nicotine naïve α4 KO mice, indicating that α4* nAChRs are necessary for 
increased anxiety during nicotine withdrawal (Fig. IV-1 A-C). 
nAChRs in the MHb cholinergic neurons are critical for the increased 
anxiety during nicotine withdrawal  
 To test the hypothesis that the anxiogenic effects of nicotine withdrawal are 
mediated, in part, through increased MHb α4* nAChR signaling, we measured 
anxiety in the EPM and MBT assay during spontaneous withdrawal from nicotine 
or control solution in C57Bl/6J mice. Mice were implanted with cannulas targeting 
the MHb and infused with vehicle or subtype selective nAChR antagonists 
including the α6* nAChR-selective antagonist α-conotoxin MII [E11A], the α4β2* 
nAChR-selective antagonist DHβE, and the α3β4 nAChR selective antagonist 
SR16584 prior to testing (McIntosh, Azam et al. 2004). In the EPM, two-way 
ANOVA revealed a significant main effect of drug infusion (F3,72 = 9.68, p < 
0.0001) and significant drug infusion × chronic treatment interaction (F3,72 = 7.01, 
p < 0.001). Posthoc analysis indicated that infusion of the antagonists into the 
MHb did not significantly modulate time spent in the open arms of the EPM in 
nicotine-naïve mice compared to vehicle infusion (Fig. IV-2A). However, mice 
undergoing nicotine withdrawal and infused with vehicle spent less time in the 
open arms compared to nicotine-naïve animals (p < 0.05) and time spent in the 
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open arms was significantly increased by infusion of α-conotoxin MII [E11A] (p < 
0.001) and DHβE (p < 0.01), but not SR16584. Total arm entries in the EPM did 
not significantly differ between nicotine-naïve and –dependent mice regardless of 
antagonist infusion into the MHb. In the MBT, marble burying was not 
significantly affected by antagonist infusion in nicotine-naïve mice; whereas mice 
undergoing nicotine withdrawal had significantly increased marble burying 
compared to control mice (p < 0.001). This increase was significantly decreased 
by MHb infusion of the antagonist α-conotoxin MII [E11A] (p < 0.01) and DHβE (p 
< 0.05), but not SR16584. Proper placement of cannulas and drug infusions were 
verified after behavioral experiments by the neutral red staining and dye infusion 
(Fig. III-5). 
These data suggest that anxiety induced by the stress of nicotine withdrawal is 
mediated by increased signaling through α6* and α4β2* nAChRs in the MHb. 
Chronic nicotine treatment upregulates α6 nAChRs in MHb neurons 
Both in humans and in rodents, long-term exposure to nicotine will cause the 
upregulation of nAChRs in the brain (Nashmi, Xiao et al. 2007, Govind, Vezina et 
al. 2009). To test the hypothesis that chronic nicotine treatment upregulates the 
nAChRs in the MHb, we measured the expression level of nAChRs in the MHb 
cholinergic neurons by qRT-PCR and western blot. 
Mice were treated with nicotine water or control solution for 4-6 weeks, as 
described above. The cholinergic neurons in the MHb were dissected by the 
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laser capture micro dissection and the nAChR subunit (α2-α7 and β2-β4 nAChR 
subunit) gene expression was detected by qRT-PCR. In both control mice and 
nicotine treated mice, all nAChR subunit genes except α2 were detected in 
cholinergic MHb neurons. As we showed in Chapter II, expression of the nAChR 
α3 and α4 subunit genes was relatively strong compared to the house-keeping 
gene GAPDH; whereas, expression of the α5, α6, and α7 genes was less robust. 
In addition, expression of the nAChR β3 and β4 subunit genes was high relative 
to GAPDH (Table IV-1). These results are consistent with a previous report 
(Sheffield, Quick et al. 2000). Interestingly, the paired t-test showed that 
significantly higher level of expression of the α6 subunit gene in the chronic 
nicotine treated mice compared to the control mice (Table IV-1), which indicated 
α6 gene was upregulated by chronic nicotine treatment. 
To check whether the nAChR subunits were also upregulated in the protein level, 
we performed western blot assays. 
First, we tested the nAChR subunit antibody specificity by comparing the 
immunoreactive bands in the specific nAChR subunit knockout mice and their 
corresponding wild type litter mates. The western blot results showed that the 
bands in the α4, α6 or β3 knockout mice are equivalent to their corresponding 
wild type litter mate, but the band in the β4 knockout mice showed a robust 
decrease compare to its wildtype litter mate (Fig. IV-3A). These results suggest 
that the β4 subunit antibody is specific, but unfortunately the antibodies for α4 α6 
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or β3 are not specific under the conditions used. However, when using Bradford 
assay to quantify protein concentration, SDS in RIPA buffer might cause high 
backgrounds. Therefore, the protein we loaded might not be accurate, 
contributing to an inaccurate outcome. 
Second, we use the specific β4 subunit antibody to test whether the β4 protein 
level was upregulated after chronic nicotine treatment. As the bands shown in Fig. 
IV-3B (left), the β4 subunit immunoactive bands are similar between the nicotine 
naïve group and chronic nicotine treated group. The quantification of the bands 
showed that there is no significant difference between the two groups (Fig IV-3B, 
right) under the conditions used, which is consistent with the qRT-PCR results. 
α6/α4β2* nAChRs in MHb neurons were functionally upregulated in chronic 
nicotine-exposed mice  
To test the hypothesis that α6/α4β2* nAChRs in MHb neurons were functionally 
upregulated in chronic nicotine-exposed mice, we measured whole-cell 
responses to nicotine in MHb neurons from nicotine-naïve and nicotine-
dependent animals and tested current sensitivity to α-conotoxin MII [E11A], 
DHβE, and SR16584. As a recent study indicated that α6* nAChRs are 
predominantly located in the medial ventral portion of the MHb, we focused our 
recordings on this sub-region (Shih, Engle et al. 2014). In control mice, 10 μM 
nicotine elicited robust whole-cell currents. One-way ANOVA revealed a 
significant main effect of antagonist on current amplitude (Kruskal-Wallis test, p < 
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0.001). Dunn‟s post-hoc test indicated that currents were relatively insensitive to 
100 nM α-conotoxin MII [E11A], but were significantly blocked by DHβE and 
SR16584 (Fig IV-2D, left). In MHb neurons from chronic nicotine-treated mice, 
whole-cell responses were significantly larger compared to control neurons 
(Mann-Whitney test, p < 0.05) (Fig IV-2D, right). In addition, one-way ANOVA 
indicated a significant main effect of antagonist on nicotine response (F3, 60 = 
34.17, p < 0.0001) (Fig IV-2E). Unlike nicotine-naïve mice, post-hoc analysis 
revealed that whole-cell responses from nicotine-treated mice were significantly 
reduced in the presence of α-conotoxin MII [E11A], as well as DHβE and 
SR16584 (Fig IV-2E). Together, these data indicate an increase in functional α6* 
nAChRs in the MHb after chronic nicotine treatment. 
Recently, we identified a novel nAChR subtype containing both α4 and α6 
subunits within the VTA that is sensitive to α6* nAChR antagonists as well as 
DHβE (Zhao-Shea, Liu et al. 2011, Liu, Zhao-Shea et al. 2012). To test if α4* 
nAChRs are expressed within the medial ventral sub-region of the MHb, we 
measured whole-cell responses to ACh in WT and α4 KO mice. Peak ACh 
induced current amplitudes were significantly reduced in α4 KO mice compared 
to WT (Fig. IV-1D), which suggest that α4 and α6 subunit may co-assemble with 
each other in the medial ventral sub-region of the MHb. 
IV.D. Discussion 
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Previous studies have implicated the MHb in physical nicotine withdrawal 
behaviors (Antolin-Fontes, Ables et al. 2014). In this study, we found that chronic 
nicotine increased gene expression of CHRNA6, the gene encoding the α6 
nAChR subunit.  In addition, nAChRs containing the α6 subunit were functionally 
upregulated in the MHb, as upregulated currents were more sensitive to a 
selective α6* nAChR antagonist compared to currents from nicotine-naïve 
animals. These data are consistent with a recent study showing that mice 
harboring α6 subunits with an eGFP tag exhibited an increase in fluorescent 
signal in MHb after chronic nicotine treatment compared to control mice, 
suggesting α6 subunit upregulation after nicotine exposure (Henderson, 
Srinivasan et al. 2014).   
Importantly, we previously identified a novel nAChR containing both α4 and α6 
subunits in DAergic neurons of the VTA (Zhao-Shea, Liu et al. 2011, Liu, Zhao-
Shea et al. 2012).  Here, we showed that nicotinic currents in the MHb subregion 
that predominantly express the α6 subunit also contain the α4 subunit. These 
data suggest that α4α6* nAChRs are upregulated by chronic nicotine exposure 
and contribute to increased anxiety-like behavior during nicotine withdrawal 
(Zhao-Shea, Liu et al. 2011, Liu, Zhao-Shea et al. 2012, Shih, Engle et al. 2014). 
Interestingly, while the α3β4 nAChR-selective antagonist SR16584 significantly 
blocked nicotine-induced whole cell currents in the medial ventral portion of the 
MHb, it did not affect anxiety during nicotine withdrawal. While α6* and α4* 
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nAChRs have unique expression patterns in discrete sub-nuclei of the MHb, 
α3β4* nAChR are expressed throughout. Thus, nAChR signaling in MHb sub-
nuclei may have opposing roles in modulating affective behaviors such that 
blockade of α3β4* nAChRs throughout the MHb ultimately may have little effect 
in modulating behavior output compared to α6/α4* nAChR antagonists which 
would be expected to block signaling in distinct MHb subregions. Alternatively, 
the concentration of SR16584 used for our analysis may have blocked non-
α3β4* nAChRs.  Regardless, these data indicate that heightened anxiety during 
nicotine withdrawal is mediated by increased nAChR signaling in the MHb, 
especially the α4α6* nAChRs. Thus, nAChRs expressed in MHb cholinergic 
neurons should be considered molecular targets for smoking cessation 
therapeutics. 
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Figure IV-1.  Expression of α4* nAChRs is necessary for affective nicotine 
withdrawal symptoms.  
A. Time spent in the open arms of the EPM in control and nicotine withdrawn WT 
and α4 KO mice.  
B. Total arm entries in the EPM from the groups in panel A.  
C. Total number of marbles buried in the MBT in control and nicotine withdrawn 
WT and α4 KO mice. For A-C, * p < 0.05, ** p < 0.01, Two-way ANOVA, 
Bonferroni post-hoc. 
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D. Representative whole-cell traces from the medial ventral portion of the MHb in 
WT and α4 KO mice (top). Averaged peak current in response to 10 mM nicotine 
in WT and α4 KO mice (bottom). * p < 0.05, ** p < 0.01, unpaired t-test. 
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Figure IV-2. Nicotine regulation of MHb α4/α6β2* nAChRs mediates increased 
anxiety during nicotine withdrawal.  
A. Time spent in the open arms of the EPM in control and nicotine withdrawn 
mice after vehicle (Veh), α-conotoxin MII[E11A] (α-Ctx[E11A]), DHβE, or 
SR16584 infusion into the MHb.  
B. Total arm entries in the EPM from the groups in panel A.  
C. Total number of marbles buried in the MBT (t = 20 min) in control and nicotine 
withdrawn mice after Veh, α-Ctx [E11A], DHβE, or SR16584 infusion into the 
MHb. For A-C, data are expressed as average values ± S.E.M. ^p<0.05, 
^^p<0.01 compared to control group with Veh infusion.  ***p < 0.01, ***p < 0.001 
compared to Veh within groups. Two-way ANOVA, Bonferroni post-hoc.  
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D. Representative whole-cell response to 10 μM nicotine under control conditions 
and in the presence of 100 nM α-Ctx[E11A], 1 μM DHβE, or 20 μM SR16584 in 
MHb slices from control-treated mice (left recordings) and chronic nicotine-
treated mice (right recordings).  
E. Averaged peak whole-cell current responses to 10 μM nicotine from the 
indicated groups as recorded in panel D from control mice (top) or chronic 
nicotine-treated mice (bottom). Data are expressed as average values ± S.E.M. 
^p<0.05, ^^p<0.01 compared to control group with Nic only.  ***p < 0.01, ***p < 
0.001 compared to Nic only within groups. 
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Table IV-1.  Relative gene expression of nAChR subunit genes in MHb 
cholinergic neurons in control and nicotine treated mice. 
 2 3 4 5 6 7 2 3 4 
Control N.D. -2.41 
±0.36 
-5.04 
±0.42 
-9.72 
±0.57 
-11.59 
±0.51 
-9.63 
±0.55 
-5.11 
±0.20 
-4.99 
±0.53 
-4.30 
±0.31 
Nicotine N.D. -1.97 
±0.68 
-4.80 
±0.17 
-10.04 
±0.25 
-10.47 
±0.28 
-9.65 
±0.20 
-5.16 
±0.33 
-4.63 
±0.49 
-4.15 
±0.53 
Fold-
Change# 
N.D. 1.76 
±0.57 
1.21 
±0.16 
0.85 
±0.16 
2.34 
±0.39* 
1.03 
±0.13 
1.04 
±0.20 
1.49 
±0.39 
1.35 
±0.43 
 
Values represent the change in the threshold cycle (-∆∆Ct) compared with 
GAPDH. * p < 0.05.  
#
 Nicotine compared to control calculated as 2
-Ct
, * p < 
0.05, n = 4/treatment. N.D., Not detected. 
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Figure IV-3 Chronic nicotine treatment did not upregulate β4 subunit expression 
level. 
A. Antibody specificity tests were done for the α4, α6, β3, β4 subunits in the 
knockout mice and corresponding wild type littermate by western blot analysis. 
Actin is used for endogenous control. 
B. Chronic nicotine treatment did not upregulate the β4 expression level. 
 Left, representative western blot of β4 subunit in nicotine treated or control 
treated mice; Right, quantitated results of western blots (n=3). Data are 
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expressed as average values ± S.E.M. Statistical analysis was performed by 
student-t test (p>0.05). 
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CHAPTER V 
Cholinergic input to the medial habenula 
 is not from the septal-diagonal band area 
 
Contributions: 
Jennifer Ngolab made the virus construct.  All other research was done by me. I 
wrote the body of the text and made the Figures. 
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V.A. Introduction 
The medial habenula is a key connection between the limbic forebrain and 
midbrain. The medial habenula receives major inputs via a white matter bundle 
called stria medullaris (sm) (Herkenham and Nauta 1977, Qin and Luo 2009). 
The most prominent input is from the two nuclei in the posterior septum: the 
triangular septal nucleus (TSN) and septofimbrial nucleus (SFi), which release 
glutamate and ATP to the MHb (Herkenham and Nauta 1977, Qin and Luo 2009). 
It also has been shown that the GABAergic inputs to the MHb are from the 
Nucleus of Diagonal band (DB) and the medial septum (MS) (Qin and Luo 2009). 
In addition, physiological and neurochemical studied have shown that the MHb 
also has the highest expression of nicotinic acetylcholine receptors (nAChRs) 
(Sheffield, Quick et al. 2000). Evidence from the lesion studies indirectly showed 
that the NDB or posterior septum might send the cholinergic input to the MHb, 
but more precise research still needs to be done (Contestabile and Fonnum 
1983). 
As mentioned in Chapter II, AAV2-ChR2-YFP were designed to express only in 
the Cre-positive neurons, and its expression is robust, therefore AAV2-ChR2-
YFP can be used as a tracer to study the precise projection of certain neuron 
population from a specific brain area.  Here, we tested whether cholinergic input 
arises from DB, MS, TSN or SFi using AAV2-ChR2 as a tracer. 
V.B. Materials and methods 
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Mice  
ChAT-Cre knock-in mice were purchased from Jackson Laboratories (stock 
number: 006410) and bred in the UMMS animal facility. Breeding was conducted 
by mating heterozygous pairs. For ChAT-Cre mice, genotypes were determined 
by PCR as previously described (Rossi, Balthasar et al. 2011) and also on 
Jackson Laboratories website. PCR of mouse tail genomic DNA was performed 
with three specific primers, WT F (5′-GTT TGC AGA AGC GGT GGG-3′), 
mutant F (5′-CCT TCT ATC GCC TTC TTG ACG -3′) and Common R (5′-
AGA TAG ATA ATG AGA GGC TC -3′). These primers amplify DNA fragments 
of 272 bp in wild-type (WT) mice, and 350 bp in ChAT-Cre mutant mice. DNA 
fragments were separated by agarose gel electrophoresis and visualized with 
ethidium bromide. Mice were group-housed four mice/cage on a light dark cycle 
with lights on at 7:00 a.m. and off at 7:00 p.m, and given food and water ad 
libitum. Male mice were used for all experiments. Mice were at least 8 weeks old 
at the start of each experiment. Behavioral experiments were performed during 
the light phase.  
All experiments were conducted in accordance with the guidelines for care and 
use of laboratory animals provided by the National Research Council, as well as 
with an approved animal protocol from the Institutional Animal Care and Use 
Committee of the University of Massachusetts Medical School. 
Surgical procedures for virus microinjection 
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Packaging of AAV-Ef1A-DIO-ChR2-eYFP plasmids into AAV2 viral particles was 
done by the University of Massachusetts Medical School Viral Vector Core. For 
viral particle injection, ChAT-Cre mice were anesthetized with a mixture of 
ketamine (100 mg/kg) and xylazine (10 mg/kg) (VEDCO). The surgical area was 
shaved and disinfected. Mice were placed in a stereotaxic frame (Stoelting Co.) 
with mouse adaptor and a small incision was cut in the scalp to expose the skull. 
Using bregma and lambda as landmarks, the skull was leveled in the coronal and 
sagittal planes. The viral particles (1x1012 viral particles/μl) were injected into the 
ChAT-Cre mice DB/MS or SFi/TS according to the coordinates: DB: AP, -0.8, ML, 
±0.2, DV, 5.0; MS: AP, -0.8, ML, 0, DV, 4.0; SFi: AP, -0.1, ML, 0, DV, 2.75; TS: 
AP, -0.46, ML, 0, DV, 2.5. The viral particles (1.5 μl/side) were injected bilaterally 
to DB or unilaterally TS, SFi, MS, at a flow rate of 0.3 μl/min. The injection needle 
was kept in place for 5 min post-injection. The incision was sutured and mice 
were returned to their home cages. 
Immunostaining 
Four weeks after the virus infection, mice were deeply anesthetized with sodium 
pentobarbital (200 mg/kg, i.p.) and perfused transcardially with 10 ml of 0.01 M 
phosphate-buffered saline (PBS) followed by 10 ml of 4 % paraformaldehyde in 
0.01 M sodium phosphate buffer (pH=7.4). Brains were removed and post-fixed 
for 2 h with the same fixative and cryoprotected in sodium phosphate buffer 
containing 30% sucrose until brains sank. MHb serial coronal sections (20 μm) 
were cut on a microtome (Leica CM 3050S, Leica Microsystems Inc.) and 
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collected into a 24-well tissue culture plate containing 1 X PBS. After rinsing 
sections in PBS twice for 5 min, they were treated with 0.4 % Triton X-100 PBS 
(PBST) twice for 2 min, followed by incubation in 2% BSA/PBS for 30 min. 
Sections were washed with PBS once and then incubated with primary 
antibodies for ChAT (Goat, 1:100, AB144P, Millipore) in 2% BSA/PBS overnight 
at 4° C. The sections were then washed with PBS three times for 5 min followed 
by incubation in secondary fluorescent labeled antibodies (donkey anti-goat 
Alexa Fluor® 594, 1:500, Molecular Probes, Inc., Eugene, USA) at room 
temperature in dark for 30 min. After washing with PBS five times for 5 min/wash, 
sections were mounted on slides by using VECTASHIELD® Mounting Medium 
(Vector laboratories, Inc., Burlingame, CA). The YFP signal was detected and 
picture was taken under the zeiss fluorescence microscope through the YFP 
fluorescence filter (Zeiss, Carl Zeiss MicroImaging Inc., NY).  
V.C. Results 
The MS/DB is cholinergic while SFi/TS are not cholinergic 
To test whether the main MHb input are cholinergic, we first performed the ChAT 
staining in mouse brain, which is a marker of cholinergic neurons. Within the MS 
and DB, we observed densely distributed ChAT-positive neurons (Figure V-1A), 
however, within the TS/SFi, there are no ChAT-positive neurons (Figure V-1B), 
suggesting that the TS/SFi is not the source of cholinergic input to the MHb. 
MS/DB cholinergic neurons project to the hippocampus not the MHb 
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To test whether DB cholinergic neurons project to the MHb, we selectively 
expressed ChR2 in the cholinergic neurons of DB/MS/SFi/TS by injecting AAV2-
ChR2-YFP into the ChAT-Cre mice. As expected, ChR2-YFP was not expressed 
in the SFi/TS, as there were no cholinergic neurons in these brain regions (see 
above). In contrast, as shown in Figure V-2A, the ChR2-YFP was expressed in 
the DB/MS cholinergic neurons. Then, we examined the distribution patterns of 
YFP labeled terminals. There are many YFP-positive terminals observed 
bilaterally in the hippocampus, but not in the MHb (Figure V-2B), suggesting that 
DB/MS cholinergic neurons project to the hippocampus but not the MHb. 
V.D. Discussion 
The MHb has been shown to be involved in several important behaviors. 
Interestingly, nAChRs are highly expressed in the MHb but where the cholinergic 
input originates is unclear. Previous lesion studies have shown that DB or the 
posterior septum might provide the cholinergic input to the MHb, but there is no 
direct evidence to support that.  
It has been shown that ChR2-YFP can be used as an anterograde tracer to study 
the neural circuitry (Hira, Ohkubo et al. 2013, Saito, Tsujino et al. 2013, Shimano, 
Fyk-Kolodziej et al. 2013). In this study, using ChR2-YFP as a tracer, we showed 
that cholinergic neurons that originate from MS/DB project to the hippocampus. 
No projections from MS/DB to MHb were detected in any of the tracing 
examination. However, there are no cholinergic neurons in SFi/TS, suggesting 
that SFi/TS are not the cholinergic input to the MHb, either.  
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All tracers have their limitations. For ChR2, it has been shown that ChR2 trafficks 
to the membrane well when expressed at low levels but forms intracellular 
aggregates at high levels (Lin, Lin et al. 2009, Lin 2011). In our study, we found 
that ChR2 in MS/DB neurons project to the hippocampus, but not to MHb. 
Therefore, it is unlikely that ChR2 was not efficiently trafficked to the membrane. 
In the future study, we could try to use other tracers, including pseudorabies virus, 
or cholera toxin B subunit, to check the projections from MS/DB to MHb. 
It is interesting that the main MHb afferents (MS/DB/SFi/TS) do not send the 
cholinergic projection to the MHb. MHb is one of the brain regions that have the 
highest nAChRs expression level, suggesting that there must be strong ACh 
release to it. Thus, there are two possibilities: 1) Some other unclear brain region 
sends the cholinergic input to the MHb; or 2) the cholinergic neurons in the MHb 
release the ACh to themselves to feed forward the neuronal circuit. More studies 
need to be done to test the possibilities. 
In conclusion, MS, DB, SFi, TS do not provide the cholinergic input to the MHb, 
and the cholinergic input to the MHb still needs to be identified. 
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Figure V-1. ChAT expression pattern in the MS, DB, SFi and TS 
A is showing that ChAT-positive neurons are clustered in the MS and DB (as 
shown in dashed line). 
B is showing that there are no ChAT-positive neurons in the SFi and TS (as 
shown in dashed line). 
Six mice were injected with virus and 20-25 slices were collected from each 
mouse. Representative slides were showing here. 
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Figure V-2. DB cholinergic neurons project to the hippocampus not the MHb 
A.The AAV2-ChR2 was injected into the MS and DB of ChAT-Cre mice. The 
picture is showing the expression of ChR2-YFP in the MS and DB (dashed line, 
above 10x, below 20x). 
B.The fluorescent images showing the distribution of ChR2-YFP labeled 
terminals of DB cholinergic neurons. The terminals are mainly located in the 
hippocampus, not in the MHb (dashed line is MHb, above 10x, below 20x). 
Six mice were injected with virus and 20-25 slices were collected from each 
mouse. Representative slides were showing here. 
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Chapter VI: 
Conclusion, Discussion and Future direction 
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Conclusion and discussion: 
Anxiety disorders are the most common of emotional disorders and the cost is a 
big burden for society, highlighting the need for identification of the underlying 
neuroanatomical bases and molecular underpinnings of anxiety (Kessler, Chiu et 
al. 2005). In the past few decades, research on anxiety disorder has focused on 
neurochemistry and genetics, and there is also growing interest in identifying the 
underlying brain circuits. Early on, chemical lesion studies combined with 
pharmacological studies provide a wealth of information about anxiety brain 
circuits. Recently, as new techniques emerged and developed, such as high 
resolution brain image and optogenetics, studies have revealed a 
major breakthrough and provided more detailed, precise information about the 
brain circuitry involved in anxiety disorders. 
Human and animal studies have shown the neurocircuitry of anxiety, including 
the amygdala, nucleus accumbens, BNST and hippocampus (Adhikari 2014). 
Recently the role of the MHb-IPN tract in anxiety and fear has attracted much 
attention. Previous work indirectly demonstrated a role for the MHb in anxiety 
regulation, either through lesioning of the habenula itself or through selective 
ablation of presumed septal glutamatergic inputs into the MHb (Yamaguchi, 
Danjo et al. 2013). However, whether MHb is directly involved in anxiety and the 
mechanism by which the MHb-IPN tract regulates anxiety are still unclear. 
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In Chapter II, by using optogenetics, we showed that MHb cholinergic neurons, 
which are clustered in the ventral portion of the MHb, regulate anxiety-like 
behavior directly. Silencing MHb cholinergic neuronal inputs to the IPN by NpHR 
reduced anxiety-like behaviors in both the EPM and MBT assays. As MHb 
cholinergic neurons release glutamate at 10 Hz stimulation or ACh at 50 Hz 
stimulation (Ren, Qin et al. 2011), we also tested whether glutamate and ACh 
mediate different behaviors in the mice. When the MHb cholinergic neurons were 
activated by low frequency of stimulation (5 Hz), the mice tend to increase the 
anxiety. It has been demonstrate that MHb cholinergic neurons display 
spontaneous tonic firing of 2-10 Hz (Gorlich, Antolin-Fontes et al. 2013). 
Therefore, the stimulation paradigm in this experiment could be influenced by the 
pacemaking activity of the neurons themselves. In the future experiments, we 
could try some different stimulation paradigms (different stimulation frequency, 
duration, intensity, etc.) and test whether low frequency stimulation-induced 
glutamate release will increase anxiety. Interestingly, when the MHb cholinergic 
neurons were activated by high frequency of stimulation (50 Hz), the mice 
showed hypolocomotion compare to the control group. These results together 
suggest that the MHb cholinergic neurons modulate anxiety, and the two different 
neurotransmitters might be involved in different behaviors in mice.  
While optogenetics provide an important tool to precisely define the relationship 
between neuronal activity and behavior in a given circuit, it provides little 
information regarding the endogenous mechanisms that may regulate this activity. 
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Previous studied have shown that nAChRs are highly expressed in the MHb-IPN 
circuit and the diversity of nAChR subtype is vast here. In addition, the nAChRs 
in the MHb-IPN pathway have been linked to acute nicotine intake and aversion. 
However, an endogenous role of nAChRs in the MHb-IPN circuitry has not been 
described.  
In chapter II, to test whether MHb nAChRs regulate anxiety-like behavior, we 
directly infused the non-selective nAChR antagonist, mecamylamine, into the 
MHb or IPN. Our data showed that only the mecamylamine infused into the MHb, 
but not the IPN, alleviated the anxiety-like behavior in mice, indicating that 
nAChRs in dendrites/soma, but not presynaptic terminals, of MHb neurons 
inherently modulate anxiety-like behaviors.  These results also suggest that 
nAChRs on the presynaptic terminals might be involved in anxiety.  
We also infused the NMDA receptor antagonist, AP-5, into the IPN, which 
resulted in the anxiolytic effect in mice, suggesting that glutamatergic signaling in 
the IPN modulates anxiety-like behavior, which is consistent with the 
optogenetics study in Chapter II. 
It has been shown that several nAChR subunit genes are expressed in the MHb, 
but why the diversity of nACh subtype is huge here is unclear. In Chapter III, we 
checked the precise repertoire of nAChR subunits specifically expressed in MHb 
cholinergic neurons by laser-microdissected and qRT-PCR. We found that α3, α4, 
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β2, β3, β4 subunit genes was relatively strong compared to the house-keeping 
gene GAPDH.  
As the α4 subunit is highly expressed in the MHb, in Chapter III, we test the 
sufficiency and necessity of α4 subunit in the activation of MHb cholinergic 
neurons in two complementary mouse lines:  α4 KO mouse line (a mouse line 
which does not express chrna4) and L9'A mouse line (a mouse line that 
expresses a single point mutation in chrna4 that renders nAChRs hypersensitive 
to agonist). When challenged with low dose of nicotine, only the L9'A mouse, but 
not wild type mice or α4 KO mice, exhibit increased c-fos (neuronal activation 
marker) expression in the MHb. In contrast, when challenged with high dose of 
nicotine, the wild type mice exhibited significant c-Fos expression in MHb 
cholinergic neurons, while c-Fos expression was dramatically lower in cholinergic 
MHb neurons of α4 KO mice. Together, these data indicate that functional 
nAChRs containing the α4 subunit are necessary and sufficient for nicotine 
activation of MHb cholinergic neurons, which is consistent with a previous study 
(Fonck, Nashmi et al. 2009). In addition, it has been shown that systemic (i.p.) 
nicotine (0.5 mg/kg) has anxiogenic effect in mice (Zarrindast, Homayoun et al. 
2000), but we did not found c-fos expression in MHb after 1 mg/kg nicotine 
injection. C-fos, has been extensively used as a marker for the neuronal 
activation since 1987  (Hunt, Pini et al. 1987), but it does not necessarily mean 
there is no neuronal activation without c-fos expression. Therefore, it is possible 
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that 1 mg/kg nicotine injection activated the MHb neurons but it is not enough to 
induce the c-fos expression. 
In order to probe the behavioral consequences of α4* receptors in MHb 
cholinergic neurons, we designed a system to express “gain-of-function” L9'S α4 
nAChR subunits in discrete neuron populations using viral-mediated gene 
delivery combined with the Cre-Lox system. These novel ACh detectors will 
facilitate identification of the behavioral role of ACh through nAChR signaling in 
individual circuits. In Chapter III, our data indicate that cholinergic signaling 
through nicotinic autoreceptors in MHb cholinergic neurons regulates anxiety-like 
behavior in mice. In detail, expression of α4 nAChR subunit ACh detectors 
selectively in MHb cholinergic neurons increased anxiety-like behavior. Anxiety 
was alleviated by blocking the hypersensitive nAChRs with a low dose of 
antagonist either systemically or locally within the MHb, indicating that 
heightened anxiety was mediated through activation of ACh detector nAChRs 
and not due to additional factors such as nAChR desensitization or excitotoxicity. 
Together, these data indicate that α4* nAChRs in the MHb cholinergic neuron are 
critical for the anxiety-like behavior in mice. Alternatively, the expression of 
hypersensitive α4* nAChRs in the MHb cholinergic neuron could increase the 
overall sensitivity of the nAChRs, increase the activity of cholinergic neurons, and 
in turn increase anxiety in mice. 
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In addition, in Chapter III, we also found that the ACh detector expressing mice 
showed prolonged hypolocomotion when challenged with high dose nicotine. 
Interestingly, in Chapter II, we showed that high frequency stimulation of MHb 
cholinergic neurons, which caused ACh release in the IPN, induced 
hypolocomotion. These two evidences together suggest that the high dose of 
nicotine or high frequency of stimulation may induce ACh release in the IPN, and 
the hypersensitive L9'S ACh detector expressing mice are more sensitive to high 
dose of nicotine, thus showed prolonged hypolocomotion. Previous studies have 
shown that the α3 and β4 nAChRs are necessary for nicotine-induced 
hypolocomotion using the α3KO mice and β4KO mice (Salas, Cook et al. 2004). 
As α3 and β4 are highly expressed in the MHb-IPN tract, together with our data, 
it suggests that the nAChRs in the MHb-IPN tract are critical for nicotine induce 
hypolocomotion. 
Previous studies implicated the MHb in physical nicotine withdrawal behaviors as 
well as acute nicotine intake and aversion. Expression of L9'S α4* nAChRs in 
MHb cholinergic neurons increased anxiety-like behavior, a predominant 
affective withdrawal symptom, essentially mimicking what may happen if one or 
more nAChR subtype was functionally upregulated after chronic nicotine 
exposure. Confirming this idea, we found that after chronic nicotine treatment, 
the α6* nAChRs are functionally upregulated (by the qRT-PCR and 
electrophysiological recording), and the anxiety during nicotine withdrawal was 
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alleviated by infusion of the α4β2* and the α6* nAChR-selective antagonist into 
the MHb.  
It has been shown that intravenous nicotine self-administration (approximately 
1.5 mg free base/kg/day) increased α6* nAChRs expression in VTA/SN and 
nucleus accumbens (Parker, Fu et al. 2004). In contrast, chronic nicotine 
treatment by minipump (3–6 mg/kg/day administrated for 14 days) or by drinking 
water (50–300 μg/ml for up to 6 weeks) decreases the number of α6* receptors 
in midbrain dopaminergic neurons (Mugnaini, Tessari et al. 2002, Lai, 
Parameswaran et al. 2005, Perry, Mao et al. 2007, Gotti, Guiducci et al. 2010). It 
is interesting that the regulation of nAChRs by long-term nicotine treatment in 
rodents may strongly depend on the dosage of nicotine, the method of nicotine 
delivery and the brain regions checked. 
A recent study showed that mice harboring α6 subunits with an eGFP tag 
exhibited an increase in fluorescent signal in the MHb after chronic nicotine 
treatment compared to control mice. In consistence with our data, we both 
showed that there is a upregulation of α6 subunit in the MHb after nicotine 
exposure and this upregulation of α6 subunit is critical for anxiety during nicotine 
withdrawal (Henderson, Srinivasan et al. 2014). 
Importantly, we previously identified a novel nAChR containing both α4 and α6 
subunits in DAergic neurons of the VTA and show here that nicotinic currents in 
the MHb subregion that predominantly expresses the α6 subunit also contains 
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the α4 subunit, suggesting that α4α6* nAChRs are upregulated by chronic 
nicotine exposure and contribute to increased anxiety-like behavior during 
nicotine withdrawal (Liu, Zhao-Shea et al. 2012, Liu, Hendrickson et al. 2013, 
Shih, Engle et al. 2014).  
In conclusion, here is our model of MHb cholinergic neuron nAChRs in regulating 
anxiety-like behaviors:  
A) Cholinergic/glutamatergic MHb neurons project to the IPN and these neurons 
synthesize and co-release the neurotransmitter glutamate, in addition to ACh 
(Ren, Qin et al. 2011) (Fig VI-1A).  
B) In chapter II, we showed that silencing the MHb cholinergic neurons activity 
reduced anxiety (Fig VI-1B), whereas activating MHb cholinergic neurons with 
high frequency induced hypolocomotion (Fig VI-1C).  
C) In chapter III, our data indicate that nAChRs expressed at the level of the 
soma/dendrites of these neurons likely regulate neuronal activity and anxiety, 
because mecamylamine infusion into the MHb reduced anxiety-like behaviors; 
whereas blockade of MHb presynaptic nAChRs in the IPN or IPN nAChRs 
themselves did not affect anxiety-like behavior (Fig. VI-1D).  
D) In Chapter III, our data suggest that expression of nAChRs that are 
hypersensitive to agonist specifically in cholinergic/glutamatergic MHb neurons 
increases anxiety-like behavior presumably through increasing glutamate release 
into the IPN (Fig. VI-1E).  
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E) In Chapter IV, during nicotine withdrawal, nAChRs are functionally 
upregulated, increasing activation of MHb neurons and glutamate release in the 
IPN leading to increased anxiety-like behavior (Fig. VI-1F). 
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Figure VI-1. Model of MHb cholinergic neuron nAChRs in regulating anxiety-like 
behaviors.  
A. Cholinergic/glutamatergic MHb neurons project to the IPN (baseline).  
B. Silencing MHb cholinergic neurons reduced anxiety-like behaviors. 
C. Activating MHb cholinergic neurons with high frequency induced 
hypolocomotion. 
D. Blockade of nAChRs in MHb or blockade of NMDA receptors in the IPN 
reduce anxiety-like behavior.  
E. Expression of nAChRs that are hypersensitive to agonist specifically in 
cholinergic/glutamatergic MHb neurons increases anxiety-like behavior 
presumably through increasing glutamate release into the IPN.  
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F. Chronic nicotine treatment upregulate the nAChRs in the MHb. During nicotine 
withdrawal, upregulated nAChRs increased activation of MHb neurons and 
glutamate release in the IPN leading to increased anxiety-like behavior. 
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Future directions 
A. Where is the MHb cholinergic input from? 
The medial habenula is a key connection between the limbic forebrain and 
midbrain. Physiological and neurochemical studied have shown that the MHb has 
the highest expression of nicotinic acetylcholine receptors (nAChRs) (Sheffield, 
Quick et al. 2000). Evidence from the lesion studies indirectly showed that the 
NDB or posterior septum might send the cholinergic input to the MHb 
(Contestabile and Fonnum 1983). However, in Chapter IV, using AAV2-ChR2 as 
a tracer, we showed that cholinergic neurons that originate from MS/DB project 
to the hippocampus but not MHb.  
MHb is one of the brain regions that have the highest nAChRs expression level, 
suggesting that there must be strong ACh release to it. Thus, there are two 
possibilities: 1) Some other unknown brain region sends the cholinergic input to 
the MHb; or 2) the cholinergic neurons in the MHb release the ACh to 
themselves to feed forward the neuronal circuit. More studies need to be done to 
test the possibilities. 
To test the first possibility, one can infuse small volume anterograde tracer into 
MHb and map all the neuronal population that project to it. To screen the 
candidate cholinergic input to MHb, the anterograde tracer labeled neuronal 
populations can also be double labeled immunohistochemically with cholinergic 
neuronal markers, like ChAT. The anterograde tracer and ChAT double positive 
neuronal population will be the cholinergic input to MHb. On the other hand, one 
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can also use AAV2-ChR2 as a tracer as I did in this thesis and double confirm 
this candidate brain region send the cholinergic input to MHb. 
To test the second possibility, one can test whether strong stimulation 
(electrically or optically by ChR2) on MHb will induce ACh release (by 
microdialysis or electrophysiology) in the MHb cholinergic neurons in the 
presence of presynaptic ACh release inhibitor. It will be interesting if the 
cholinergic neurons feed forward themselves, and the behavior output of it will be 
worth to study. 
B. Are MHb cholinergic neurons involved in general anxiety? 
Human and animal studies have shown the neurocircuitry of anxiety, including 
the amygdala, nucleus accumbens, BNST and hippocampus (Adhikari 2014). 
Recently the role of the MHb-IPN tract in anxiety and fear has attracted much 
attention. Previous work indirectly demonstrated a role for the MHb in anxiety 
regulation, either through lesioning of the habenula itself or through selective 
ablation of presumed septal glutamatergic inputs into the MHb (Yamaguchi, 
Danjo et al. 2013). Here in my study, we showed that MHb is directly involved in 
anxiety during nicotine withdrawal. In addition, expression of nAChRs that are 
hypersensitive to agonist specifically in cholinergic/glutamatergic MHb neurons 
increases anxiety-like behavior. However, whether the cholinergic neurons in the 
MHb are involved in general anxiety is still unclear.  
To answer this question, one can test whether blocking nAChRs in the MHb will 
alleviate anxiety in other anxiety or stress animal models (repeated social defeat 
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model, forced swimming, tail suspension test). On the other hand, one can also 
test the expression of hypersensitive in MHb cholinergic neurons increases 
anxiety/stress-like behavior in these animal models.  
C. Is MHb-IPN circuit also involved in other drugs of abuse? 
Some evidence showed that MHb may contribute to the development of 
morphine tolerance and withdrawal. For instance, chronic morphine 
administration (20, 40, 60, 80, 100, and 100 mg/kg three times per day) results in 
a reduction in acetylcholinesterase (AChE) activity in the MHb, but not IPN 
(Neugebauer, Einstein et al. 2013). In addition, morphine dependent mice 
showed increased nicotinic acetylcholine receptor (nAChR) levels in MHb 
(Neugebauer, Einstein et al. 2013). For cocaine abuse, a study by Maroteaux 
and Mameli (2012) showed the synaptic plasticity of LHb neurons, but not MHb 
neurons in mice after exposure to cocaine. Therefore, it is worth studying 
whether and how the MHb- IPN circuit is involved in regulating response to other 
drugs of abuse, like morphine and cocaine. If they do, whether all drug abuse 
share the same mechanism in MHb-IPN circuit to signal anxiety during 
withdrawal is still questionable.  
D. Are other neurotransmitter signalings other than nAChR involved in 
anxiety? 
It has been shown that different subregions of the medial habenula (MHb) use 
different combinations of neurotransmitter systems (Aizawa, Kobayashi et al. 
2012). It could be categorized as exclusively glutamatergic (sMHb), both 
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substance P-ergic and glutamatergic (dMHb), or both cholinergic and 
glutamatergic (vMHb) (Aizawa, Kobayashi et al. 2012). How these different 
neurotransmitter systems involved in different behaviors are still unclear. The 
cellular mechanism of these neurotransmitter involved in anxiety also need to be 
studied. One can use the immunostaining, western blot, in combination with 
pharmacological treatment and behavior test to study the role of different 
neurotransmitter system of MHb in anxiety. 
E. How MHb subregions talk to IPN subregions and control different behavior? 
The medial habenula sends major inputs to the interpeduncular nucleus (IPN) via 
fasciculus retroflexus (fr) (Herkenham and Nauta 1977, Carlson, Noguchi et al. 
2001). MHb projects to distinct subnuclei of the IPN, and releases three distinct 
neurotransmitters: ACh, Glu, and SP (Ren, Qin et al. 2011, Aizawa, Kobayashi et 
al. 2012). The dorsal MHb innervate the lateral IPN (IPL and IPR, described 
below) in a cluster pattern and release the SP; the ChAT positive neurons in the 
ventral MHb innervate the ventral IPN (Contestabile, Villani et al. 1987) and the 
MHbVl part only innervates the dorsal IPN (IPR, described below) (Shih, Engle et 
al. 2014), and they release ACh and Glu at different transmission modes 
(Herkenham and Nauta 1979, Contestabile and Flumerfelt 1981, Ren, Qin et al. 
2011). This highly restricted neurotransmitter expression and projection pattern 
suggest that the subnuclei might have specific functions in the brain. To test this 
idea, one can use subregion specific promoter to drive the expression of ChR/ 
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NpHR or other gain of function/loss of function tools, and test the acitivity change 
in the cell level and behavior level. 
In conclusion, MHb is a key connection between the limbic forebrain and 
midbrain. It might be involved in several important behaviors, like aversion and 
anxiety. But the mechanisms underlie that are still largely unknown and need to 
be further studied. 
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Appendix 1. 
Light illumination is a critical determinant of the behavior  
of mice in the elevated plus maze 
 
 
Contributions: 
I did all the experiments, wrote all the text, and made all the figures. 
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A1.A. Introduction 
A variety of animal models of anxiety has been developed to screen effects of 
drugs and to study the psychological and neurochemical basis of anxiety 
disorders, such as elevated plus maze test (EPM), social interaction test, fear-
potentiated startle test, light-dark exploration and mirrored chamber. The 
elevated plus test is one of the most commonly used animal models. Usually, 
mice show exploratory behavior on the EPM apparatus and tend to stay in the 
closed arms of the maze. When the mice were forced onto the open arm, the 
plasma corticosterone concentrations increased, which is indicative of increased 
anxiety (File, Zangrossi et al. 1994, Rodgers, Haller et al. 1999).  Administration 
of anxiolytic compound increase the time spent in the open arm and the number 
of entries to the open arms (Dawson and Tricklebank 1995). The locomotor 
activity also can be assessed by monitoring the total arm entries to both the 
closed and open arms in the EPM. 
However, when using this assay, researchers often get contradictory results from 
the same pharmacological experiments. In addition to the sensitivity of the 
different stains and the dose of drug used in the experiment, the inter–laboratory 
variability in implementation of the EPM may also be a key factor that causes 
contradictory results. But, only few studies provide clear information on the 
detailed experimental design for EPM, such as level of illumination, strain, traits, 
155 
 
habituation and handling the mice. Therefore, the aim of the present study is to 
test several methodological factors (illumination level, mice strain, food baits, and 
habituation) that may contribute to the variability in mice behavior in the elevated 
plus maze. 
A1.B. Materials and methods 
Animals 
C57BL/6J mice and ChAT-Cre mice were used for the experiments in this 
chapter. All the mice used in the experiments were bred in our animal facilities. 
For ChAT-Cre mice, genotypes were determined by PCR as previously 
described (Rossi, Balthasar et al. 2011) and also on Jackson Laboratories 
website. PCR of mouse tail genomic DNA was performed with three specific 
primers, WT F (5′-GTT TGC AGA AGC GGT GGG-3′), mutant F (5′-CCT 
TCT ATC GCC TTC TTG ACG -3′) and Common R (5′-AGA TAG ATA ATG 
AGA GGC TC -3′). These primers amplify DNA fragments of 272 bp in wild-
type (WT) mice, and 350 bp in ChAT-Cre mutant mice. DNA fragments were 
separated by agarose gel electrophoresis and visualized with ethidium bromide. 
The mice were group housed four mice/cage on a light-dark cycle with lights on 
at 7:00 a.m. and off at 7:00 p.m, and given food and water ad libitum. Mice were 
between 8-10 weeks old for all experiments. Behavioral experiments were 
performed during the light cycle. Independent groups of animals were used for 
each behavioral experiment.  
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All experiments were conducted in accordance with the guidelines for care and 
use of laboratory animals provided by the National Research Council (National 
Research Council Institute for Laboratory Animal 1996), as well as with an 
approved animal protocol from the Institutional Animal Care and Use Committee 
of the University of Massachusetts Medical School. 
Apparatus 
The experimental apparatus consisted of a central axis and four arms elevated 
45 cm above the floor, with each arm positioned at 90° relative to the adjacent 
arms. One red light arranged at 100 cm above the maze was used as the source 
of illumination. The mice were individually placed in the center of the maze with 
their heads facing one of the open arms and allowed 5 min of free exploration. 
The number of entries into the open and closed arms, and the total time spent in 
the open and closed arms were measured by MED-PC IV software (MED 
Associates, Inc.) The time spent in open and closed arms was calculated as 
standard anxiety indices. The total number of arm entries was considered as an 
index of locomotor activity. The apparatus was cleaned thoroughly between trials. 
Mice that froze in the initial arm without moving were not included in the analysis. 
Procedures 
Experiment 1: Effect of level of illumination 
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Experiments were carried out at two different light intensities: low intensity or 
high intensity. For the low intensity, the level of the illumination on the central 
platform in the center and both the open arms was 40 lux, whereas for the high 
intensity, the level of the illumination on the central platform in the center and 
both the open arms was 400 lux. 
Experiment 2: Effect of different stains 
C57BL/6J mice and ChAT-Cre mice were used for the experiments.  
Experiment 3: Effect of habituation 
Mice were divided into two groups: with habituation or no habituation. For the no 
habituation group, mice were directly taken from the colony room to the behavior 
room, and put on the EPM apparatus. For the habituation group, mice were put 
into the behavior room for 30 min, and then put on the EPM apparatus. 
Experiment 4: Effect of bait 
Mice were divided into two groups: with baits or no baits. For the baits group, 
standard mouse chow was taken from their home cage and put onto the open 
arms of the apparatus 1/3 away from the distal end of the open arm. For the no 
baits group, no food was put onto the apparatus. 
Statistics 
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Data were analyzed using Student‟s t-test. Results were considered significant at 
p < 0.05. All data are expressed as means ± SEM. 
A1.C. Results 
Light intensity 
Analysis with the Student t-test shows that in the ChAT-Cre mice line, mice with 
high intensity condition significantly reduced the time spent in open arms 
compared to the mice with low intensity condition, from 72.59 ± 7.74s to 18.12 ± 
8.70s in the no food group, and from 159.74 ± 31.07s to 42.89 ± 4.04s in the food 
baits group (Figure A1-1, Figure A1-2A ). 
Habituation 
In the C57BL/6J line, mice with habituation tend to spend less time in the open 
arm compared to the no habituation group (Figure A1-1, Figure A1-2B), but these 
differences were not significant. 
Strain 
Analysis with the student t-test shows that there is no significantly difference 
between C57BL/6J mice line and ChAT-Cre mice line when they have no 
habituation (Figure A1-1, Figure A1-2C). 
Bait 
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In all the groups, mice with food baits tended to increase the time spend in the 
open arm compare to the no food baits groups. Only for the ChAT-Cre mice with 
low intensity illumination, there is significant difference between the mice with 
food baits and those without food baits (Student‟s t-test, * p<0.05). In this 
condition, time spent in the open arm increase from 72.59 ± 7.74s (no food baits) 
to 159.74 ± 31.07s (with food baits) (Figure A1-1, Figure A1-2D). 
Lomomoter activity 
Overall, for the locomotor acitivity, there were no significant differences among all 
the groups (Figure A1-2). 
A1.D. Discussion 
In the elevated plus maze test, rodents are placed in the intersection of the four 
arms of the elevated plus maze and their behavior is typically recorded for 5 min 
(Montgomery 1955), the behavioral results showed that the mice prefer the 
closed arms to the open arms. However, when use these animal model, 
researchers often get contradictory results from the same pharmacological 
experiments, as the EPM conditions used in different labs might be distinct. 
Here we tested several determinants that might influence the behavior of mice in 
the elevated plus-maze. Our results showed that the level of illumination of the 
experimental area is a critical determinant of the time spent in the open arm of 
the mice in EPM. In a highly illuminated room, mice showed a greater avoidance 
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of the open arms than in a less intensely illuminated one. These results are 
consistent with previous studies that brightly lit test areas are aversive to many 
strains of rats and mice (Crawley and Goodwin, 1980; File, 1980; Crawley, 1985; 
Morato and Castrechini, 1989; Benjamin et al., 1990).  
The second factor evaluated here is the baits such as food from the mice home 
cage which has the familiar smell. The food baits also played an important role in 
the performance of mice in the EPM. Animals tested with the food baits showed 
increased time spent in open arms than those without food baits. Especially for 
the ChAT-Cre line, food baits group significantly spend more time in the open 
arms. These data suggest that the familiar smell from the food bait and the food 
itself might have anxiolytic effect on mice, thus mice spend more time in the open 
arm. In addition, our lab has found that in the ChAT-Cre line, the ChAT 
expression level is lower than that in the C57BL/6J mice. Together with our data 
in this study, cholinergic system in the brain might be involved in the feeding 
behavior and anxiety. 
The third factor evaluated here is habituation to the EPM room. Previously, it has 
been shown that rats did not habituate with repeated test trials. Instead, they 
appeared to become more anxious as open-arm avoidance increased on the 
repeated trials (Treit, Menard et al. 1993). Here we showed that habituation to 
the room also affected level of performance in mice. Mice with habituation spent 
around 20% less time compare to the mice without habituation. Together with 
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previous study, we conclude that habituation to either the apparatus or the 
behavior room has the anxiogenic effect. 
We also test the difference between the C57black6 mice line and ChAT-Cre mice  
line at 40 Lux in absence of habituation, but no significant difference were found.  
In summary, when using the elevated plus-maze, the light intensity, habituation 
and food baits are critical determinants, which should be taken into account by 
each laboratory when attempting to identify the optimal conditions for their 
investigation. 
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Figure A1-1. Effects of illumination, mice strain, baits, and habituation on the time 
spent in the open arms of mice in the elevated plus-maze. C57 mice and ChAT-
Cre mice line were used at two illumination conditions (40 lux or 400 lux), with or 
without food baits, with or without habituation. Results are expressed as time 
spent (seconds) in the open arms (mean ± SEM). 
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Figure A1-2. Effects of illumination, mice strain, baits, and habituation on the time 
spent in the open arms of mice in the elevated plus-maze (Data are replotted 
from Fig. A1-1).  
A. ChAT-Cre mice were tested at two illumination conditions (40 lux or 400 lux). 
Mice with 400 lux intensity spend significantly less time compare to the mice with 
40 Lux. 
B. In the C57BL/6J line, mice with habituation tend to spend less time in the open 
arm compared to the no habituation group under 40 lux light intensity. 
C. C57BL/6J mice and ChAT-Cre mice spent similar time in the open arm under 
40 lux light intensity. 
D. ChAT-Cre mice with food baits increase the time spent in the open arm 
compare to the no food baits groups.  
164 
 
Results are expressed as time spent (seconds) in the open arms (mean ± SEM). 
For A-D, * p < 0.05, Student‟s t-test. 
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Figure A1-3. Effects of illumination, mice strain, baits, and habituation on the total 
arm entries of mice in the elevated plus-maze. C57 mice and ChAT-Cre mice 
were used at two illumination conditions (40 lux or 400 lux), with or without food 
baits, with or without habituation. Results are expressed as total entries in all the 
arms (mean ± SEM). 
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APPENDIX 2. 
Dicer expression is essential for adult midbrain dopaminergic neuron 
maintenance and survival 
 
This chapter has been published separately in: 
Pang, X., E. M. Hogan, A. Casserly, G. Gao, P. D. Gardner and A. R. Tapper 
(2014). Dicer expression is essential for adult midbrain dopaminergic neuron 
maintenance and survival. Mol Cell Neurosci 58: 22-28. 
Contributions: 
Eric Hogan and Alison Casserly did the qRT-PCR, Guangping Gao made the 
virus, I did all the other experiments and made all the figures. Dr. Andrew Tapper 
and Paul Gardner wrote most of the text. 
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A2.A. Introduction 
MicroRNAs (miRNAs) are small, non-coding RNAs that modulate mRNA 
expression  (Cao, Yeo et al. 2006, Bicker and Schratt 2008, Fiore, Siegel et al. 
2008, Pietrzykowski, Friesen et al. 2008, Huang and Li 2009, Karr, Vagin et al. 
2009). miRNAs bind to miRNA-recognition elements (MRE), specific sequences 
usually located in target mRNA 3′-untranslated regions (UTRs) resulting in either 
mRNA cleavage (Bartel 2004, Huppi, Martin et al. 2005, Martin and Caplen 2006) 
or inhibition of translation (Ambros 2004, Bartel 2004, Zamore and Haley 2005). 
In some cases, miRNAs have been shown to increase expression of their target 
genes (Vasudevan, Tong et al. 2007). miRNAs are derived from long primary 
transcripts that are sequentially processed by the ribonuclease, Drosha, and the 
type III RNAse, Dicer. While it is clear that miRNA expression and function is 
critical during CNS development (Davis, Cuellar et al. 2008, De Pietri Tonelli, 
Pulvers et al. 2008, Li, Bian et al. 2011, McLoughlin, Fineberg et al. 2012) and 
neuronal maintenance and survival in some brain regions during post-natal 
periods (Schaefer, O'Carroll et al. 2007), the role of miRNAs in the adult CNS is 
still largely unknown. 
In the dopaminergic (DAergic) neuron-rich midbrain, a structure critical for 
voluntary locomotor processing and motivation (Salamone and Correa 2012, 
Sulzer and Surmeier 2013), miRNA expression is essential for midbrain 
formation during development and DAergic neuron differentiation. Wnt1-Cre-
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mediated conditional loss of Dicer in mice results in embryos with smaller 
midbrains compared to control embryos (Huang, Liu et al. 2010). In addition, 
Wnt1-Cre Dicer knock-out (KO) mice express DAergic precursor neurons that do 
not properly differentiate into DAergic neurons at E12.5. In cell culture, Dicer 
deletion in DAergic neurons derived from embryonic stem cells, triggers 
apoptosis and neuronal-like cell death (Kim, Inoue et al. 2007). Finally, 
conditional knock-out of Dicer in dopamine transporter (DAT)-expressing neurons 
results in significant death of midbrain DAergic neurons in mice by three weeks 
of age. However, whether expression of Dicer dependent miRNAs is critical for 
maintenance and survival of adult midbrain DAergic neuron areas is unknown. 
We sought to test the hypothesis that Dicer expression, and by extension 
miRNAs, are critical for DAergic neuron maintenance and survival even in adult 
animals. To do this, we knocked-out Dicer expression in mice homozygous for a 
floxed Dicer allele (Dicerflox/flox) allowing for conditional knock-out of Dicer in 
neuronal populations that express Cre (Harfe, McManus et al. 2005). However, 
to induce Dicer deletion in discreet midbrain areas during adulthood, we 
delivered Cre into the VTA and SNpc using adeno-associated virus (AAV)- 
mediated gene delivery. 
A2.B. Materials and methods 
Animals 
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Dicerflox/flox mice, which contain loxP sites on either side of exon 23 of the Dicer1 
(Dicer1, Dcr-1 homolog (Drosophila)) gene, were purchased from Jackson 
Laboratories and bred in our animal facilities. Breeding was conducted by mating 
heterozygous pairs. The mice were group housed four mice/cage on a 12-h light-
dark cycle and given food and water ad libitum. Male mice were used for all 
experiments. Mice were at least 8 weeks old at the beginning of each experiment. 
All experiments were conducted in accordance with the guidelines for care and 
use of laboratory animals provided by the National Research Council (National 
Research Council Institute for Laboratory Animal 1996), as well as with an 
approved animal protocol from the Institutional Animal Care and Use Committee 
of the University of Massachusetts Medical School. 
Virus microinjection 
AAV2-CMV-PI-Cre-ZsGreen and AAV2-eGFP virus particles were provided by 
the viral vector core facility of the University of Massachusetts Medical School. 
Dicerflox/flox mice were anesthetized with a mixture of ketamine (100 mg/kg) and 
xylazine (10 mg/kg) (VEDCO). The surgical area was shaved and disinfected. 
Mice were placed in a stereotaxic frame (Stoelting Co.) with mouse adaptor and 
a small incision was cut in the scalp to expose the skull. Using bregma and 
lambda as landmarks, the skull was leveled in the coronal and sagittal planes. 
AAV2-Cre-ZsGreen or AAV2-eGFP was injected into either VTA or SNpc. For the 
VTA, the coordinates were: anterior-posterior (AP), −3.3 mm from bregma; 
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medial-lateral (ML), ±0.5 mm from midline; dorsal-ventral (DV), −4.0 mm from 
brain surface. For the SNpc, the coordinates were: AP, −3.0 mm from bregma; 
ML, ±1.5 mm from midline; DV, −4.0 mm from brain surface. The virus (1 × 1012 
viral particles/ml, 0.5 μl/side) was injected at a flow rate of 0.1 μl/min. The 
injection needle remained in place for 5 min post-injection before slowly being 
withdrawn. 
Genotyping 
As described previously (Harfe, McManus et al. 2005), two sets of primers were 
used to verify the insertion of the loxP site and the deletion of the Dicer gene. 
The conditional floxed allele was genotyped using primers DicerF1 (5′-
CCTGACAGTGACGGTCCAAAG-3′) and DicerR1 (5′-
CATGACTCTTCAACTCAAACT-3′), which amplify a DNA fragment that is 351 bp 
in wild-type (WT) mice, and 420 bp in Dicerflox/flox (Figure A1-1). Four weeks after 
the AAV2-Cre-ZsGreen virus infection, brain tissue was laser captured 
(described below). Total DNA was extracted with a tissue DNA extraction kit 
(DNeasy Blood & Tissue Kit, Qiagen). The deletion allele was genotyped using 
primers DicerF1 and DicerDel (5′-CCTGAGCAAGGCAAGTCATTC-3′). The band 
for the deleted allele is 471 bp whereas the band for a WT allele is 1,300 bp 
(Figure A1-1). 
Laser capture microdissection 
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Eight weeks after virus infection, mice were sacrificed and the brains were 
removed, snap-frozen in dry ice-cooled 2-methylbutane (−60°C) and stored at 
−80°C. Coronal serial sections (10 μm) were cut using a cryostat (Leica 
Microsystems Inc.) and mounted on pre-cleaned glass slides (Fisher Scientific). 
The sections were immediately placed in a slide box on dry ice until completion 
of sectioning followed by storage at −80°C. Frozen sections were allowed to thaw 
for 30 s and then immediately fixed in cold acetone for 4 min. The slides were 
washed twice in PBS (prepared in DEPC water) and subsequently dehydrated in 
a graded ethanol series (for 30 s each in 70% ethanol, 95% ethanol, 100% 
ethanol, and once for 5 min in xylene). Slides were allowed to dry for 5 min. All 
ethanol solutions and xylene were prepared fresh to preserve RNA integrity. The 
Veritas Microdissection System Model 704 (Arcturus Bioscience) was used for 
laser capture microdissection (LCM). ZsGreen- or EGFP-positive neurons were 
captured on CapSure Macro LCM caps (Arcturus Bioscience) for total RNA 
isolation. 
Real-time PCR 
Total RNA was extracted from individual replicate samples using a Micro Scale 
RNA Isolation Kit (Ambion). miRNAs were amplified from laser-captured material 
except for miR-133b which was amplified from tissue punches of infected areas 
due to low yield. RNA samples extracted from ZsGreen- or eGFP-positive 
neurons were reverse-transcribed into cDNA using a miRNA TaqMan Reverse 
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Transcription Kit (Applied Biosystems). Quantitative reverse transcription-PCR 
(qRT-PCR) was performed using an Applied Biosystems 7500 Real-Time System 
and miRNA TaqMan assays (Applied Biosystems). Samples containing no 
reverse transcriptase were used as negative controls. Relative gene expression 
differences between eGFP-positive neurons and ZsGreen-positive neurons were 
calculated using the 2−ΔΔCt method. Expression values were normalized to 
expression of sno202, a small nucleolar RNA not produced by Dicer (Politz, 
Hogan et al. 2009, Brattelid, Aarnes et al. 2011). Samples were analyzed in 
triplicate. Student's t-test was used for statistical analysis. 
Immunohistochemistry 
Eight weeks after virus infection, mice were sacrificed and the brains removed to 
make coronal serial sections (10 μm) and mounted onto pre-cleaned glass slides. 
Immunolabeling was done as previously described (Zhao-Shea, Liu et al. 2011). 
Briefly, the sections were immediately placed in a slide box on dry ice until 
completion of sectioning followed by storage at −80°C. The frozen sections were 
thawed for 30 s and fixed in 4 % paraformaldehyde in 0.01 M sodium phosphate 
buffer (pH 7.4). The slides were rinsed in PBS twice for 5 min, and treated with 
0.2 % Trition X-100 PBS (PBST) for 5 min followed by incubation in 2 % 
BSA/PBS for 30 min. Sections were washed with PBS once and then incubated 
in primary antibodies directed to tyrosine hydroxylase (TH, monoclonal, 1:250 
dilution, Santa Cruz Biotechnology) in 2 % BSA/PBS overnight at 4°C. The 
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sections were washed with PBS three times for 5 min followed by incubation in 
secondary fluorescent labeled (goat anti-mouse Alexa Fluor 594, 1:300 dilutions, 
Invitrogen) at room temperature in the dark for 30 min. For NeuN and TH double 
labeling, the sections were washed with PBS and incubated with primary 
antibodies NeuN (monolclonal, 1:100 dilution, Millipore) and TH (polyclonal, 
1:1000 dilution, Santa Cruz Biotechnology) overnight at 4°C. After PBS washing, 
the secondary antibodies (goat anti-mouse Alexa Fluor 594 and goat anti-rabbit 
Alexa Fluor 488, 1:300 dilutions, Invitrogen) were incubated at room temperature 
in the dark for 30 min. After washing with PBS 5 times for 5 min/wash, sections 
were covered with cover slides using VECTASHIELD® Mounting Medium (Vector 
laboratories, Inc.). Neurons were counted as signal-positive if intensities were at 
least 2 times higher than that of the average value of background (sections 
stained without primary antibodies). 
TUNEL staining 
Frozen sections were made as described above at different time points (2 weeks, 
4 weeks, 6 weeks and 8 weeks) after virus infection. The TUNEL assay (Roche 
Diagnostics, Mannheim, Germany) was performed according to the 
manufacturer's instructions. 
Locomotor activity 
Locomotor activity was recorded using an automated system (San Diego 
Instruments, La Jolla, CA, USA) with photobeams, which recorded ambulation 
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(consecutive beam breaks). Before virus microinjection, mice were placed 
individually in a novel cage and recorded for 90 min for their baseline locomotor 
activity. At different time points after the virus infection (4 weeks, 6 weeks, and 8 
weeks), locomotor activity was recorded in a novel cage. For amphetamine 
treatment, mice were placed in a novel cage and activity was recorded for 20 min, 
followed by an i.p. injection of amphetamine (0.5 mg/kg) or saline. Activity post-
injection was recorded for 3 h. 
Rotarod test 
A rotarod apparatus (San Diego Instruments, San Diego, CA) was used to 
evaluate motor coordination and balance. Mice were placed on an accelerating 
rod (4 to 40 rpm) over a period of 300 s. Any mice remaining on the apparatus 
after 300 s were removed and the rotor rod time scored as 300. The length of 
time that the mouse remained on the rod (latency to fall) was recorded. Each 
mouse underwent seven consecutive trials with 10 min intervals between trials. 
At the end of each behavioral experiment, brains of mice were isolated, sliced, 
and stained to verify infection site and loss of DAergic neurons as described 
above. Mice that were mis-injected were subsequently removed from behavioral 
analysis. 
Data analysis 
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Data were analyzed using 1- or 2-way ANOVAs as indicated followed by 
Bonferroni post-hoc tests. Data were analyzed using GraphPad software. 
Student's t tests were used to analyze fold expression of qRT-PCR data and 
immunohistochemistry data. Results were considered significant at p < 0.05. All 
data are expressed as the mean ± SEM. 
A2.C. Results 
To test the hypothesis that Dicer expression is critical for maintenance and 
survival of DAergic neurons in adult midbrain areas, we selectively expressed 
Cre recombinase in either the VTA or SNpc of adult (>8 week old) Dicerflox/flox 
mice. To do this, recombinant adeno-associated virus serotype 2 (AAV2) co-
expressing Cre under the control of the CMV promotor and the green fluorescent 
marker, ZsGreen under the control of the β-actin promotor, were injected into 
VTA or SNpc. Control mice received AAV2 encoding enhanced green fluorescent 
protein (eGFP) alone. To verify loss of Dicer expression, 4-6 weeks post AAV2 
injection, midbrain areas expressing Cre, identified by expression of ZsGreen 
under fluorescence microscopy, were isolated and genotyped. Deletion of the 
floxed NEO-cassette was verified by PCR using primers spanning the floxed 
region (Fig. A2-1A). To verify loss of miRNA expression, infected areas were 
laser dissected followed by isolation of small RNAs and quantitation using qRT-
PCR. Expression of Cre in midbrain of Dicerflox/flox mice resulted in statistically 
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significant reduction of common neuronal miRNAs including miR-124a, -328, -9, 
and -133b (Fig. A2-1B). 
To determine the effect of Dicer deletion in the VTA on behavior, Dicerflox/flox mice 
were infected with AAV2-eGFP (control) or AAV2-Cre-ZsGreen in the VTA, 
bilaterally. Locomotor activity was monitored weekly 4-8 weeks post infection. In 
control animals, locomotor activity 4-8 weeks after infection did not differ from 
baseline (activity measured prior to infection, Fig. A2-2A, C). In contrast, 
locomotor activity in AAV2-Cre-ZsGreen-infected animals progressively 
increased from 6-8 weeks post-infection (Fig. A2-2B, C). Two-way ANOVA 
revealed a significant main effect of virus (F1, 140 = 58.7, p < 0.001) and time (F3, 
140 = 16.3, p < 0.001) and significant time x virus interaction (F3, 140 = 20.3, p < 
0.001). Post-hoc analysis indicated a statistically significant increase in locomotor 
activity six and eight weeks post-infection for AAV2-Cre-ZsGreen (p < 0.001), but 
not AAV2-eGFP infected mice. To determine the role of DA in hyperactivity 
elicited by reduced Dicer expression in the VTA, we injected control and 
hyperactive VTA Cre-expressing Dicerflox/flox mice with the DA agonist, 
amphetamine (Fig. A2-2D, E, F). Two-way ANOVA indicated a significant drug 
treatment and virus interaction (F1, 23 = 7.52, p < 0.05). Control animals 
responded to amphetamine with increased locomotor activity compared to a 
saline injection (Fig. A2-2D, F). Interestingly, hyperactivity in VTA Cre-expressing 
animals was paradoxically reduced in response to amphetamine similar to what 
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is seen in models of attention deficit hyperactivity disorder (p < 0.05, Fig. A2-2E, 
F) (Gong et al., 2011, Won et al., 2011). 
To test the hypothesis that reduction of Dicer expression was necessary for VTA 
DAergic neuron maintenance and survival, Dicerflox/flox mice were injected with 
AAV2-Cre-ZsGreen unilaterally into the VTA. Six weeks post-infection, brains 
were harvested, sliced, and labeled with the nuclear stain, DAPI, the neuronal 
specific nuclear stain, NeuN, and the TH antibody allowing for detection of total 
cells, total neurons, and DAergic neurons, respectively, in infected and control 
midbrain regions. The number of non-neuronal cells (DAPI positive, NeuN 
negative), DAergic (TH immunopositive), and non-DAergic neurons (NeuN 
positive, TH immunonegative) in the VTA were counted and compared to the 
non-infected side 6 weeks after injection (Fig. A2-3A, B). Two-way ANOVA 
indicated a significant effect of virus infection (F1, 12 = 7.93, p < 0.05), cell type (F2, 
12 = 623.6, p < 0.001), and a significant virus x cell type interaction (F2,12 = 20.6, 
p<0.001). Post-hoc analysis revealed that reduction of Dicer expression 
significantly reduced the number of TH immunopositive neurons within the VTA 
compared to the non-infected side (Fig. A2-3B, p < 0.001) while increasing the 
number of non-neuronal cells (p<0.05), presumably glia which proliferate or 
migrate to the lesioned area (Maia, Arlicot et al. 2012). Although there was a 
trend for decreased non-TH immunopositive neurons with reduced Dicer 
expression compared to control, it was not statistically significant. In addition, TH 
staining was dramatically reduced in the nucleus accumbens (NAc) indicating 
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loss of DAergic neuron terminals (Fig. A2-3C). Reduction of TH staining was 
localized to the NAc; whereas dorsal striatum (DSt) was relatively unaffected 
consistent with loss of DAergic neurons specifically in the VTA. To further control 
for the specificity of our viral-mediated approach, we unilaterally infected the VTA 
of Dicerflox/flox mice with AAV2-eGFP and unilaterally infected the VTA of WT mice 
(Dicerwt/wt) with AAV2-Cre-ZsGreen. The number of VTA DAergic neurons in the 
infected sides of both sets of control mice did not significantly differ compared to 
the number of VTA DAergic neurons in the non-infected sides (Fig. A2-4A). 
To determine if reducing Dicer expression induced apoptosis as the mechanism 
of cell death in DAergic neurons within the VTA, we infected the VTA of a cohort 
of Dicerflox/flox mice with AAV2-Cre-ZsGreen and performed TUNEL staining at 
various time points post-infection including 2, 4, 6, and 8 weeks (Fig. A2-4B, C). 
One-way ANOVA indicated a main effect of time on TUNEL-positive cells (F4, 32 = 
49.6, p < 0.001, Fig. A2-4C). Post-hoc analysis revealed a significant increase in 
neurons undergoing apoptosis at four and six weeks post-infection compared to 
two weeks post-infection (p < 0.001). Thus, TUNEL staining was detected as 
early as two weeks post-infection, but peaked at 4 weeks indicating reduced 
Dicer expression triggers apoptosis in adult VTA. Interestingly, the majority of 
TUNEL stained nuclei within the infected area did not co-localize with Zs-Green 
expression. As TUNEL stained slices are processed at fixed time intervals, this is 
likely due to loss of Zs-Green expression in dying/dead neurons or diffusion of 
fluorophore in apoptotic neurons with compromised membrane integrity. 
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To determine the effect of Dicer deletion in SNpc, adult Dicerflox/flox mice were 
infected with AAV2-Cre-ZsGreen bilaterally in SNpc. Locomotor activity was 
monitored weekly post-infection (Fig. A2-5). Locomotor activity was not affected 
by reduced Dicer expression in the SNpc as locomotor activity did not differ from 
baseline up to 8 weeks post-Cre expression (Fig. A2-5A, B, C). Because DA is 
critical for motor coordination learning in addition to voluntary movement (Beeler, 
Cao et al. 2010), we compared rotarod performance of AAV2-Cre-ZsGreen-
infected animals at 4- and 8-weeks post-infection to control-infected animals (Fig. 
A2-5D). Two-way ANOVA indicated a significant main effect of trial (F6, 162 = 13.3, 
p < 0.001) and virus (F2, 27 = 5.05, p < 0.05) but not a significant interaction. Over 
seven successive trials on the accelerating rotarod, control mice significantly 
increased their latency to fall of the apparatus indicating motor coordination 
learning. Post-hoc analysis revealed that AAV2-Cre-ZsGreen-infected animals 
exhibited poorer performance at 8- but not 4-weeks post-infection, compared to 
controls as reflected in decreased latency to fall on trials 3-7 compared to AAV2-
eGFP infected mice (p<0.05). As with the VTA, the number of TH 
immunopositive neurons in the SNpc of AAV2-Cre-ZsGreen-infected animals 
was significantly reduced compared to control indicating Dicer expression is 
necessary for DAergic neuron survival in adult animals (Fig. A2-6A, B). This was 
also confirmed by decreased TH labeling in DSt of infected animals (Fig. A2- 6C). 
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A1.D. Discussion 
Here we show that Dicer expression is critical for survival and maintenance of 
adult DAergic midbrain neurons in C57BL/6J mice. Genetic deletion of Dicer 
specifically in midbrain elicited a progressive loss of both VTA and SNpc DAergic 
neurons through an apoptotic mechanism. The present data extend previous 
studies (Kim, Inoue et al. 2007) and indicate that Dicer expression is necessary 
for survival of DAergic neurons even in adulthood. The progressive loss of 
DAergic neurons over time in the VTA resulted in hyperactivity and this 
hyperactivity was, paradoxically, reduced by amphetamine. These data are 
consistent with previous VTA lesioning studies in rats, which also induced 
amphetamine-sensitive hyperactivity (Galey, Simon et al. 1977, Le Moal, Stinus 
et al. 1977, Stinus, Gaffori et al. 1977). Interestingly, Dicer loss in SNpc did not 
affect locomotor activity but did impair rotarod performance cogent with prior 
work implicating a role for striatal DA in acquisition of motor learning (Beeler, Cao 
et al. 2010). Our results also support recent data indicating that, at least in mice, 
skilled motor learning is more sensitive to the effects of partial DAergic neuron 
depletion compared to simple motor activity (Chagniel, Robitaille et al. 2012). 
A previous study examined Dicer deletion under control of the DAT promoter and 
found that animals that develop without Dicer expression in DAT-expressing 
neurons exhibit significant loss of neurons by three weeks of age and a 90 % 
loss by 8 weeks (Kim, Inoue et al. 2007). Neuronal loss occurred via apoptosis. 
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Similarly, our study indicates knockout of Dicer in adult DAergic neuron-rich 
midbrain areas also induces apoptosis. Apoptosis peaked 4 weeks post-infection 
returning to baseline after 8 weeks matching the progressive severity of the 
measured motor behavioral phenotype in these animals and also mirroring the 
peak time of Cre-expression using AAV2-mediated gene delivery. 
The criticality of Dicer expression and Dicer-processed miRNA function in the 
CNS differs between brain regions, is developmentally-dependent, and depends 
on neuronal sub-type. For example, genetic deletion of Dicer in cells that express 
calmodulin kinase II (CAMKII), a marker for glutamatergic neurons in cortex and 
hippocampus, has different phenotypes in mice depending on the developmental 
period when the deletion occurs. Crossing Dicerflox/flox mice with a-R1AG-5 
CAMKII-Cre mice results in Dicer deletion at embryonic day 15.5 (e15.5) (Davis, 
Cuellar et al. 2008). The resulting phenotype included microcephaly, significant 
increase in early post-natal apoptosis, and death by 20 days of age. Deleting 
Dicer in CamKII-expressing neurons beginning at P18 using a different Cre line 
also induces neurodegeneration with abnormal tau hyperphosphorylation (Hebert, 
Papadopoulou et al. 2010). In contrast, inducing Dicer deletion in CaMKII-
expressing neurons during adulthood using a tamoxifen-inducible promoter 
enhances learning and memory in mice without dramatic neurodegeration for up 
to 14 weeks post-deletion (Konopka, Kiryk et al. 2010). Similarly, Dicer deletion 
in adult amygdala or in striatal dopaminoceptive medium spiny neurons does not 
induce apoptosis or neurodegeneration in these brain areas (Cuellar, Davis et al. 
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2008, Haramati, Navon et al. 2011). Interestingly, deletion of Dicer in Purkinje 
neurons of the cerebellum elicits a relatively slow neurodegenerative process 
whereby these neurons appear normal up to 10 weeks of age but begin to 
degenerate over the next several weeks of life (Schaefer, O'Carroll et al. 2007). 
In contrast, our data indicate that in the absence of Dicer expression, DAergic 
neurons degenerate rapidly; whereas non-DAergic (presumably GABAergic) 
neurons within the VTA were more resistant to cell death similar to striatal 
medium spiny neurons and Purkinje neurons which are also GABAergic 
(Schaefer, O'Carroll et al. 2007, Cuellar, Davis et al. 2008). 
Interestingly, Kim et. al. identified a specific miRNA, miR-133b, that is enriched in 
DAergic neurons and depleted in Parkinson's disease brains, regulates DAergic 
neuron differentiation (Kim, Inoue et al. 2007). While the precise role of miRNA-
133b in DAergic neuron maintenance is unclear (Heyer, Pani et al. 2012), it 
raises the intriguing possibility that a specific set of miRNAs may be critical for 
DAergic neuron integrity throughout their lifespan. Identification of miRNAs 
integral for DAergic neuron health could lead to new strategies for treatment of 
DAergic neuron degenerative diseases such as Parkinson's disease. 
In summary, our data indicate that Dicer expression and Dicer-dependent 
miRNAs appear to be necessary for adult DAergic neuron maintenance and 
survival. Combined with previous studies, Dicer expression is critical for DAergic 
neuron integrity from early post-natal periods throughout adulthood. 
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Figure A2-1. Verification of conditional Dicer knock-out.  
A. DNA agarose gel illustrating amplified DNA fragments from genomic DNA of 
WT and homozygous Dicerflox/flox mice using Dicer F1 and Dicer R1 primers (left). 
Right, amplified fragments from midbrain DNA of WT and Dicerflox/flox infected with 
AAV2-Cre-ZsGreen using the Dicer F1 and Dicer Del primers.  
B. Midbrain miRNA expression from Dicerflox/flox mice infected with AAV2-eGFP 
(white bars) or AAV2-Cre-ZsGreen (green bars). *p < 0.05, *** p < 0.001, 
Student's t-test (n =3 mice/treatment). 
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Figure A2-2. Dicer loss in adult VTA elicits locomotor hyperactivity.  
A. Ambulation in Dicerflox/flox mice infected with AAV2-eGFP in the VTA. 
Ambulation at baseline (prior to injection) and 4, 6, and 8 weeks (wk) post-
infection over 90 min are shown. Each data point represents summed ambulation 
during 5 min intervals (the VTA was correctly targeted in 25/26 mice).  
B. Ambulation in Dicerflox/flox mice infected with AAV2-Cre-ZsGreen in the VTA. 
Ambulation at baseline and 4, 6, and 8 weeks post-infection are shown (the VTA 
was correctly targeted in 14/16 mice).  
C. Summed total ambulation over 90 min in each group at each time point post-
infection.  
D. Ambulatory response to saline (i.p., open circles) or 0.5 mg/kg amphetamine 
(AMPH, i.p., green squares) in Dicerflox/flox mice expressing eGFP in VTA (the 
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VTA was correctly targeted in 4/4 mice). Time of injection is indicated by the 
arrow.  
E. Ambulatory response to saline or AMPH in Dicerflox/flox mice expressing Cre in 
VTA (the VTA was correctly targeted in 10/12 mice).  
F. Summed total ambulation over 90 min post-saline or -AMPH injection in each 
group. Two-way ANOVA, Bonferroni post-hoc, * p < 0.05, ***p < 0.001. 
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Figure A2-3. Dicer expression is necessary for DAergic neuron survival in the 
adult VTA.  
A. Representative photomicrograph from a Dicerflox/flox mouse infected with AAV2-
Cre-ZsGreen unilaterally. Dicer loss leads to significant reduction of TH 
immunopositive neurons (stained red, top left panel) on the infected side 
(indicated by the white asterisk). Photomicrograph of virus infected area (green, 
top right panel) is shown. DAPI-labeled cells are depicted in blue (bottom left 
panel). Merged image is illustrated in the bottom right panel.  
B. Average total number of non-neuronal cells, TH-immunonegative (non-TH+) 
neurons and TH-immunopositive (TH+) neurons in the VTA of AAV2-Cre-
ZsGreen-infected (infected compare to the non-infected side). Cell counts were 
calculated 8 weeks after virus injection (n = 15-42 slices from 3 mice/treatment).  
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C. Representative photomicrograph illustrating loss of TH expression in the NAc. 
Twoway ANOVA, Bonferroni post-hoc, *p < 0.05, *** p < 0.001. 
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Figure A2-4. Loss of adult VTA DAergic neurons with reduced Dicer expression 
is specific and triggered by apoptosis.  
A. Averaged sum of TH immunopositive VTA neurons in Dicerflox/floxmice infected 
with AAV2-eGFP and Dicerwt/wt mice infected with AAV2-Cre-ZsGreen. TH 
immunopositive neurons are compared between the infected and control, non-
infected side.  
B. Representative photomicrographs illustrating AAV2-Cre-ZsGreen expression 
in the VTA (green, left), TUNEL stained neurons (red, middle) and merged 
images (right) at different time points after virus injection in Dicerflox/flox mice.  
C. Number of TUNEL-positive neurons in infected Dicerflox/flox mice at different 
time points. One-way ANOVA, Bonferroni post-hoc, *** p < 0.001. 
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Figure A2-5. Loss of Dicer expression in SNpc impairs motor-learning.  
Ambulation in Dicerflox/flox mice infected with (A) AAV2-eGFP or (B) AAV2-Cre-
ZsGreen in the SNpc at baseline (prior to injection) and 4, 6, and 8 weeks post-
infection over 90 min are shown (the SNpc was correctly targeted in A) 10/10 and 
6/7 mice, respectively).  
C. Summed total ambulation from (A) and (B).  
D. Normalized latency to fall off an accelerating rotarod on 7 consecutive trials in 
Dicerflox/flox mice infected with AAV2-eGFP or AAV2-Cre-ZsGreen (4- or 8-weeks 
post-infection) in the SNpc. Each trial was normalized to the average latency of 
trials 5-7 in control, AAV2-eGFP-infected animals (i.e. when rotarod performance 
reached a stable baseline). Two-way ANOVA, Bonferroni Post-hoc, * p < 0.05. 
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Figure A2-6. Dicer expression is necessary for DAergic neuron survival in the 
adult SNpc.  
A. Representative photomicrographs illustrating TH expression (red, top left 
panel), AAV2-Cre-ZsGreen-infected area (green, top right panel), DAPI staining 
(blue, bottom left panel) and merged signals (bottom right panel). The infected 
side is denoted by a white asterisk.  
B. Average total number of TH-immunopositive neurons in the SNpc of AAV2-
eGFP (control) and AAV2-Cre-ZsGreen infected mice. Neurons were quantified 8 
weeks after virus injection (n = 18-20 slices from 4 mice/treatment).  
C. Representative photomicrograph illustrating loss of TH expression in the DSt. 
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